Michael R. Griffinger Sheila F. McShane GIBBONS P.C. One Gateway Center Newark, New Jersey 07102-5310 Telephone No.: (973) 596-4500 Facsimile No.: (973) 596-0545

Of Counsel:

Edgar H. Haug
Angus Chen
Nicholas F. Giove
Leann M. Clymer
FROMMER LAWRENCE & HAUG LLP
745 Fifth Avenue

New York, New York 10151 Telephone No.: (212) 588-0800

Telephone No.: (212) 588-0800 Facsimile No.: (212) 588-0500

Attorneys for Plaintiffs Chiesi USA, Inc., Cornerstone BioPharma, Inc., and EKR Therapeutics, LLC

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

CHIESI USA, INC., CORNERSTONE BIOPHARMA, INC., and EKR THERAPEUTICS, LLC,)))
Plaintiffs, v.)) Civil Action No. 1:13-cv-05723-NLH-AMD
SANDOZ INC., SANDOZ AG, and ACS DOBFAR INFO SA,))
Defendants.))

AMENDED COMPLAINT AGAINST SANDOZ INC., SANDOZ AG, AND ACS DOBFAR INFO SA

Plaintiffs Chiesi USA, Inc. ("Chiesi USA," formerly known as Cornerstone Therapeutics Inc.), Cornerstone BioPharma, Inc., and EKR Therapeutics, LLC ("EKR") (collectively

"Chiesi"), by its undersigned attorneys, for its Complaint against defendants Sandoz Inc. and Sandoz AG (individually and/or collectively "Sandoz"), and ACS Dobfar Info SA ("Dobfar") (Sandoz and Dobfar collectively, "Defendants") herein, allege as follows:

NATURE OF THE ACTION

1. This is an action for patent infringement arising under the patent laws of the United States, Title 35, United States Code, involving United States Patent No. 7,612,102 ("the '102 patent") (attached as Exhibit A hereto), United States Patent No. 7,659,291 ("the '291 patent") (attached as Exhibit B hereto), United States Patent No. 8,455,524 ("the '524 patent") (attached as Exhibit C hereto), and United States Patent No. 7,659,290 ("the '290 patent") (attached as Exhibit D hereto) (collectively "the Patents-in-Suit").

THE PARTIES

- 2. Plaintiff Chiesi USA (formerly known as Cornerstone Therapeutics Inc.) is a corporation organized and existing under the laws of the State of Delaware, having a place of business at 1255 Crescent Green Drive, Suite 250, Cary, North Carolina 27518.
- 3. Plaintiff Cornerstone BioPharma, Inc. is a corporation organized and existing under the laws of the State of Nevada, having a place of business at 1255 Crescent Green Drive, Suite 250, Cary, North Carolina 27518.
- 4. Plaintiff EKR (formerly known as EKR Therapeutics, Inc.) is a wholly-owned subsidiary of Chiesi USA, organized and existing under the laws of the State of Delaware, having a place of business at 1255 Crescent Green Drive, Suite 250, Cary, North Carolina 27518.
- 5. Upon information and belief, Sandoz Inc. is a corporation organized and existing under the laws of the State of Colorado, having its principal place of business at 506 Carnegie Center, Suite 400, Princeton, New Jersey 08540.

- 6. Upon information and belief, Sandoz AG is a corporation organized and existing under the laws of Switzerland, having a place of business at Lichtstraße 35 CH 4056 Basel BS Switzerland.
- 7. Upon information and belief, Sandoz Inc. is an affiliate of and/or related to Sandoz AG.
- 8. Upon information and belief, Sandoz Inc. acts at the direction of, under the control of, and for the direct benefit of Sandoz AG and is controlled and/or dominated by Sandoz AG.
- 9. Upon information and belief, Sandoz develops, manufactures, and distributes generic drugs throughout the United States, including in New Jersey.
- 10. Upon information and belief, Dobfar is a corporation organized and existing under the laws of Switzerland, having a place of business at CH-7748 Campascio, Switzerland.

JURISDICTION AND VENUE

- 11. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201, 2202 and/or 35 U.S.C. § 271.
- 12. This Court has personal jurisdiction over Sandoz because, *inter alia*: (i) Sandoz maintains a principal place of business in this judicial district; (ii) Sandoz has committed, induced, or contributed to acts of patent infringement in this judicial district; (iii) Sandoz resides and is doing business in this judicial district and maintains continuous, systematic, extensive, and pervasive contacts with this judicial district; (iv) Sandoz is registered as a drug manufacturer and wholesale drug distributor in the State of New Jersey under the registration number 5003732; (v) Sandoz has consented to the jurisdiction of this Court in numerous prior actions; and (vi) Sandoz has availed itself of the rights, benefits, and privileges of this Court by asserting claims and counterclaims in numerous prior actions in this judicial district. This Court may also exercise

personal jurisdiction over Sandoz because, *inter alia*: (i) Sandoz entered into a Manufacture and Supply Agreement with Dobfar to manufacture, use, offer for sale, and sell the generic nicardipine hydrochloride injection products that are the subject of the Abbreviated New Drug Application ("ANDA") giving rise to this action; (ii) Sandoz submitted and filed the ANDA giving rise to this action; and (iii) Sandoz availed itself of the rights, benefits, and privileges of this Court and agreed that its agreement with Dobfar is governed by New Jersey law and that the state and federal courts in New Jersey would have exclusive jurisdiction over disputes.

- 13. This Court has personal jurisdiction over Dobfar because, *inter alia*: (i) Dobfar has committed, induced, or contributed to acts of patent infringement in this judicial district; (ii) Dobfar entered into a Manufacture and Supply Agreement with Sandoz to manufacture, use, offer for sale, and sell the generic nicardipine hydrochloride injection products that are the subject of the ANDA giving rise to this action; (iii) Dobfar availed itself of the rights, benefits, and privileges of this Court and agreed with Sandoz that their agreement is governed by New Jersey law and that the state and federal courts in New Jersey would have exclusive jurisdiction over disputes; (iv) Dobfar has continuous, systematic, extensive, and pervasive contacts with this judicial district and markets, sells, and/or distributes pharmaceutical products in this judicial district, including through Sandoz, and derives substantial revenue from such products; (v) Dobfar has consented to the jurisdiction of this Court in prior actions; and (vi) Dobfar has availed itself of the rights, benefits, and privileges of this Court by asserting counterclaims in this judicial district.
 - 14. Venue is proper in this judicial district under 28 U.S.C. §§ 1391 and 1400(b).

FACTS AS TO ALL COUNTS

15. Chiesi USA is the current owner of New Drug Application ("NDA") No. 19-734, approved by the U.S. Food and Drug Administration ("FDA") for the manufacture and sale of

- Cardene® I.V. Premixed Injection, 0.1 mg/mL and 0.2 mg/mL. Cardene® I.V. is a nicardipine hydrochloride premixed injection for intravenous administration indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable.
- 16. The '102 patent, titled "Pre-mixed, Ready-to-Use Pharmaceutical Compositions" was duly and legally issued on November 3, 2009. The '102 patent is generally directed to pharmaceutical compositions comprising nicardipine hydrochloride.
- 17. The '291 patent, titled "Methods of Treatment with Pre-Mixed, Ready-to-Use Pharmaceutical Compositions" was duly and legally issued on February 9, 2010. The '291 patent is generally directed to methods of treatment with pharmaceutical compositions comprising nicardipine hydrochloride.
- 18. The '524 patent, titled "Methods of Treatment with Pre-mixed, Ready-to-Use Pharmaceutical Compositions" was duly and legally issued on June 4, 2013. The '524 patent is generally directed to methods of treatment with pharmaceutical compositions comprising nicardipine hydrochloride.
- 19. The '290 patent, titled "Methods of Preparing Pre-Mixed, Ready-to-Use Pharmaceutical Compositions" was duly and legally issued on February 9, 2010. The '290 patent is generally directed to methods of preparing pharmaceutical compositions comprising nicardipine hydrochloride. The '290 patent issued from U.S. Patent Application No. 12/407,551, a division of U.S. Patent Application No. 11/788,076 which issued as the '102 patent.
- 20. The Patents-in-Suit all claim priority to U.S. Provisional Application No. 60/793,074, filed on April 18, 2006. EKR has been assigned, and currently owns, all rights, title, and interest in the Patents-in-Suit.

- 21. Pursuant to 21 U.S.C. § 355(b)(1), the '102 patent, the '291 patent and the '524 patent are listed in FDA's publication titled "Approved Drug Products with Therapeutic Equivalence Evaluations" (commonly known as the "Orange Book") as covering Cardene® I.V. Premixed Injection.
- 22. Upon information and belief, Sandoz prepared, submitted, and filed Abbreviated New Drug Application No. 203978 ("Sandoz's ANDA") to the FDA under § 505(j) of the Federal Food, Drug, and Cosmetic Act ("FDCA") (codified at 21 U.S.C. § 355(j)) seeking approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation of generic Nicardipine HCl Intravenous Injection 0.1 mg/mL in sodium chloride and 0.2 mg/mL in sodium chloride ("Sandoz's Generic Products").
- 23. Upon information and belief, Sandoz and Dobfar are partners in a cooperative venture to develop, manufacture, use, distribute, sell, offer to sell, and/or import Sandoz's Generic Products.
- 24. Upon information and belief, Sandoz and Dobfar entered into a Manufacture and Supply Agreement dated July 27, 2011 ("the Agreement"), pursuant to which Sandoz manages the administrative activities related to Sandoz's ANDA and Dobfar is responsible for all development work related to Sandoz's ANDA and Sandoz's Generic Products. Upon information and belief, Sandoz has the right to assign its interest in the Agreement to a Sandoz affiliate without the consent of Dobfar.
- 25. Upon information and belief, Dobfar agreed to provide services, materials and information to support Sandoz's ANDA, and which Sandoz is using to obtain FDA approval for Sandoz's ANDA and Sandoz's Generic Products, including sourcing raw materials, formulating, manufacturing, performing analytical development, preparing and distributing technical

documents and reports, assembling data necessary for Sandoz's ANDA, providing responses to FDA issues, comments or questions, and performing stability studies.

- 26. Upon information and belief, Dobfar provided to Sandoz information and materials necessary for the submission, filing, maintenance, and/or approval of Sandoz's ANDA, including a current good manufacturing practices certification, a debarment certification and conviction statement, manufacturing site information, a pharmaceutical development report for Sandoz's Generic Products, data concerning Sandoz's Generic Products including certificates of analyses, and/or batch records for the manufacture of Sandoz's Generic Products.
- 27. Upon information and belief, Dobfar agreed to commercially manufacture, label, use, sell, offer for sale, package, ship, deliver and/or import Sandoz's Generic Products, including supplying Sandoz's Generic Products to Sandoz for Sandoz's exclusive right to distribute, market and/or sell such products in the United States.
- 28. Upon information and belief, Dobfar has the right to request transfer of ownership of Sandoz's ANDA to Dobfar.
- 29. Upon information and belief, Dobfar is a prime mover in the chain of events leading to infringement.
- 30. Sandoz sent a letter to Cornerstone Therapeutics Inc., Cornerstone BioPharma, Inc., and EKR Therapeutics, LLC purporting to provide notification that Sandoz's ANDA contains certifications under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (a "paragraph IV certification") with regard to the '102, '291, and '524 patents ("Sandoz's Notice Letter").
- 31. Sandoz's Notice Letter does not provide non-infringement contentions for any claim of the '102, '291, or '524 patents.

FIRST COUNT

(Infringement of the '102 Patent by Defendants)

- 32. Chiesi repeats and realleges each of the foregoing paragraphs as if fully set forth herein.
- 33. Upon information and belief, Sandoz seeks FDA approval for the manufacture, marketing, sale, and/or distribution of Sandoz's Generic Products.
- 34. Upon information and belief, Sandoz included a paragraph IV certification to the '102 patent to obtain approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation of Sandoz's Generic Products before the expiration of the '102 patent.
- 35. Upon information and belief, Sandoz will commercially manufacture, sell, offer for sale, and/or import Sandoz's Generic Products upon, or in anticipation of, FDA approval and before the expiration of the '102 patent.
- 36. Upon information and belief, as of the date of Sandoz's Notice Letter, Sandoz was aware of the statutory provisions and regulations set forth in 21 U.S.C. § 355(j)(2)(B)(iv)(II) and 21 C.F.R. § 314.95(c)(6).
- 37. The inclusion of a paragraph IV certification to the '102 patent in ANDA No. 203978 for the purpose of obtaining approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation of Sandoz's Generic Products before the expiration of the '102 patent is an act of direct and/or indirect infringement (including induced and/or contributory infringement) by Sandoz of one or more claims of the '102 patent under 35 U.S.C. § 271(e)(2)(A).
- 38. Upon information and belief, Sandoz's commercial manufacture, use, sale, offer for sale and/or importation into the United States of Sandoz's Generic Products that are the

subject of ANDA No. 203978 will infringe one or more claims of the '102 patent under 35 U.S.C. § 271 et seq., including § 271(a), § 271(b), and/or § 271(c).

- 39. Upon information and belief, Dobfar's agreement with Sandoz and Dobfar's provision of services, information and materials to support Sandoz's ANDA and that Sandoz is using to obtain FDA approval for its ANDA and Sandoz's Generic Products is an intentional act of infringement of one or more claims of the '102 patent under 35 U.S.C. § 271(e)(2)(A) directly and/or indirectly in a cooperative venture, including by inducement and/or contributory infringement.
- 40. Upon information and belief, Defendants have planned to commercially manufacture, sell, offer for sale, and/or import Sandoz's Generic Products upon, or in anticipation of, FDA approval and before expiration of the '102 patent.
- 41. Upon information and belief, Dobfar's commercial manufacture, use, sale, offer for sale and/or importation into the United States of Sandoz's Generic Products that are the subject of Sandoz's ANDA will infringe one or more claims of the '102 patent directly and/or indirectly under 35 U.S.C. § 271 et seq., including § 271(a), § 271(b), and/or § 271(c).
- 42. Upon information and belief, Defendants are partners in a cooperative venture, and their plan to commercially manufacture, use, sell, offer for sale and/or import Sandoz's Generic Products into the United States constitute acts of infringement of one or more claims of the '102 patent directly and/or indirectly under 35 U.S.C. § 271 et seq., including § 271(a), § 271(b), and/or § 271(c).
- 43. Upon information and belief, Defendants were and are aware of the existence of the '102 patent and acted without a reasonable basis for believing that they would not be liable

for infringement of the '102 patent, thus rendering this case "exceptional" under 35 U.S.C. § 285.

44. Defendants' infringement of the '102 patent has caused and will cause Chiesi to suffer irreparable harm. Defendants' infringement will continue unless enjoined by the Court. Chiesi has no adequate remedy at law and thus preliminary and permanent injunctions are appropriate to prohibit Defendants from infringing the '102 patent.

SECOND COUNT

(Infringement of the '291 Patent by Defendants)

- 45. Chiesi repeats and realleges each of the foregoing paragraphs as if fully set forth herein.
- 46. Upon information and belief, Sandoz seeks FDA approval for the manufacture, marketing, sale, and/or distribution of Sandoz's Generic Products.
- 47. Upon information and belief, Sandoz included a paragraph IV certification to the '291 patent to obtain approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation of Sandoz's Generic Products before the expiration of the '291 patent.
- 48. Upon information and belief, Sandoz will commercially manufacture, sell, offer for sale, and/or import Sandoz's Generic Products upon, or in anticipation of, FDA approval and before the expiration of the '291 patent.
- 49. Upon information and belief, as of the date of Sandoz's Notice Letter, Sandoz was aware of the statutory provisions and regulations set forth in 21 U.S.C. § 355(j)(2)(B)(iv)(II) and 21 C.F.R. § 314.95(c)(6).
- 50. The inclusion of a paragraph IV certification to the '291 patent in ANDA No. 203978 for the purpose of obtaining approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation of Sandoz's Generic Products before the expiration of the

- '291 patent is an act of direct and/or indirect infringement (including induced and/or contributory infringement) by Sandoz of one or more claims of the '291 patent under 35 U.S.C. § 271(e)(2)(A).
- 51. Upon information and belief, Sandoz's commercial manufacture, use, sale, offer for sale and/or importation into the United States of Sandoz's Generic Products that are the subject of ANDA No. 203978 will infringe one or more claims of the '291 patent under 35 U.S.C. § 271 et seq., including § 271(b) and/or § 271(c).
- 52. Upon information and belief, Dobfar's agreement with Sandoz and Dobfar's provision of services, information, and material to support Sandoz's ANDA and that Sandoz is using to obtain FDA approval for its ANDA and Sandoz's Generic Products is an intentional act of infringement of one or more claims of the '291 patent under 35 U.S.C. § 271(e)(2)(A) directly and/or indirectly in a cooperative venture, including by inducement and/or contributory infringement.
- 53. Upon information and belief, Defendants have planned to commercially manufacture, sell, offer for sale, and/or import Sandoz's Generic Products upon, or in anticipation of, FDA approval and before expiration of the '291 patent.
- 54. Upon information and belief, Dobfar's commercial manufacture, use, sale, offer for sale and/or importation into the United States of Sandoz's Generic Products that are the subject of Sandoz's ANDA will infringe one or more claims of the '291 patent indirectly under 35 U.S.C. § 271 et seq., including § 271(b) and/or § 271(c).
- 55. Upon information and belief, Defendants are partners in a cooperative venture, and their plan to commercially manufacture, use, sell, offer for sale and/or import Sandoz's

Generic Products into the United States constitute acts of infringement of one or more claims of the '291 patent indirectly under 35 U.S.C. § 271 et seq., including § 271(b) and/or § 271(c).

- 56. Upon information and belief, Defendants were and are aware of the existence of the '291 patent and acted without a reasonable basis for believing that they would not be liable for infringement of the '291 patent, thus rendering this case "exceptional" under 35 U.S.C. § 285.
- 57. Defendants' infringement of the '291 patent has caused and will cause Chiesi to suffer irreparable harm. Defendants' infringement will continue unless enjoined by the Court. Chiesi has no adequate remedy at law and thus preliminary and permanent injunctions are appropriate to prohibit Defendants from infringing the '291 patent.

THIRD COUNT

(Infringement of the '524 Patent by Defendants)

- 58. Chiesi repeats and realleges each of the foregoing paragraphs as if fully set forth herein.
- 59. Upon information and belief, Sandoz seeks FDA approval for the manufacture, marketing, sale, and/or distribution of Sandoz's Generic Products.
- 60. Upon information and belief, Sandoz included a paragraph IV certification to the '524 patent to obtain approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation of Sandoz's Generic Products before the expiration of the '524 patent.
- 61. Upon information and belief, Sandoz will commercially manufacture, sell, offer for sale, and/or import Sandoz's Generic Products upon, or in anticipation of, FDA approval and before the expiration of the '524 patent.

- 62. Upon information and belief, as of the date of Sandoz's Notice Letter, Sandoz was aware of the statutory provisions and regulations set forth in 21 U.S.C. § 355(j)(2)(B)(iv)(II) and 21 C.F.R. § 314.95(c)(6).
- 63. The inclusion of a paragraph IV certification to the '524 patent in ANDA No. 203978 for the purpose of obtaining approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation of Sandoz's Generic Products before the expiration of the '524 patent is an act of direct and/or indirect infringement (including induced and/or contributory infringement) by Sandoz of one or more claims of the '524 patent under 35 U.S.C. § 271(e)(2)(A).
- 64. Upon information and belief, Sandoz's commercial manufacture, use, sale, offer for sale and/or importation into the United States of Sandoz's Generic Products that are the subject of ANDA No. 203978 will infringe one or more claims of the '524 patent under 35 U.S.C. § 271 et seq., including § 271(b) and/or § 271(c).
- 65. Upon information and belief, Dobfar's agreement with Sandoz and Dobfar's provision of services, information, and material to support Sandoz's ANDA and that Sandoz is using to obtain FDA approval for its ANDA and Sandoz's Generic Products is an intentional act of infringement of one or more claims of the '524 patent under 35 U.S.C. § 271(e)(2)(A) directly and/or indirectly in a cooperative venture, including by inducement and/or contributory infringement.
- 66. Upon information and belief, Defendants have planned to commercially manufacture, sell, offer for sale, and/or import Sandoz's Generic Products upon, or in anticipation of, FDA approval and before expiration of the '524 patent.

- 67. Upon information and belief, Dobfar's commercial manufacture, use, sale, offer for sale and/or importation into the United States of Sandoz's Generic Products that are the subject of Sandoz's ANDA will infringe one or more claims of the '524 patent indirectly under 35 U.S.C. § 271 et seq., including § 271(b) and/or § 271(c).
- 68. Upon information and belief, Defendants are partners in a cooperative venture, and their plan to commercially manufacture, use, sell, offer for sale and/or import Sandoz's Generic Products into the United States constitute acts of infringement of one or more claims of the '524 patent indirectly under 35 U.S.C. § 271 et seq., including § 271(b) and/or § 271(c).
- 69. Upon information and belief, Defendants were and are aware of the existence of the '524 patent and acted without a reasonable basis for believing that they would not be liable for infringement of the '524 patent, thus rendering this case "exceptional" under 35 U.S.C. § 285.
- 70. Defendants' infringement of the '524 patent has caused and will cause Chiesi to suffer irreparable harm. Defendants' infringement will continue unless enjoined by the Court. Chiesi has no adequate remedy at law and thus preliminary and permanent injunctions are appropriate to prohibit Defendants from infringing the '524 patent.

FOURTH COUNT

(Infringement of the '290 Patent by Defendants)

- 71. Chiesi repeats and realleges each of the foregoing paragraphs as if fully set forth herein.
- 72. Upon information and belief, Sandoz seeks FDA approval for the manufacture, marketing, sale, and/or distribution of Sandoz's Generic Products.

- 73. Upon information and belief, Sandoz seeks FDA approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation of Sandoz's Generic Products before the expiration of the '290 patent.
- 74. Upon information and belief, Sandoz will commercially manufacture, sell, offer for sale, and/or import Sandoz's Generic Products upon, or in anticipation of, FDA approval and before expiration of the '290 patent.
- 75. Upon information and belief, the submission and/or filing of ANDA No. 203978 for the purpose of obtaining approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation of Sandoz's Generic Products before the expiration of the '290 patent is an act of direct and/or indirect infringement (including induced and/or contributory infringement) by Sandoz of one or more claims of the '290 patent under 35 U.S.C. § 271(e)(2)(A).
- 76. Upon information and belief, Sandoz's commercial manufacture, use, sale, offer for sale and/or importation into the United States of Sandoz's Generic Products that are the subject of ANDA No. 203978 before the expiration of the '290 patent will infringe one or more claims of the '290 patent under 35 U.S.C. § 271 et seq., including § 271(a), § 271(b), § 271(c) and/or § 271(g).
- 77. Upon information and belief, Dobfar's agreement with Sandoz and Dobfar's provision of services, information, and material to support Sandoz's ANDA and that Sandoz is using to obtain FDA approval for its ANDA and Sandoz's Generic Products is an intentional act of infringement of one or more claims of the '290 patent under 35 U.S.C. § 271(e)(2)(A) indirectly in a cooperative venture, including by inducement and/or contributory infringement.

- 78. Upon information and belief, Defendants have planned to commercially manufacture, sell, offer for sale, and/or import Sandoz's Generic Products upon, or in anticipation of, FDA approval and before expiration of the '290 patent.
- 79. Upon information and belief, Dobfar's commercial manufacture, use, sale, offer for sale and/or importation into the United States of Sandoz's Generic Products that are the subject of Sandoz's ANDA will infringe one or more claims of the '290 patent directly and/or indirectly under 35 U.S.C. § 271 et seq., including § 271(a), § 271(b), § 271(c), and/or § 271(g).
- 80. Upon information and belief, Defendants are partners in a cooperative venture, and their plan to commercially manufacture, use, sell, offer for sale and/or import Sandoz's Generic Products into the United States constitute acts of infringement of one or more claims of the '290 patent directly and/or indirectly under 35 U.S.C. § 271 et seq., including § 271(a), § 271(b), § 271(c) and/or § 271(g).
- 81. Upon information and belief, Defendants were and are aware of the existence of the '290 patent and acted without a reasonable basis for believing that they would not be liable for infringement of the '290 patent, thus rendering this case "exceptional" under 35 U.S.C. § 285.
- 82. Defendants' infringement of the '290 patent has caused and will cause Chiesi to suffer irreparable harm. Defendants' infringement will continue unless enjoined by the Court. Chiesi has no adequate remedy at law and thus preliminary and permanent injunctions are appropriate to prohibit Defendants from infringing the '290 patent.

PRAYER FOR RELIEF

WHEREFORE, Chiesi respectfully requests the following relief:

i. A judgment declaring that the '102 patent is valid and enforceable;

- ii. A judgment declaring that, pursuant to 35 U.S.C. § 271(e)(2)(A), the submission to the FDA and filing of ANDA No. 203978 with a paragraph IV certification to obtain approval for the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of Sandoz's Generic Products was an act of infringement of the '102 patent by Defendants directly and/or indirectly, including by inducement and/or contributory infringement;
- iii. A judgment declaring that, pursuant to 35 U.S.C. § 271 et seq., including § 271(e)(2)(A), § 271(a), § 271(b) and/or § 271(c), the commercial manufacture, use, sale, offer for sale and/or importation into the United States of Sandoz's Generic Products prior to the expiration of the '102 patent, including any regulatory extensions, will constitute an act of infringement by Defendants directly and/or indirectly, including by inducement and/or contributory infringement;
- iv. An order that, pursuant to 35 U.S.C. §§ 271(e)(4)(A), 281, and/or 283, the effective date of any approval of Sandoz's Generic Products shall be no earlier than the date on which the '102 patent expires including any regulatory extensions;
- v. A judgment pursuant to 35 U.S.C. §§ 271(e)(4)(B), 281, and/or 283, preliminarily and permanently enjoining Defendants and their officers, agents, servants, employees, and attorneys, and those persons in active concert or participation or privity with them or any of them, from engaging in the commercial manufacture, use, sale, offer for sale, and/or importation in the United States of the product that is the subject of ANDA No. 203978 until the expiration of the '102 patent including any regulatory extensions;
- vi. A judgment awarding Chiesi damages or other monetary relief, pursuant to 35 U.S.C. §§ 271(e)(4)(C) and/or 284, if Defendants commercially manufacture, use, sell, offer to

sell, and/or import any product that is the subject of ANDA No. 203978 that infringes the '102 patent;

- vii. A judgment declaring that infringement of the '102 patent is willful if Defendants commercially manufacture, use, sell, offer to sell, and/or import any product that is the subject of ANDA No. 203978 that infringes the '102 patent;
 - viii. A judgment declaring that the '291 patent is valid and enforceable;
- ix. A judgment declaring that, pursuant to 35 U.S.C. § 271(e)(2)(A), the submission to the FDA and filing of ANDA No. 203978 with a paragraph IV certification to obtain approval for the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of Sandoz's Generic Products was an act of infringement of the '291 patent by Defendants directly and/or indirectly, including by inducement and/or contributory infringement;
- x. A judgment declaring that, pursuant to 35 U.S.C. § 271 et seq., including § 271(e)(2)(A), § 271(b) and/or § 271(c), the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of Sandoz's Generic Products prior to the expiration of the '291 patent, including any regulatory extensions, will constitute an act of infringement by Defendants directly and/or indirectly, including by inducement and/or contributory infringement;
- xi. An order that, pursuant to 35 U.S.C. §§ 271(e)(4)(A), 281, and/or 283, the effective date of any approval of Sandoz's Generic Products shall be no earlier than the date on which the '291 patent expires including any regulatory extensions;
- xii. A judgment pursuant to 35 U.S.C. §§ 271(e)(4)(B), 281, and/or 283, preliminarily and permanently enjoining Defendants and their officers, agents, servants, employees, and attorneys, and those persons in active concert or participation or privity with them or any of them, from engaging in the commercial manufacture, use, sale, offer for sale, and/or importation

into the United States of the product that is the subject of ANDA No. 203978 until the expiration of the '291 patent including any regulatory extensions;

- xiii. A judgment awarding Chiesi damages or other monetary relief, pursuant to 35 U.S.C. §§ 271(e)(4)(C) and/or 284, if Defendants commercially manufacture, use, sell, offer to sell, and/or import any product that is the subject of ANDA No. 203978 that infringes the '291 patent;
- xiv. A judgment declaring that infringement of the '291 patent is willful if Defendants commercially manufacture, use, sell, offer to sell, and/or import any product that is the subject of ANDA No. 203978 that infringes the '291 patent;
 - xv. A judgment declaring that the '524 patent is valid and enforceable;
- xvi. A judgment declaring that, pursuant to 35 U.S.C. § 271(e)(2)(A), the submission to the FDA and filing of ANDA No. 203978 with a paragraph IV certification to obtain approval for the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of Sandoz's Generic Products was an act of infringement of the '524 patent by Defendants directly and/or indirectly, including by inducement and/or contributory infringement;
- xvii. A judgment declaring that, pursuant to 35 U.S.C. § 271 et seq., including § 271(e)(2)(A), § 271(b) and/or § 271(c), the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of Sandoz's Generic Products prior to the expiration of the '524 patent, including any regulatory extensions, will constitute an act of infringement by Defendants directly and/or indirectly, including by inducement and/or contributory infringement;
- xviii. An order that, pursuant to 35 U.S.C. §§ 271(e)(4)(A), 281, and/or 283, the effective date of any approval of Sandoz's Generic Products shall be no earlier than the date on which the '524 patent expires including any regulatory extensions;

- xix. A judgment pursuant to 35 U.S.C. §§ 271(e)(4)(B), 281, and/or 283, preliminarily and permanently enjoining Defendants and their officers, agents, servants, employees, and attorneys, and those persons in active concert or participation or privity with them or any of them, from engaging in the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the product that is the subject of ANDA No. 203978 until the expiration of the '524 patent including any regulatory extensions;
- xx. A judgment awarding Chiesi damages or other monetary relief, pursuant to 35 U.S.C. §§ 271(e)(4)(C) and/or 284, if Defendants commercially manufacture, use, sell, offer to sell, and/or import any product that is the subject of ANDA No. 203978 that infringes the '524 patent;
- xxi. A judgment declaring that infringement of the '524 patent is willful if Defendants commercially manufacture, use, sell, offer to sell, and/or import any product that is the subject of ANDA No. 203978 that infringes the '524 patent;
 - xxii. A judgment declaring that the '290 patent is valid and enforceable;
- xxiii. A judgment declaring that, pursuant to 35 U.S.C. § 271(e)(2)(A), the submission to the FDA and filing of ANDA No. 203978 with a paragraph IV certification to obtain approval for the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of Sandoz's Generic Products was an act of infringement of the '290 patent by Defendants directly and/or indirectly, including by inducement and/or contributory infringement;
- xxiv. A judgment declaring that, pursuant to 35 U.S.C. § 271 et seq., including § 271(e)(2)(A), § 271(a), § 271(b), § 271(c) and/or § 271(g), the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of Sandoz's Generic Products prior to the expiration of the '290 patent, including any regulatory extensions, will constitute an act of

infringement by Defendants directly and/or indirectly, including by inducement and/or contributory infringement;

xxv. An order that, pursuant to 35 U.S.C. §§ 271(e)(4)(B), 281 and/or 283, the effective date of any approval of Sandoz's Generic Products shall be no earlier than the date on which the '290 patent expires including any regulatory extensions;

and permanently enjoining Defendants and their officers, agents, servants, employees, and attorneys, and those persons in active concert or participation or privity with them or any of them, from engaging in the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the product that is the subject of ANDA No. 203978 until the expiration of the '290 patent including any regulatory extensions;

xxvii. A judgment awarding Chiesi damages or other monetary relief, pursuant to 35 U.S.C. §§ 271(e)(4)(C) and/or 284, if Defendants commercially manufacture, use, sell, offer to sell, and/or import any product that is the subject of ANDA No. 203978 that infringes the '290 patent;

xxviii. A judgment declaring that infringement of the '290 patent is willful if Defendants commercially manufacture, use, sell, offer to sell, and/or import any product that is the subject of ANDA No. 203978 that infringes the '290 patent;

xxix. A judgment declaring that, pursuant to 35 U.S.C. § 285, this is an exceptional case and awarding Chiesi its attorneys' fees and costs;

xxx. Such other and further relief as this Court may deem just and proper.

Of Counsel:

Edgar H. Haug Angus Chen Nicholas F. Giove Leann M. Clymer FROMMER LAWRENCE & HAUG LLP 745 Fifth Avenue New York, New York 10151 Telephone No.: (212) 588-0800 Facsimile No.: (212) 588-0500

Dated: June 18, 2014

Respectfully submitted,

By: s/ Michael R. Griffinger
Michael R. Griffinger
Sheila F. McShane
GIBBONS P.C.
One Gateway Center
Newark, New Jersey 07102-5310
Telephone No.: (973) 596-4500
Facsimile No.: (973) 596-0545

Attorneys for Plaintiffs Chiesi USA, Inc., Cornerstone BioPharma, Inc., and EKR Therapeutics, LLC

EXHIBIT A



US007612102B2

(12) United States Patent Duncan et al.

(10) Patent No.:

US 7,612,102 B2

(45) Date of Patent:

Nov. 3, 2009

(54) PRE-MIXED, READY-TO-USE PHARMACEUTICAL COMPOSITIONS

(75) Inventors: Michelle Renee Duncan, Glenview, IL (US); Supriya Gnpta, Sunnyvale, CA (US); David Hartley Hass, Fremont, CA (US); Norma V. Stephem, Skokie, IL (US); Camellia Zamiri, Fremont, CA (US)

(73) Assignee: EKR Therapeuties, Inc.

(*) Notice: Subject to any disclaimes, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 252 days.

(21) Appl. No.: 11/788,076

(22) Filed: Apr. 18, 2007

(65) Prior Publication Data

US 2007/0249689 A1 Oct. 25, 2007

Related U.S. Application Data

(60) Provisional application No. 60/793,074, filed on Apr. 18, 2006.

(51) Int. Cl. A61K 31/44 (2006.01)

(52) U.S. CL 514/354; 424/400

(56) References Cited

U.S. PATENT DOCUMENTS

	3,985,7	58	Á		10/1976	Murakami		
	4,711,9	02	Ă		12/1987	Semo		
	4,880,8	23	A	*	11/1989	Ognwa et al.	######################################	514/356
	4,940,5					MacFarlane		
	5,079,2	37	A		1/1992	Hum et al.		
	5,164,40	35	A	٠	11/1992	McFarlane et	al	514/354
	5,198,22					MacFarlane		
	RE34,6	8	E		5/1994	Ogawa		
	5,376,64	15	À		12/1994			
	5,519,01	Ź	A		5/1996	Fercej-Temel	iotov	
	5,904,92	ğ	A			Uekama		
	6,595,92	6	B1		7/2003	Larach		
001	7/011204	i.	A1			Bhowmick		
001	7/024416	б	Al		10/2007	Gupta		

FOREIGN PATENT DOCUMENTS

EP	0149475 B	l.	7/1985
EP	D162705 B	L	11/1985
GB	2228412 A		8/1990
WO	WO 01/07086		2/2001

OTHER PUBLICATIONS

Kaise, Barb, Patrick D. Ragan, and Hollie Shaner, Solutions to Health Care Waste: Life-Cycle Thinking and "Green" Purchasing, Environmental Health Perspectives, vol. 109, No. 3, Mar. 2001, pp. 1-4.* Pemponio, R., J. Flori, V. Cavrini, P. Muna, M. Cirri and F. Macstrelli, Photostability studies on aicardipine-cyclodextrin complexes by capillary electrophoresis, Journal of Pharmaceutical and Biomedical Analysis 35 (2004) 267-275.*

Yang et al., "Nicardipine versus nitroprusside infusion as antihypertensive fiterapy in hypertensive emergencies," J. Int Med Research, vol. 32(2):118-123 (Mar.-Apr. 2004).

Atlee et al., "The use of earnelol, alcardipine, or their combination to blunt hemodynamic changes after laryngoscopy and tracheal intubation," Anesth Analg, vol. 90:280-285 (Feb. 2000).

Aya et al., "Intravenous nicardipine for severe hypertension in preeclampsis.—effects on mother and foetns," Intensive Care Med., vol. 25(11):1277-1281 (Nov. 1999).

Choing et al., "Nicardipine intravenous bolus dosing for acutely decreasing arterial blood pressure during general anesthesia for cardiac operations; pharmacokinetics, pharmacodynamics, and associated effects on felt ventricular function," Anesth Analg, vol. 89:1116-1134 (Nov. 1999).

1133 (Nov. 1999).

Colson et al., "Haemodynamic heterogeneity and treatment with the calcium channel blocker nicardipine during phasochromocytoma surgery," Act Annesthesiol Scand., vol. 42(9):1114-1119 (Oct. 1998). Blatrous et al., "Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalcl," Intensive Care Med., vol. 28(9):1281-1286 (Jul. 26, 2002).

Fernandes et al., "Physiochemical characterization and in vitro dis-

Remandes et al., "Physiochemical characterization and in vitro dissolution behavior of nicardiplne-cyclodextrins inclusion compounds," Eur. J. of Pharma. Sci. 15: pp. 79-88, 2002.

Flynn et al., "Intravenous nicardipine for treatment of severe hypertension in children," J Pediatr., vol. 139(1):38-43 (Jul. 2001).

Kwak et al., "Comparison of the effects of nicardipine and sodium nitrograsside for control of increased blood pressure after coronary bypass graft surgery," J Int Med Res, vol. 32:342-350 (Jul.-Aug. 2004)

Vincent et al., "Intravenous nicardipine in the treatment of postopcrative arterial hypertension," J Cardiothorac Vasc Anesth, vol. 11(2):160-164 (Apr. 1997).

Non Final Office Action for U.S. Appl. No. 11/737,067, dated Oct. 29, 2008.

PDL Bioplazma, Inc.; "Cardens IV (aicardipine hydrochloxide);" Product Insert, Jan. 2006, USA.

Sweetana and Akers, "Solubility principles and practices for parenteral drug desage from development," PDA J Pharmaceutical

Science & Technology, 50(5):330-342 (1996).

Zhang et al., "The use of nicardipine for electroconvulsive fherapy: a dose-ranging study," Amesth Analg., vol. 100:378-381 (Feb. 2005).

Endoh et al., "Effects of nicardipine-, nitroglycerin-, and prostaglandin El-induced hypotension on human cerebrevascular carbon dioxide reactivity during propofol-fentanyl anesthesis," J Clin Anesth, vol. 11(7):545-549 (Nov. 1999).

Bernard et al., "Long-term hypotensive technique with nicasdipine and nitropruseide during isoflurans anesthesia for spinal surgery," Anesth Analg., vol. 75(2):179-185 (Aug. 1992).

Chen et al., "The comparative potentry of intravenous nicardipine and verapamil on the cardiovascular response to tracheal intubation," Acta Anandhesiol Sin., vol. 34(4):197-202 (Dec. 1996).

Song et al., "Optimal dose of nicardipine for maintenance of hemodynamic stability after trachest intubation and skin incision," Anesth Analg, vol. 85:1247-1251 (Dec. 1997).

Cheung et al., "Acute pharmacoltmetic and hemodynamic effects of intravenous bolus dosing of alcardipine," Am Heart I., vol. 119(2 Pt 2):43E-442 (Feb. 1990).

(Continued)

Primary Examiner—M P Woodward
Assistant Examiner—Lyndsey Beckhardt
(74) Attorney, Agent, or Firm—Lowenstein Sandler PC

(57) ABSTRACT

Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

15 Claims, 5 Drawing Sheets

Page 2

OTHER PUBLICATIONS

Yalkowsky et al., "Formulation-related problems associated with intravenous drug delivery," J Pharm Sciences, vol. 87(7):787-796 (Jul. 1998).

Mauria et al., "Solubilization of nicardipine hydrochloxide via complexation and salt formation," J Pharm Sciences, vol. 83(10):1418-1420 (Oct. 1994).

* cited by examiner


U.S. Patent

Nov. 3, 2009


Sheet 1 of 5


US 7,612,102 B2


FIG. 1





U.S. Patent Nov. 3, 2009 Sheet 2 of 5 US 7,612,102 B2
















U.S. Patent

Nov. 3, 2009

Sheet 5 of 5

US 7,612,102 B2





1

PRE-MIXED, READY-TO-USE PHARMACEUTICAL COMPOSITIONS

1. CROSS REFERENCE TO RELATED APPLICATIONS

This application claims benefit under 35 U.S.C. § 119(e) to U.S. Provisional application Ser. No. 60/793,074, filed Apr. 18, 2006, the contents of which are incorporated herein by reference.

2. BACKGROUND

Nicardipine hydrochloride ((±)-2-(henzyl-methyl amino) ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3, 15 5-pyridinedicarboxylate monohydrochloride) is a calcium ion influx inhibitor useful for the treatment of cardiovascular and cerebrovascular disorders (see, e.g., U.S. Pat. No. 3,985, 758). Nicardipine hydrochloride is currently sold in capsule form and in an injectable intravenous form. The capsule form 20 is marketed as CARDENE® and is available as an immediate release oral capsule and as an extended release oral capsule. The injectable intravenous form of CARDENE® is marketed in glass ampuls suitable for intravenous administration following dilution in a compatible intravenous fluid, such as 25 dextrose or sodium chloride (CARDENE® I.V.). Each milliliter of a CARDENE® I.V. ampul contains 2.5 mg nicardipine hydrochloride in water, 48.0 mg sorbitol, buffered to pH 3.5 with 0.525 mg citric acid monohydrate and 0.09 mg sodium hydroxide. For infusion, each milliliter of the diluted formu- 30 lation contains 0.1 mg of nicardipine hydrochloride, with a variable pH due to the diluent selected by the end user. U.S. Reissue Pat. No. 34,618 (a reissue of U.S. Pat. No. 4,880,823) describes an injectable composition of nicardipine hydrochloride that is stored in a light resistant brown ampul. U.S. 35 Pat. No. 5,164,405 describes a buffered pharmaceutical composition containing micardipine designed for parentaral administration, that is also stored in an ampul.

The requirement for diluting CARDHNE® I.V. before use is associated with a number of disadvantages. One disadvantage is that the diluted solution is only stable for 24 hours at room temperature. Another disadvantage is that the pH of the diluted formulation varies depending on the choice of diluent. Since CARDENE® I.V. can be used under emergency conditions to control blood pressure, dilution of the concentrated 45 ampul formulation consumes valuable time that could be used under a patient. Other disadvantages associated with the dilution step include the potential for contamination, dosage errors, and safety hazards associated with the use of glass ampuls.

The phannaceutical compositions and methods described herein overcome these disadvantages. In particular, the ready-to-use, injectable formulations described herein are stable, allow medical personal to use prepared containers containing an injectable formulation off the shelf without additional 55 preparation, swoid potential contamination problems, and eliminate dosage errors.

3. SUMMARY

Described herein are ready-to-use, premixed pharmaceutical compositions of nicardipine or pharmaceutically acceptable salts thereof, which are suitable for continuous intravenous infusion. By providing ready-to-use, premixed pharmaceutical compositions with a buffered pH, these pharmaceutical compositions are stable at room temperature for at least one year. When stored at room temperature, the pharmaceutical compositions exhibit between 0% to about 15% loss of drug and between 0% to about 3% (w/w) total impurity formation over an eighteen to twenty four month period.

Additional benefits of the pre-mixed, ready-to-use, injectsable pharmacentical compositions include convenience and ease of use as compared to an ampul formulation, improved safety for patients due to elimination of dosage errors and solution contamination, reduction of medical waste, and ease of administration in emergency situations.

The present disclosure relates to premixed pharmaceutical compositions comprising nicardipine or pharmaceutically acceptable saits thereof, one or more tonicity agents, and a buffer. In some ambodiments, the compositions optionally comprise one or more cosolvents. Nicardipine hydrochloride can be present at concentrations between about 0.05 mg/ml to about 15 mg/ml. Typically, the concentration range for nicardipine hydrochloride is between about 0.1 mg/ml to about 0.2 mg/ml. Optionally, the pharmaceutical compositions can comprise acids and bases.

The pharmaceutical compositions described herein require no dilution prior to administration and typically have a pH within the range from about 3.6 to about 4.7. The compositions can be administered by parenteral routes, including, subcutaneous, intramuscular, intravenous, intra-atrial, or intra-arterial continuous infusion to a patient. The compositions are suitable for the short-term treatment of hypertension when oral therapy is not feasible or desirable.

Methods for making a premixed nicardipine hydrochloride formulation suitable for intravenous administration comprise the steps of providing an effective amount of nicardipine hydrochloride in a solution comprising one or more tonicity agents, a buffer, and optionally, one or more cosolvents. Sufficient water is added to make up the final volume. If required, the pH of the solution can be adjusted using a suitable pH adjuster. The compositions are dispensed in pharmaceutically acceptable containers for storage and direct administration to patients.

4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 provides a diagrammatic illustration of the effect of various diluents on the pH and stability of an ampul formulation post dilution over a twenty four hour period at room temperature.

FIGS. 2A and 2B provide a diagrammatic illustration of the effect of pH on drug loss (FIG. 2A) and total impurity formation (FIG. 2B) in a premixed non-sorbitol formulation comprising 0.1 mg/ml nicardipine hydrochloride, 0.1 mM citric acid and 5% descrose at 40° C.;

FIGS. 3A and 3B provide a diagrammatic illustration of the effect of pH on drug loss (FIG. 3A) and total impurity formation (FIG. 3B) in a premixed non-sorbital formulation comprising 0.1 mg/ml nicardipins hydrochloride, 0.1 mM citric acid and 0.9% saline at 40° C.;

FIGS. 4A and 4B provide a diagrammatic illustration of the effect of nicardipine concentration on impurity formation in non-sorbitol dextrose formulations comprising 0.1 mg/ml nicardipine hydrochloride, 0.1 mM citrate, 5% dextrose, or 0.2 mg/ml nicardipine hydrochloride, 0.2 mM citrate and 5% dextrose after aix months at 40° C. (FIG. 4A); and, in non-sorbitol saline formulations comprising 0.1 mg/ml nicardipine hydrochloride, 0.1 mM citrate, 0.9% saline, or 0.2 mg/ml nicardipine hydrochloride, 0.2 mM citrate and 0.9% saline after 3 months at 40° C. (FIG. 4B); and

FIGS. 5A and 5B provide a diagrammatic illustration of the affect of incompatible (FIG. 5A) and compatible (FIG. 5B) plastic film composition on product stability at 40° C. in a

premixed non-sorbitol formulation comprising 0.2 mg/ml micardipine HCL, 0.2 mM citric acid, 5% dextrose, at a pH of 4.0 to 4.2.

5. DETAILED DESCRIPTION

The premixed pharmaceutical compositions described herein comprise nicardipine or a pharmaceutically acceptable salt thereof as the active ingredient, at least one tonicity agent and a buffer. As used herein, the term "pre-mixed" refers to a 10 pharmaceutical composition that does not require reconstitution or dilution before administration to a patient. In contrast to smpul formulations comprising micardipine hydrochloride that must be diluted prior to use in a diluent and container selected by hospital personnel, the premixed pharmaceutical 15 compositions provided herein are stable at room temperature for 6 months or longer due to the inclusion of a buffer capable of maintaining the pH within an optimal pH range, which is typically between 3.6 to about 4.7. In some embodiments, suitable pH adjusters and/or cosolvents are added to the pharmaceutical compositions.

5.2 Premixed Pharmaceutical Compositions

The production of stable, ready-to-use, premixed pharmaceutical compositions comprising nicardipine and/or its pharmaceutically acceptable salts as the active ingredient presents different development hardles than does the development of the concentrated ampul product sold commercially as CARDENE® 1.V. As shown in FIG. 1, the percent of nicardipine remaining in solution decreases as function of pH over a twenty-four hour peciod. The percent decrease in nicardipine varies with the diluent and container chosen by the hospital staff.

As described in the Examples, pH (see, also, e.g., FIGS. 2A, 2B, 3A and 3B), the concentration of the active ingredient (see, also, e.g., FIGS. 4A and 4B), and the composition of the container material (see, also, e.g., FIGS. SA and SB) affect the stability of the active ingredient and the formation of impurities. Thus, the development of a stable, ready-to-use premixed pharmaceutical composition requires simultaneous optimization of pH and nicardipine hydrochloride concentration, as well as selection of a pharmaceutically compatible container. The ready-to-use pharmacentical compositions described herein exhibit 0% to 15% drop in drug concentration and 0% to 3% formation of impurities when maintained at room temperature for 6 to at least 24 months. Typically, the pharmaceutical compositions are stable when maintained at room temperature for at least 6 months, at least 12 months, at least 18 months, and at least 24 months. The compositions are also stable over extended periods of time when maintained at temperatures from about 2° to 8° C. The term "stable", as used herein, means remaining in a state or condition that is suitable for administration to a patient.

Compounds for use according to the compositions and methods described herein that can contain one or more asymmetric centers can occur as racemates, racemic mixtures, and as single enantiomers. Accordingly, the compositions and methods described herein are meant to comprehend all isomeric forms of such compounds.

The premixed pharmaceutical compositions described so herein comprise nicardipine and/or its pharmaceutically acceptable salts. Nicardipine, its pharmaceutically acceptable salts, preparation, and use are known in the art (see, e.g., U.S. Pat. No. 3,985,758, incorporated herein by reference its entirety). Examples of pharmaceutically acceptable salts of nicardipine include hydrochlorides, sulfates, phosphates, acctates, fumarates, maleates and tarrates.

Typically, the premixed pharmaceutical compositions comprise 0.05-15 mg/ml nicardipine or a pharmaceutically acceptable salt thereof. For example, suitable concentrations of nicardipine or a pharmaceutically acceptable salt thereof, include, but are not limited to: 0.05-0.1 mg/ml, 0.1-15 mg/ml, 0.1-10 mg/ml, 0.1-5 mg/ml, 0.1-3.0 mg/ml, 0.1-2.0 mg/ml, 0.5 mg/ml,

In some embodiments, the premixed pharmaceutical compositions comprise nicardipine hydrochloride as the active
ingradiant at a concentration sufficient to permit intravenous
administration at a concentration between 0.1 mg/ml to 0.2
mg/ml. In some embodiments, the concentration of nicardipine hydrochloride suitable for use in the compositions and
methods described herein includes, but is not limited to, at
least about 0.1 mg/ml. In other embodiments, the concentration of nicardipine hydrochloride suitable for use in the compositions and methods described herein includes, but is not
limited to, at least about 0.2 mg/ml.

In some embodiments, the premixed formulation comprises, in addition to micardipine and/or its pharmaceutically acceptable salts, a buffer that has sufficient buffering capacity to maintain the desired pH range throughout the shelf-life of the product. As shown in FIGS. 2A and 2B, pH is important for the long term stability of nicardipine in the premixed pharmaceutical compositions. Although the pH of the premixed pharmaceutical compositions can range from between about 3.0 to about 7.0, pharmaceutical compositions having a pH within the range of about 3.6 to about 4.7 exhibit a lower percentage of drug degradation and total impurities (See FIGS. 2A, 2B, 3A and 3B). Accordingly, suitable pH ranges for use in the premixed pharmaceutical compositions include, but are not limited to, pH range of at least about 3.0, at least about 3.1, at least about 3.2, at least about 3.3, at least about 3.4, at least about 3.5, at least about 3.6, at least about 3.7, at least about 3.8, at least about 3.9, at least about 4.0, at least about 4.1, at least about 4.2, at least about 4.3, at least about 4.4, at least about 4.5, at least about 4.6, at least about 4.7, at least about 4.8, at least about 4.9, at least about 5.0, at least about 5.2, at least about 5.5, at least about 6.0, at least about 6.5, at least about 7.0.

In some embodiments, the pH of the premixed pharmaceutical compositions is between about 3.0 to about 5.0. In other embodiments, the pH of the premixed pharmaceutical compositions is between about 3.6 to about 4.7. In other embodiments, the pH of the premixed pharmaceutical compositions is between about 4.0 to about 4.4. In yet other embodiments, the pH of the premixed pharmaceutical compositions is 4.2.

Buffers suitable for use in the pharmaceutical compositions described herein include, but are not limited to, pharmaceutically acceptable salts and acids of acetate, glutamate, citrate, tartrate, benzoate, lactate, histidine or other amino scids, gluconate, phosphate, malate, succinate, formate, propionate, and carbonate, "Pharmaceutically acceptable" is used herein in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Accordingly, the term "pharmaceutically acceptable salt' references salt forms of the active compounds which are prepared with counter ions which are nontoxic under the conditions of use and are compatible with a stable formulation. The concentration of the buffer in the formulation can be expressed in mg/ml, g/L or as a molar concentration. In typical embodiments, from about 0.0001 mg/ml to about 100 mg/ml of a suitable buffer is present in the pharmaceutical compositions. Thus, the premixed pharmaceutical compositions can comprise from about 0,0001 to about 0.001 mg/ml of a suitable buffer, from about 0.001 to

about 0.01 mg/ml of a suitable buffer, from about 0.01 to about 0.1 mg/ml of a suitable buffer, from about 0.1 to 1 mg/ml of a suitable buffer, from about 1 to about 5 mg/ml of a suitable buffer, from about 5 to about 10 mg/ml of a suitable buffer, from about 10 to about 15 mg/ml of a suitable buffer. from about 15 to about 20 mg/ml of a suitable buffer, from about 20 to about 25 mg/ml of a suitable buffer, from about 25 to about 50 mg/ml of a suitable buffer, from about 50 to about 75 mg/ml of a suitable buffer, and from about 75 to about 100 mg/ml of a suitable buffer.

Alternatively, the buffer concentration can be expressed as molar concentrations. In typical embodiments, from about 0.1 to 100 mM of a suitable buffer is present in the pharmacentical compositions. Thus, the premixed pharmaceutical compositions can comprise a suitable buffer having a concer- 15 tration from about 0.1 to about 100 mM, from about 0.1 to about 0.5 mM, from about 0.5 to about 1.0 mM, from about 1.0 to about 5 mM, from about 5 to about 10 mM, from about 10 to about 15 mM, from about 15 to about 25 mM, from from about 75 to about 100 mM.

In some embodiments, the premixed pharmacoutical compositions further comprise a pH adjuster. Suitable pH adjusters typically include at least an acid or a salt thereof, and/or a base or a salt thereof. Acids and bases can be added on an as 25 peeded basis in order to achieve a desired pH. For example, if the pH is greater than the desired pH, an acid can be used to lower the pH to the desired pH. Acids suitable for use in premixed pharmaceutical compositions include, but are not limited to, hydrochloric acid, phosphoric acid, citric acid, 30 ascorbic acid, acetic acid, sulphuric acid, carbonic acid and nitric acid. In some embodiments, hydrochloric acid is used to adjust the pH. By way of another example, if the pH is less than the desired pH, a base can be used to adjust the pH to the desired pH. Bases suitable for use in premixed pharmacenti- 35 cal compositions include, but are not limited to, sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, sodium citrate, sodium acetate, and magnesium hydroxide. In some embodiments, sodium hydroxide is used to adjust the pH.

In some embodiments, the premixed pharmaceutical compositions further comprise one or more tonicity agents. Typically, tonicity agents are used to adjust the esmolality of the premixed pharmaceutical compositions to bring it closer to the osmotic pressure of body fluids, such as blood or plasma. 45 In some embodiments the torricity of the premixed formulation can be modified by adjusting the concentration of buffer and/or other components present in the premixed formula-

Provided that the compositions are physiologically com- 50 patible, the compositions do not require any particular osmolality. Thus, the compositions can be hypotonic, isotonic or hypertonic. Typically the premixed pharmaceutical compositions have a tonicity between about 250 to about 350 mOam/

Suitable tonicity agents for use in the premixed pharmacentical compositions include, but are not limited to, anhydrous or hydrous forms of sodium chloride, dextrose, sucrose, xylital, froctose, glycerol, sorbital, mannital, potassium chloride, mannose, calcium chloride, magnesium chloride and so in the solubilization of nicardipine and/or a pharmaceutically other inorganic salts. The quantity of the torneity agent in the formulation can be expressed in mg/ml or in g/L. In typical embodiments, the tonicity agent(s) is present from about 1 mg/ml to about 90 mg/ml. Thus, the premixed pharmaceutical compositions can comprise one or more tonicity agents at 65 about 1-5 mg/ml, at about 5-10 mg/ml, at about 10-15 mg/ml, at about 15-25 mg/ml, at about 25-50 mg/ml, at about 50-60

mg/ml, at about 60-70 mg/ml, at about 70-80 mg/ml, and at about 80 to 90 mg/ml, as well as combinations of the above

Alternatively, the tonicity agent concentration is measured in weight/volume percent. In typical embodiments, the tonicity agent(s) is present from about 0.1% to about 10%. For example, suitable tonicity agent concentrations include, but are not limited to, from about 0.1% to about 0.2%, from about 0.2% to about 0.3%, from about 0.3% to about 0.4%, from about 0.4% to about 0.5%, from about 0.5% to about 0.6%, from about 0.6% to about 0.7%, from about 0.7% to about 0.8%, from about 0.8% to about 0.9%, from about 0.9% to about 1%, from about 1% to about 2%, from about 2% to about 5%, from about 3% to about 4%, from about 4% to about 5%, from about 5% to about 6%, from about 6% to about 7%, from about 7% to about 8%, from about 8% to about 9%, and from about 9% to about 10%, as well as combinations of the above ranges.

In some embodiments, the tonicity agent is dectrose. Typiabout 25 to about 50 mM, from about 50 to about 75 mM, and 20 cally, the concentration of dextrose suitable for use in the premixed pharmaceutical compositions is between about 2.5% (w/v) to about 7.5%. By way of example, mitable dextrose concentrations include, but are not limited to, from about 2.5% to about 3%, from about 3% to about 3.5%, from about 3.5% to about 4% (which is equivalent to about 40 mg/ml), from about 4% to about 4.5%, from about 4.5% to about 5% (which is equivalent to about 50 mg/ml), from about 5% to about 5.5%, from about 5.5% to about 6% (which is equivalent to about 60 mg/ml), from about 6% to about 6.5%, from about 6.5% to about 7%, as well as combinations of the above ranges.

> In some embodiments, the tonicity agent is sodium chloride. Typically, the concentration of sodium chloride suitable for use in the premixed pharmaceutical compositions is between about 0.1% (w/v) to about 1.8%. By way of example, suitable sodium chloride concentrations include, but are not limited to, from about 0.1% to about 0.2%, from about 0.2% to about 0.3%, from about 0.3% to about 0.4%, from about 0.4% to about 0.5%, from about 0.5% to about 0.6%, from about 0.6% to about 0.7%, from about 0.7% to about 0.8% (which is equivalent to 8 mg/ml), from out 0.8% to about 0.9% (which is equivalent to 9 mg/ml), from about 0.9% to about 1.0%, from about 1% to about 1.2%, from 1.2% (which is equivalent to 12 mg/ml) to about 1.4%, from about 1.4% to about 1.6%, and from about 1.6% to about 1.8%.

In some embodiments, the premixed pharmaceutical compositions comprise two, three, four, or more tonicity agents. In these embodiments, the concentration of each tonicity agent is typically less than the concentration that is used when only a single agent is present in the premixed formulation. For example, if the premixed formulation comprises sorbitol at 1.92 mg/ml, a suitable concentration of sodium chloride is 8.6 mg/ml. By way of another example, if the premixed formulation comprises 1.92 mg/ml sorbitol, a sultable concentration of dextrose is 48 mg/ml.

In some embodiments, the premixed pharmaceutical compositions further comprise one or more cosolvents. A "cosolvent" is a solvent which is added to the aqueous formulation in a weight amount which is less than that of water and assists acceptable salt thereof, cahances stability of the premixed formulation, and/or adjusts the osmolality of the premixed pharmaceutical compositions. Cosolvents suitable for use in the premixed pharmaceutical compositions include, but are not limited to, glycols (e.g., polyethylene glycol, propylene glycol), ethanol, and polyhydric alcohols (e.g., sorbitol, mannitol, xylitol).

The quantity of the cosolvent used in the formulation can be expressed in mg/ml or in g/L. In typical embodiments, the cosolvent(s) is present from about 1 mg/ml to about 100 mg/ml. Thus, the premixed pharmaceutical compositions can comprise one or more cosolvent(s) at about 1 to about 2 mg/ml, at about 2 to about 3 mg/ml, at about 3 to about 4 mg/ml, at about 4 to about 5 mg/ml, at about 5 to about 10 mg/ml, at about 10 to about 15 mg/ml, at about 15 to about 25 mg/ml, at about 25 to about 50 mg/ml, at about 50 to about 60 .mg/ml, at about 60 to about 70 ing/ml, at about 70 to about 80 mg/ml, at about 80 to 90 mg/ml, and at about 90 to 100 mg/ml, as well as combination of the above ranges.

Alternatively, the cosolvent concentration is measured in weight/volume percent. In typical embodiments, the cosolvent(s) is present from about 0.1% to about 25%. For example, suitable cosolvent concentrations include, but are not limited to, at least about 0.1% to 0.3%, from about 0.3% to about 0.5%, from about 0.5% to about 0.7%, from about 0.7% to about 0.9%, from about 0.9% to about 1%, from 20 about 1% to about 3%, from about 3% to about 5%, from about 5% to about 7%, from about 7% to about 9%, from about 9% to about 11%, from about 11% to about 13% from about 13% to about 15%, from about 15% to about 20%, and from about 20% to about 25%, as well as combination of the 2 above ranges.

In some embodiments, the premixed pharmaceutical compositions further comprise one or more cyclodextrins. Due to plexes, or inclusion complexes, with a variety of organic and inorganic molecules. Complexes of nicardipine with cyclodextrins have been described (see, e.g., U.S. Pat. No. 5,079, 237 which describes an inclusion complex of nicardipine or its hydrochloride with alpha-cyclodextrin, beta-cyclodextrin 35 or gamma-cyclodextrin; U.S. Pat. No. 5,519,012 which describes inclusion complexes of dihydropyridines, including nicardipine, with hydroxy-alkylated-β-cyclodextrins; and, U.S. Pat. No. 5,904,929 which describes numerous drugs in a pharmacentical composition with per-C2-18 acylated cyclodextrins). None of the above references discloses a dinydropyridine in combination with a cyclodextrin comprising a sulfate group. An example of a commercially available sulfated cyclodextrin is CAPTISOL®, CAPTISOL® is a polyanionic β-cyclodextrin derivative with a sodium sulfonate salt that is separated from the lipophilic cavity by a butyl other spacer group, or sulfobutylether. Methods for making the sulfoalkyl ether cyclodextrin derivatives are well known in the art and are taught in U.S. Pat. No. 5,376,645. Methods for 50 forming complexes of the derivatives with a drug are also well known in the art as disclosed in U.S. Pat. No. 5,376,645.

The cyclodextrin concentration can be measured in weight/ volume percent. In typical embodiments, cyclodextrin(s) is present from about 0.1% to about 25%. For example, suitable 55 cyclodextrin(s) concentrations include, but are not limited to, at least about 0.1% to 0.3%, from about 0.3% to about 0.5%, from about 0.5% to about 0.7%, from about 0.7% to about 0.9%, from about 0.9% to about 1%, from about 1% to about 3%, from about 3% to about 5%, from about 5% to about 7%, $_{50}$ from about 7% to about 9%, from about 9% to about 11%, from about 11% to about 13% from about 13% to about 15%, from about 15% to about 20%, and from about 20% to about

Examples of stable, premixed pharmaceutical composi- 65 tions comprising the active ingredient, a tonicity agent, a buffer and optionally, a cosolvent are shown in Table 1.

TABLE 1

5	Active Ingredient	Tanicity Agent(s) (mg/ml)	Buffer (mg/ml)	Conclvent (mg/ml)	pН
	nicardipine hydrochloride (0.1 mg/ml)	NaCl (8.6 mg/ml)	Citric seid, anhydrous (0.0192 mg/mi)	Sorbitol (1.92 mg/ml)	3,6-4,7
10	(0.1 mg/ml)	Destrose, hydrous (48 mg/ml)	Citric sold, anhydrous (0.0192 mg/ml)	Sorbitol (1.92 ang/ml)	3,6-4.7
	nicerdipine hydrochloride (0.1 mg/ml)	NaCi (9 mg/mi)	Citric soid, anhydrous (0.0192 mg/ml)	None	3.6-4.7
15	nicerdipine hydrochloride (0.1 mg/ml)	Destrose, hydrous (50 mg/ml)	Citric soid, anhydrous (0.0192 mg/ml)	None	3.6-4.7
	nicardipine hydrochloride (0.2 mg/ml)	NeCl (9 mg/ml)	Citrio acid, anhydrous (0.0354 mg/m/)	None	3.6-4.7
20	nicardipine hydrochloride (0.2 mg/ml)	Destrose, hydrous (50 mg/ml)	Citric seid, anhydrous (0.0384 mg/ml)	None	3.6-4.7
	nicardipine hydrochloride (0.2 mg/ml)	NaCl (6.3 mg/ml)	Citric said, anhydraus (0.0384 mg/ml)	Sorbitol (3.84 mg/ml)	3.6-4.7
15	nicardipins hydrahlorids (0.2 mg/ml)	Dextrose, hydrour (46 mg/ml)	Citric sold, anhydrous (0.0384 mg/ml)	Sorbitol (3.84 mg/ml)	3.6-4.7

In some embodiments, the pharmaceutical compositions are any as described in U.S. Provisional Application Ser. No. their structure, cyclodextrins have the ability to form com- 30 60/793,084, filed Apr. 18, 2006, which is incorporated herein by reference.

The order in which various components comprising the compositions is added to the buffered solution is not critical. provided that the resulting compositions are stable and are suitable for continuous intravenous infusion. Accordingly, the compositions described herein can be made by prepared in a number of different ways. For example, in some embodiments, the compositions can be prepared by adding buffer, a tonicity agent and/or a cosolvent to water; adding nicardipine to the buffered water solution; adding an pH adjuster to achieve the desired pH; and then adding sufficient water to make up the final volume. If necessary, the pH can be readjusted to achieve the desired pH range. By way of another 45 example, the compositions can be prepared by adding huffer and nicardinine or a pharmaceutically acceptable salt thereof to water, adding a tonicity agent and/or cosolvent, adjusting the pH to achieve the desired pH range; and then adding sufficient water to make up the final volume. By way of another example, a cosolvent can be added prior to the addition of nicardipine or a pharmaceutically acceptable salt thereof, and a tonicity agent can be added after the addition of nicardipine or a pharmaceutically acceptable salt thereof. By way of another example, a tonicity agent can be added prior to the addition of nicardipine or a pharmaceutically acceptable salt thereof, and a cosolvent can be added after the addition of nicardipine or a pharmaceutically acceptable salt thereof. By way of another example, the compositions can be prepared by adding buffer, tonicity agent and/or cosolvent to water; adjusting the pH to a first pH range suitable for dissolving nicardipine (for example, less than pH 3.6); adding nicardipine or a pharmacentically acceptable salt thereof; adjusting the pH to achieve the desired final pH range; and then adding sufficient water to make up the final volume.

In some embodiments, pharmaceutical compositions comprising nicardipine hydrochloride, dextrose, and citric buffer at pH 3.6-4.7 can be prepared by adding citric acid to water.

9

adding dextrose to the buffered water, adding nicardipine hydrochloride to the buffered water solution, adjusting the pH if necessary to the range 3.6-4.7, and adding sufficient water to make up the final volume. If necessary, the pH can be readjusted to between about 3.6 to about 4.7.

In some embodiments, pharmaceutical compositions comprising micardipine hydrochloride, sodium chloride, and citrate buffer at pH 3.6 to about 4.7 can be prepared by adding citric acid to water, adding nicardipine to the buffered water solution, adding sodium chloride to the huffered water solution, adjusting the pH to between about 3.6 to about 4.7, and adding sufficient water to make up the final volume. If sorbital is included in the formulation, sorbital is added at the same time as the citric acid.

In some embediments, the pharmaceutical compositions is can be prepared by adding nicardipine or a pharmaceutically acceptable sait thereof to an acidic solution having a pH less than 5.0. For example, the acidic solution can be prepared by adding an acidic component of a buffer system. A buffer, one or more tonicity agents, and/or cosolvents can be added to the 20 acidic solution before or after dissolving the nicardipine. Sufficient water is then added to make up the final volume. If necessary, the pH of the composition can be adjusted to between about 3.6 to about 4.7.

In some embodiments, the pharmaceutical compositions can be made by adding nicardipine or a pharmaceutically acceptable sait thereof to a solution that has been heated to a temperature greater than 35° C.; adding buffer, one or more tonicity agents and/or cosolvents to the acidic solutions; and adding sufficient water to make up the final volume. If necessary, the pH of the composition can be adjusted to between about 3.6 to about 4.7.

The pharmaceutical compositions can be packaged for use in a variety of containers. The compositions are preferably packaged in a pharmaceutically acceptable container, such as 35 an intravenous bag or bottles. Due to the light sensitivity of nicardipine, packages can be used that reduce the amount of light which can reach the composition. For example, in some embodiments, the container may, optionally, further comprise a light barrier, such as an aluminum overpouch or a 40 centon.

In some embodiments, the premixed pharmaceutical compositions are dispensed in intravenous bags, such as pre-mix bags and admix bags. Intravenous bags are well known in the art and commercially available. Examples of intravenous 45 bags include, but are not limited to: GALAXY®, INTRAVIA®, SOLOMIX®, STEDIM® 71, STEDIM® 100, VIAPLEX®, EXCEL®, VISIV®, VIAPLO™, ADDEASEØ, ADD-VANTAGE®, DUPLEX™, FIRST CHOICE™, PROFYFLEX™ and BFS™.

In some embodiments, the components of the bag that come into contact with the pharmaceutical compositions should not contain polar polymers, such as polyvinyl chloride (PVC) and ethylene vinyl acctate (EVA). Examples of hags that do not contain polar polymers and thus, are suitable for 55 use in these embodiments, include, but are not limited to, GALAXY®, EXCHL®, VISIV®, and VIAPLO™.

Procedures for filling pharmaceutical compositions in pharmaceutically acceptable containers, and their subsequent processing are known in the art. These procedures can be used so to produce sterile pharmaceutical drug products often required for health care. See, e.g., Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), "Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications 55 for Human and Veterinary Drug Products", (November 1994). Examples of suitable procedures for producing sterile

pharmaceutical drug products include, but are not limited to, terminal moist heat sterilization, ethylene oxide, radiation (i.e., gamma and electron beam), and sceptic processing techniques. Any one of these sterilization procedures can be used to produce the sterile pharmaceutical compositions described

In some embodiments, sterile pharmaceutical compositions can be prepared using asceptic processing techniques. Sterility is maintained by using sterile materials and a controlled working environment. All containers and apparatus are sterilized, preferably by heat sterilization, prior to filling. Then, the container is filled under asceptic conditions, such as by passing the composition through a filter and filling the units. Therefore, the compositions can be sterile filled into a container to avoid the heat stress of terminal sterilization.

In some embodiments, the compositions are terminally sterilized using moist beat. Terminal sterilization can be used to destroy all viable microorganisms within the final, sealed container containing the pharmaceutical composition. An autoclave is typically used to accomplish terminal heat-sterilization of drug products in their final packaging. Typical autoclave cycles in the pharmaceutical industry to achieve terminal sterilization of the final product are 121° C. for at least 10 minutes.

The pharmaceutical compositions described herein can be used for prevention or treatment of acute elevations of blood pressure in a human patient in need thereof. In some embodiments, the patients being treated may be volume-restricted due to a co-existing medical condition and thus can benefit from the administration of higher concentration and lower fluid volume of meardipins. Examples of medical conditions in which it would be advantageous to administer low volume formulations include, renal failure, ascites, cerebral edema, concestive heart failure, liver failure, or a CNS injury. Dosages can be individualized depending upon the severity of hypertension and the response of the individual patient during doxing. Typically, the dosage is administered as a continuous infusion of a pre-mixed product. In some embodiments, the patient has an elevated blood pressure with a systolic equal to or greater than 150 mm Hg. In other embodiments, the subject has an elevated blood pressure with a diastolic value greater than or equal to 90 mm Hg.

In some embodiments, the pharmaceutical compositions can be used to prevent acute elevations of blood pressure 45 associated with various medical procedures. Examples of medical procedures associated with acute elevations of blood pressure include, but are not limited to, electroconvulsive therapy (see, e.g., Avramov, et al., 1998, J. Clinical Anesthesia, 10:394-400), carotid enderterectomy (see, e.g., I)orman, 50 et al., 2001, J. Clinical Anesthesia, 13:16-19, tracheal intubation (Song, et al., 2001, Anesth Analg., 85:1247-51) and skin incision (Song, et al., 2001, Anesth Analg., 85:1247-51).

In some embodiments, the pharmaceutical compositions can be used to treat acute elevations in blood pressure due to certain cardiovascular and cerebrovascular conditions. Examples of cardiovascular conditions that are associated with acute elevations of blood pressure include, but are not limited to, essential hypertension, angina, acute ischemia, systemic arterial hypertension, congestive heart failure, coronary artery disease, myocardial infarction, cardiac arrhythmias, cardiomyopathics and arteriosclerosis. Examples of cerebrovascular conditions are associated with acute elevations of blood pressure include, but are not limited to pulmonary hypertension, cerebral insufficiency and migraine head-ache.

In some embodiments, the pharmaceutical compositions can be used to treat other conditions that cause hypertension

11

including, but not limited to, renal disorders (e.g., renal parenchymal disorders or renal vascular disease), conretation of the acrts, pheochromocytoms, hyperthyroidism, metabolic syndroms, solid organ transplant and drug-related hypertension.

In some embodiments, the pharmaceutical compositions can be used to induce hypotension during surgical procedures including, but not limited to cardiothoracic surgery, spinal surgeries and head and neck surgeries.

6. ALTERNATIVE ASPECTS

In an alternative aspect, the present invention relates to pre-mixed, ready-to-use, injectable pharmaceutical compositions comprising a cardiac medication or a pharmaceutically 15 acceptable salt thereof, and at least one of a co-solvent and a complexing agent, and a buffering agent. The composition may further comprise a tonicity agent. The compositions are preferably isotonic. The pH of the compositions is preferably between 3 and 7. The compositions are preferably packaged 20 in a pharmaceutically acceptable container, such as an intravenous bag, syringe or vial. Preferably, the compositions are used for the treatment of cardiovascular and cerebrovascular conditions. The present invention also relates to methods for preparing such compositions. In this other aspect, the term 25 'pre-mixed", as used herein, means a phermacentical composition that is already mixed from the point of manufacture and does not require dilution or further processing before administration. The term "pre-mixed" may also mean a pharmaceutical composition wherein the liquid solution and the 30 active pharmaceutical ingredient are separated from the point of manufacture and in storage, such as when the solution is stored in an intravenous hag and the active pharmaccutical ingredient is lyophilized and stored in a vial that is connected to the bag, but not in fluid contact with the solution until just as before administration to a patient. Preferably, the pharmaceutical compositions are aqueous solutions that are administered by injection. Alternatively, the pharmaceutical compositions may be lyophilized and then reconstituted in isotonic saline, for example, before intravenous administration.

In this alternative aspect, the pharmaceutical compositions of the present invention comprise a cardiac medication or a phermacentically acceptable salt thereof. Examples of classes of cardiac medications include beta-blockers, calcium channel antagonists, angiotensin converting enzyme inhibi- 45 tors, diuretics, vasodilators, nitrates, anti-platelet medications and anti-coagulants. Preferably, the cardino medication is a calcium channel antagonist or a pharmaceutically acceptable sait thereof. More preferably, the cardiac medication is a dihydropyridine derivative or a pharmaceutically acceptable 50 salt thereof. Most preferably, the cardiac medication is nicerdipine or a pharmacentically acceptable sait thereof. Examples of pharmaceutically acceptable salts of nicardipine are hydrochlorides, suifates, phosphates, acetates, fumarates, malestes and tartarates. The preferred pharmaceutically 55 acceptable salt of micardipine is nicardipine hydrochloride. The pharmaceutical compositions may comprise 0.05-1.5 mg/ml of nicardipine or a pharmaceutically acceptable salt thereof. Preferably, the pharmaceutical compositions comprise 0.15-0.35 mg/mi of nicardipine or a pharmaceutically 60 acceptable salt thereof. More preferably, the compositions comprise 0.2-0.3 mg/ml of nicardipine or pharmacentically acceptable salt thereof. Nicardipine and its pharmaceutically acceptable salts, their preparation, and their use are known in the art. For example, they are disclosed in, among other 65 references, U.S. Pat. No. 3,985,758, which is incorporated herein by reference in its entirety.

In some embodiments, the pharmaceutical compositions comprise 0.1-15 mg/ml nicardipins or a pharmaceutically acceptable salt thereof. For example, suitable concentrations of nicardipine or a pharmaceutically acceptable salt thereof, include, but are not limited to: 0.1-15 mg/ml, 0.1-10 mg/ml, 0.1-5 mg/ml, 0.1-3.0 mg/ml, 0.1-2.0 mg/ml, 0.1-1.0 mg/ml, 0.9 mg/ml, 0.8 mg/ml, 0.7 mg/ml, 0.6 mg/ml, 0.5 mg/ml, 0.4

12

mg/ml, 0.3 mg/ml, 0.2 mg/ml or 0.1 mg/ml.

In this alternative aspect, the pharmaceutical compositions can be used to treat cardisc conditions. Preferably, the compositions can be used to treat conditions that are alleviated by the administration of calcium channel antagonists, such as cardiovascular and cerebrovascular conditions. Cardiovascular conditions that can be treated with the pharmaceutical compositions of the present invention include angina, ischemia, systemic arterial hypertension, congestive heart failure, coronary artery disease, myocardial infarction, cardiac antitythmias, cardiomyopathies and arteriosclerosis. Cerebrovascular conditions that can be treated with the pharmaceutical compositions of the present invention include pulmonary hypertension, cerebral insufficiency and migraine. Preferably, the compositions are used to treat hypertension.

In this alternative aspect, the pharmaceutical compositions of the present invention also comprise at least one of a conclivent and a complexing agent. Therefore, the compositions may comprise a cosolvent, a complexing agent, multiple cosolvents, multiple complexing agents, a cosolvent and complexing agent, a cosolvent and multiple complexing agents, a complexing agent and multiple convents, or multiple cosolvents and multiple complexing agents.

In this alternative aspect, Nicardipine and its pharmaceutically acceptable salts are only slightly soluble in water. Cosolvents and complexing agents help solubilize nicardipine in the acqueous solution of the pharmaceutical composition. Cosolvents and complexing agents are especially beneficial when a high concentration of nicardipine is present, such as in the compositions of the present invention. An advantage of the compositions of the present invention is that they have a high concentration of micardipine, which allows the composition to be administered using a lower volume of intravenous fluid. Such compositions can be a treatment option for a greater number of patients, especially volume restricted patients.

In this alternative aspect, patients and medical conditions that may benefit from a higher concentration and lower fluid volume of micardipine include, but are not limited to, the following: acute congestive cardiac failure; pediatrics; hypertensive crises in elderly patients where fluid overload is a major concern; all acute stroke areas including AIS, ICH and SAH to control blood pressure; controlled hypotension during surgical procedures including cardiothoracic surgery (CABG, coarctation of the sorta, etc.), spinal surgeries, and head and neck surgeries; and neurosurgery for the control of breakthrough hypertension post carotidendanterectomy, traumatic brain injury and potential treatment of hypertension and vasoapasm.

In this alternative aspect, in addition to enhancing solubility, cosolvents and complexing agents enhance the stability of the pharmaceutical compositions. Furthermore, changes may be made to the concentration of cosolvents and complexing agents in the pharmaceutical compositions in order to adjust the tonicity of the pharmaceutical compositions. Pharmaceutically acceptable cosolvents are known in the art and are commercially available. Typical cosolvents include polyethylene glycol (PEG), propylene glycol (PG), ethanol and sorbitol. Preferably, the cosolvent concentration is 0.1-10% weight/volume percent, which will depend on the pH of the

13

composition. More preferably, the cosolvent concentration is 0.1-5%. Most preferably, the cosolvent concentration is 0.1-2%. Preferred cosolvents for the pharmaceutical compositions are propylene glycol and sorbitol. Preferably, the concentration of propylene glycol is 0.1-2%. More preferably, the concentration of propylene glycol is 0.1-1%. Most preferably, the concentration of propylene glycol is 0.3%. A preferred concentration of sorbitol is 0.1-2%. An even more preferred concentration of sorbitol is 0.1-1%. A most preferred concentration of sorbitol is 0.5%.

In this alternative aspect, pharmaceutically acceptable complexing agents are known in the art and commercially available. Typical complexing agents include cyclodextrins, such as natural cyclodextrins and chemically modified cyclodextrins. Preferably, the complexing agent is a beta cyclodex- 15 trin. Preferred complexing agents for the pharmaceutical compositions are 2-hydroxypropyl-β-cyclodentzin (2HP-BCD) and sulfobutylether-β-cyclodextrin (SBEBCD). Preferably, the complexing agent concentration is 0.1-25% weight/volume percent. More preferably, the complexing 20 agent concentration is 0.1-10%. Most preferably, the complexing agent concentration is 0.1-5%. Preferably, the concentration of 2HPBCD is 15-25%. More preferably, the concentration of 2HPBCD is 20-25%. The preferred concentration of SBEBCD is 0.1-10%. An even more pre- 25 ferred concentration of SBEBCD is 0.1-5%. The most preferred concentration of SBEBCD is 0.75 to 1%.

In addition, the pharmaceutical compositions in this alternative aspect can comprise a buffering agent. However, the compositions may comprise multiple buffering agents. The pharmaceutical compositions of the present invention are preferably close to physiological pH in order to minimize the incidence of phlebitis upon administration. However, the pH of the pharmaceutical composition also affects the solubility and stability of nicardipine in the composition. Generally, as the pH of the pharmaceutical composition increases, the aqueous solubility of nicardipine decreases. As a result, it is difficult to solubilize nicardipine close to physiological pH. In addition, the composition should have sufficient buffering capacity such that the solution does not precipitate upon dilution with blood when administered.

In this alternative aspect, typical buffering agents include acctate, glutamate, citrate, tartrate, benzoate, lactate, histidine or other amino acids, gluconate, phosphate and succinate. The preferred buffering agent concentration is 1-100 mM. A more preferred buffering agent concentration is 1-50 mM. An accent more preferred buffering agent concentration is 25-35 mM.

In this alternative aspect, preferably, the pharmaceutical compositions of the present invention are isotonic, i.e., in the range of 270-328 mOsm/kg. However, the compositions may have a tonicity in the range of 250-350 mOsm/kg. Therefore, the compositions may be either alightly hypotonic, 250-269 mOsm/kg, or slightly hypertonic, 329-350 mOsm/kg. Preferably, the tonicity of the pharmaceutical compositions is rendered isotonic by adjusting the concentration of any one or more of cosolvent, complexing agent and buffering agent in the solution.

In this alternative aspect, the pharmaceutical compositions of the present invention may further comprise a tonicity agent. However, the compositions may further comprise multiple tonicity agents. Tonicity agents are well known in the art and commercially available. Typical tonicity agents include as sodium chloride and dextrose. The preferred tonicity agent is sodium chloride. A preferred tonicity agent concentration is

1-200 mM. A more preferred tonicity agent concentration is 75-125 mM. An even more preferred tonicity agent concentration is 90-110 mM.

The pharmaceutical compositions of the present invention are preferably packaged in pharmaceutically acceptable containers in this alternative aspect. Pharmaceutically acceptable containers include intravenous bags, bottles, vials, and syringes. Preferred containers include intravenous bags and syringes, which are preferably polymer-based, and vials and intravenous bottles, which are preferably made of glass. It is also preferred that the components of the container that come into contact with the pharmaceutical composition do not contain polyvinylchloride (PVC). The most preferred container is an intravenous beg that does not have any PVC containing components in contact with the pharmaceutical composition. It is also desirable to protect the pharmaceutical compositions from light. Therefore, the container may, optionally, further comprise a light berrier. A preferred light batrier is an aluminum overpouch.

This alternative aspect also provides methods as described above for preparing the pharmaceutical compositions which are sterile.

7. EXAMPLES

Examples I through 6 are intended to be illustrative and not limiting as to the general disclosure. Examples 7 through 12 disclose specific embodiments of the pharmaceutical compositions that are principally illustrative of the alternative as aspects described herein.

Examples 1 through 6

Example 1

Effect of Various Diffeents on Stability of Concentrated CARDENE® I.V.

Stability results for the concentrated ampul product diluted to 0.1 mg/ml with various commonly used intravenous infusion fluids in an IV bag are shown in FIG. 1. pH after mixing was measured and is reported on the X-axis. Product stability was measured by monitoring the % drug remaining after duration of 24 hours by RP-HPLC and is shown on the Y-axis.

As shown in FIG. 1, the instability of nicardipine hydrochloride is related to the initial pH of the infusion fluid and to the final pH of the solution after mixing. The magnitude of drug loss post dilution increases as the final pH of the solution after mixing increases, for example, a very pronunced drug loss is obtained when the pH is above 4.5. Besed on these findings, the product insert for the marketed ampul product requires product dilution be carried out using specific infusion fluids. Furthermore, the diluted product must be used within 24 hours.

Example 2

Riffect of pH on Stability

Stability results for a 0.1 mg/mL nicardipine HCl, 0.1 mM citric acid, and 5% dextrose formulation dispensed in a GAL-AXY® bag are shown in FIGS. 2A and 2B. Stability results for a 0.1 mg/mL nicardipine HCl, 0.1 mM citric acid, 0.9% saline formulation dispensed in a GALAXY® bag are shown in FIGS. 3A and 3B. Stability assessments are done by measuring the % drug remaining and the total impurity formation as a function of time using RP-HPLC.

14

15

Stability testing was done at an accelerated temperature of 40° C. Based on published literature, activation energies for drug decompositions usually fall in the range of 12 to 24 Kcal/mol, with typical value of 19-20 Kcal/mol. Under these conditions (assumption Ea=19.4 Kcal/mol) 15 weeks storage 5 at 40° C. corresponds to a product with approximately 18 months expiration at 25° C. (see, e.g., Connors, K. A., et al., Chemical Stability of Pharmaceuticals, A Handbook for Pharmacists, John Wiley & Sons, 2d ed. 1986).

As shown in FIGS. 2A and 3A, loss in product potency (drop in % drug remaining) due to degradation and adsorption on to the beg surface increased as the formulation pH was increased. For example, after 6 months storage at 40° C. for the dextrose formulations, a clear trend indicating increased drug loss for formulations at pH 4.4 and 4.7 can be observed. Is At pH 3.3, the drop in % drug remaining is attributed to an increase in total impurities (FIGS. 2B and 3B), rather than drug loss due to adsorption. In addition to the observed drug loss, the formation of nicardipine-related impurities (FIGS. 2B and 3B) was also found to be strongly pH dependent. In this case, however, the reverse trend was observed; as the pH was decreased, the total impurities increased.

The results from this study indicate that the formulation pH has a significant effect on stability of a ready-to-use diluted product. The findings of this study indicate that the optimal 2s formulation pH range is between about 3.6 to about 4.7. However, depending on the degree of acceptable drug degradation and/or total impurity formation, other pH ranges can be chosen.

Example 3

Effect of Nicardipine Concentration on Impurity Pormation

The effect of nicardipine concentration on impurity formation in ready to use premixed compositions comprising 0.1 mg/mL and 0.2 mg/ml non-sorbitol formulations with destrose over 6 months at 40° C. is shown in FIG. 4A. The effect of nicardipine concentration on impurity formation in ready 40 to use premixed compositions comprising 0.1 mg/ml and 0.2 mg/mL non-sorbitol formulations with saline over 3 months at 40° C. is shown in FIG. 4B. The formulations are dispensed in GALAXY® bags. Stability assessments are done as described in Example 2.

As shown in FIGS. 4A and 4B, in addition to pH, product concentration is another factor that impacts product stability, in particular the formation of nicardipine-related impurities. The concentration dependence observed with respect to total impurity formation is minimized as the formulation pH is so increased. For example, in FIGS. 4A and B, the effect of concentration is significant at pH 3.3 and is minimized as the pH approaches 4.7.

These results indicate that impurity formation is greater for the 0.1 mg/ml formulations as compared to the 0.2 mg/ml 55 formulations for both the dextrose and saline formulations. Simultaneous optimization of the drug concentration along with the viable formulation pH range is important in the development of ready-to-use premixed drug formulations.

Example 4

Stability Comparison of Sorbitol and Non-Sorbitol Formulations

A stability comparison of sorbitol and non-sorbitol formulations was conducted under accelerated conditions (4 weeks at 40° C.) using a 0.1 mg/mL nicardipine HCl, 1.92 mg/mL sorbitol, 48 mg/mL dextrose, 0.0192 mg/mL citric acid, pH 4.2 and a 0.1 mg/mL nicardipine HCl, 50 mg/mL dextrose, 0.0192 mg/mL citric acid, pH 4.0. Both formulations were dispensed in GALAXY® bags. Stability assessments were done by measuring the % drug remaining and total impurity formation as a function of time using RP-HPLC. The results are shown in Tables 2 and 3.

16

TARLE 2

	Destrose Formulation with	out Sorbitol
Time	% Daug Remaining	% Total Logueities
Ò	100.0	80.0
4	98.1	0.17

TABLE 3

Derivose Formulation with Sorbital

	Time	% Drug Remaining	% Total Impurities
5	0	100.0 96.4	NMT ¹ 0.05 0.13

NMT refers to no more than.

As shown in Tables 2 and 3, minimal differences between the two formulations were observed in the measured paramsters. Based on these results, as well as the results shown in Examples 1 and 2, the presence or absence of sorbitol is not predicted to alter the impact of formulation pH and drug concentration on the stability of the premixed pharmaceutical compositions comprising nicardipine HCl and dextrose or sodium chloride.

Example 5

The Riffect of Plastic Film Composition on Stability

The effect of plastic film composition on the stability of ready to use premixed compositions comprising 0.2 mg/mL nicardipine HCl, 0.2 mM citrate, 5% dextrose, pH 4.0-4.2 for "incompatible" bags and "compatible" bags is shown in FIGS. 5A and 5B respectively. "Incompatible" bags contain polar polymers, such as polyvinyl chloride (PVC) and ethylene vinyl acetate (HVA). "Compatible" bags do not contain polar polymers.

Stability evaluations were done for the 0.2 mg/ml. nonsorbitol dextrose formulation in various commercially available IV infusion bag systems. EXCEL®, VIAFLEX®, VIAFLOTM, INTRAVIA®, and VISIV® bags were rinsed in
water and covered with aluminum foil over pouches. The
bags were filled with the above formulation and autoclaved at
105° C. for 21 minutes. STEDIM®71 and GALAXY® bags
were asceptically filled with the above formulation. Stability
wassessments were done by measuring the % drug remaining
and total impurity formation (data not shown) as a function of
time using RP-HPIC for samples incubated for up to 24
weeks at 40° C. The % drug remaining was calculated relative
to the concentration measured post-mixing in tank.

As shown in FIG. 5A, various commercially available IV 6s bags were not compatible with nicardipine HCl. Significant loss in product potency was observed upon storage primarily due to product adsorption in bags that contained the polymer

17

PVC (e.g., VIAFLEX® and INTRAVIA®). Nicardipine was also incompatible with bags containing the polymer ethylenewinyl scetate (EVA) in the contact layer (e.g., STEDIM®71). PVC and EVA are examples are of polar plastic materials that are incompatible with nicardipine HCl. Because nicracingine sHCl is a weak base with a pKa of ~7.2, it is increasingly hydrophobic as the formulation pH increases, and therefore, compatibility with polymeric contact surfaces is dependent on surface charge-related properties.

As shown in FIG. 5B, minimal drop in product potency was 10 observed with commercial bags comprising copolyester (e.g., HXCEL®), polyethylens (e.g., GALAXY®), and polyelefin blends (e.g., VISIV® and VIAFLOPS).

Example 6

Effect of CAPTISOLAR on Product Stability

The effect of CAPTISOL® on the stability of ready to use premixed compositions comprising 0.3 mg/ml Nicardipine, 20 30 mM NaAcstate, 1.8% Captisol, 112 mM NaCl, pH 4.5 or 0.3 mg/ml Nicardipine, 30 mM NaAcstate, 1.8% Captisol, 3.7% Dectross, pH 4.5 dispensed in 100 ml GALAXY® bags was monitored for 12 weeks at 5, 25 and 40° C. in (sec, e.g., Table 4). Because the drug was stable at 5° C., the data is not 25 shown. In addition, the formulations were monitored at 45° C. in 2 mL glass vials (see, e.g., Table 5). All formulations were filled asceptically into the vials and bags by filtering the solution through a 0.22 µm filter.

TABLE 4

				remaining 0° C.
Time (weeks)	NaCl Formulation	Descrose Fontulation	NaCl Formulation	Dexirose Formulation
0	100.00	100.00	100.00	100.0D
1	96.37	99.86	97.15	98.86
2	98,09	100.80	97,07	100.40
4	99.45	104.01	98,46	102.56
12	97.23	101.18	95.36	99.00

TABLE 5

5	Destrose Formulation	NaCi Formulation	Time (weeks)
	100,00	100.00	0
	105.78	107.69	2
	105.22	105.18	4
	102.80	102.72	14

Pharmaceutical compositions comprising CAPITSOL® exhibited minimal drug loss and impurity formation (data not shown) as a function of time and temperature. Based on the accelerated stability data at 40° and 45° C., formulations comprising CAPTISOL®, decrease or NACI should be stable at room temperature for at least 12 months.

Examples 7 through 12

Examples 7-12 illustrate experiments performed using specific embodiments. The experiments in Examples 7-12

18

were performed at 45° C. in order to simulate stressed conditions that cause sufficient product degradation in a relatively short period of time. Stability comparisons were done against the control formulation (CF) and/or the commercial product formulation (CPF) in order to assess relative differences in their degradation profiles. The CPF is a marketed drug product and, therefore, degradation behavior of the molecule is well understood as a function of temperature and time. Stability data are available for the marketed product up to 36 months at room temperature, 22-27° C., and 40° C.

The rationale used in this preliminary acreening evaluation is that if the degradation kinetics of the evaluated formulation prototypes were comparable to the CPF at stressed temperatures, drug product stability would likely be comparable or botter at room temperature. The current prototype formulation is stable for at least 18 months at 25° C., and therefore it is projected that the evaluated formulation prototypes can have comparable or better stability.

Bxample 7

Formulation Preparation and Analysis

Appropriate buffers, such as acetate or succinate, containing the desired cosolvents, such as sorbitol or propylene glycol, and/or complexing agents, such as SBEBCD or 2HPBCD, were prepared. Appropriate tonicity agents, such as sodium chloride, were prepared and added to some of the pharmaceutical compositions. Based upon the final formula-30 tion volume and the target drug concentration, usually 0.2-0.3 mg/mL, nicerdipine was weighed into an appropriate glass container and prepared builter was added to dissolve the thug. Tonicity agent, if any, was then added. The solution was then sonicated for up to 45 minutes to facilitate drug dissolution. 35 Following drug dissolution, the solution was filtered through a 0.45 µm syringe filter (Acrodisc LC 13 mm Syringe filter, PVDF Membrane from Life Sciences, PN 4452T). When filtering, the first few drops were discarded and the remaining solution was collected into another glass container. The pre-40 pared formulations were subsequently dispensed into either vials or intravenous bags.

The following isotonic pharmaceutical compositions were made according to the above protocol:

Pharmaceutical Composition 1 (PC 3): 0.2-0.3 mg/ml nicardipine hydrochloride, 3.7% surbitol, and 50 mM Naacetate, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 2 (PC 2): 0.2-0.3 mg/ml nicanlipine hydrochloride, 1.7% propylene glycol, and 50 miM Na-acetate, wherein the pH of the composition is 5.0

Pharmaccutical Composition 3 (PC 3): 0.2-0.3 mg/ml nicardipine hydrochloride, 2.8% sorbitol, and 50 mM Nasuccinste, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 4 (PC 4): 0.2-0.3 mg/ml nicardipine hydrochloride, 1.1% propylene glycol, and 50 mM Na-succinate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 5 (PC 5): 0.2-0.3 mg/ml nicardipine hydrochloride, 4.1% surbitol, and 50 mM Nascetate, wherein the pH of the composition is 3.5.

Pharmaceutical Composition 6 (PC 6): 0.2-0.3 mg/ml nicardipine hydrochloride, 1.9% propylene glycol, and 50 mM Na-acetate, wherein the pH of the composition is 3.5.

Pharmaceutical Composition 7 (PC 7): 0.2-0.3 mg/ml nicardipine hydrochloride, 4.1% sorbitol, and 50 mM Naacetate, wherein the pH of the composition is 4.5.

- Phermaceutical Composition 8 (PC 8): 0.2-0.3 mg/ml nicardipine hydrochloride, 1.8% propylene glycol, and 50 mM Na-acetate, wherein the pH of the composition is
- Pharmaceutical Composition 9 (PC 9): 0.2-0.3 mg/ml nicandipine hydrochloride, 6.5% sulfobutylether-β-cyclodextrin, and 50 mM Na-succinate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 10 (PC 10): 0.2-0.3 mg/ml nicardipine hydrochloride, 6.5% sulfabutylether-fi-cy-10 clodextrin, and 50 mM Na-succinate, wherein the pH of the composition is 6.0.
- Pharmaceutical Composition 11 (PC 11): 0.2-0.3 mg/ml nicardipine hydrochloride, 8.5% sulfobutylether-6-cyclodextrin, and 50 mM Na-succinate, wherein the pH of 15 the composition is 5.5.
- Pharmaceotical Composition 12 (PC 12): 0.2-0.3 mg/ml nicardipine hydrochloride, 8.5% sulfobutylether-B-cyclodextrin, and 50 mM Na-succinate, wherein the pH of the composition is 6.0.
- Pharmaceutical Composition 13 (PC 13): 0.2-0.3 mg/ml nicardipine hydrochloride, 8.5% sulfobutylether-6-cyclodestrin, and 50 mM Na-acetate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 14 (PC 14); 0.2-0.3 mg/ml ²⁵ nicardipine hydrochloride, 8.5% sulfobutylether-6-cyclodextrin, and 50 mM Na-citrate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 15 (PC 15): 0.2-0.3 mg/ml nicardipine hydrochloride, 22.5% 2-hydroxypropyl-βcyclodextrin, and 50 mM Na-acetate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 16 (PC 16): 0.2-0.3 mg/ml nicardipine hydrochloride, 22.5% 2-hydroxypropyl-βcyclodextrin, and 50 mM Na-succinate, wherein the pH 35 of the composition is 5.5.
- Pharmaceutical Composition 17 (PC 17): 0,2-0.3 mg/ml nicardipine hydrochlorids, 17.5% 2-hydroxypropyl-βcyclodextrin, and 50 mM Na-acetate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 18 (PC 18): 0.2-0.3 mg/ml nicardipine hydrochloride, 17.5% 2-hydroxypropyl-ficyclodextrin, and 50 mM Na-succinate, wherein the pH of the composition is 5.5
- Commercial Product (Ampul) Formulation (CPF): 2.5 45 mg/ml nicardipine hydrochloride, 2.5 mM citrate, and 5% sorbital, wherein the pH of the composition is 3.5.
- Control Formulation (CF): 0.3 mg/ml nicardipine hydrochloride, 2.5 mM citrate, and 5% sorbitol, wherein the pH of the composition is 3.5.
- Pharmaceutical Composition 19 (PC 19): 0.3 mg/ml nicardipine hydrochloride, 50 mM sodium acetate, 50 mM sodium citrate, and 50 mM disodium succinate, wherein the pH of the composition is 3.5.
- Pharmaceutical Composition 20 (PC 20): 0.3 mg/ml nicaadipine hydrochloride, 50 mM sodium acetate, 50 mM sodium citrate, and 50 mM disodium succinate, wherein the pH of the composition is 4.5.
- Pharmaceutical Composition 21 (PC 21): 0.3 mg/ml nica- 60 rdipine hydrochloride, 50 mM sodium acetate, 50 mM sodium citrate, and 50 mM disodium succinate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 22 (PC 22): 0.3 mg/ml nicardipine hydrochloride, 50 mM sodium acetate, 50 mM 55 sodium citrate, and 25 mM disodium succinate, wherein the pH of the composition is 5.5.

- Pharmaceutical Composition 23 (PC 23): 0.3 mg/ml nicardipine hydrockloride, 4.1% sorbitol, and 50 mM sodium acetate, wherein the pH of the composition is
- Pharmaceutical Composition 24 (PC 24): 0.3 mg/ml nicardipine hydrochloride, 4.1% sorbitol, and 50 mM sodium acetate, wherein the pH of the composition is
- Pharmaceutical Composition 25 (PC 25): 0.3 mg/ml nicardipine hydrochloride, 3.7% sorbitol, and 50 mM sodium acetate, wherein the pH of the composition is
- Pharmaceutical Composition 26 (PC 26): 0.3 mg/ml nicardipine hydrochloride, 2.8% sorbitol, and 50 mM sodium acetate, wherein the pH of the composition is
- Pharmaceutical Composition 27 (PC 27): 0.3 mg/ml nicardipine hydrochloride, 1.9% propylene glycol, and 50 mM sodium acetate, wherein the pH of the composition
- Pharmacentical Composition 28 (PC 28): 0.3 mg/ml nicardipine hydrochloride, 1.8% propylene glycol, and 50 mM sodium acetate, wherein the pH of the composition is 4.5,
- Pharmaceutical Composition 29 (PC 29): 0.3 mg/ml nicardipine hydrochloride, 1.7% propylene glycol, and 50 mM sodium acetate, wherein the pH of the composition
- Pharmaceutical Composition 30 (PC 30): 0.3 mg/ml nicerdipine hydrochloride, 1.1% propylene glycol, and 50 mM sodium succinate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 31 (PC 31): 0.3 mg/ml nicardipine hydrochloride, 6.5% sulfobutylether-β-cyclodextrin, and 50 mM sodium succinate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 32 (PC 32): 0.3 mg/ml nicardipine hydrochloride, 6.5% sulfobutylether-β-cyclodestrin, and 50 mM sodium succinate, wherein the pH of the composition is 6.0.
- Pharmaceutical Composition 33 (PC 33): 0.3 mg/ml nicardipine hydrochloride, 22.5% 2-hydroxypropyl-β-cyclodestrin, and 50 mM sodium acetate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 34 (PC 34): 0.3 mg/ml nicardipine hydrochloride, 17% 2-hydroxypropyl-β-cyclodextrin, and 50 mM disodium succinate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 35 (PC 35): 0.3 mg/ml nicardipine hydrochloride, 0.3% propylene glycol, 0.5% sorbitol, 30 mM sodium acetate, and 90 mM NaCl, wherein the pH of the composition is 5.2.
- Pharmaceutical Composition 36 (PC 36): 0.3 mg/ml nicardipine hydrochloride, 0.3% propylene glycol, 2.0% sorbitol, 30 mM sodium acetate, 45 mM NaCl, wherein the pH of the composition is 5.2.
- Pharmaceutical Composition 37 (PC 37): 1.5 mg/ml nicardipine hydrochloride, 9% sulfobutylether-β-cyclodextrin, and 30 mM sodium acetate, wherein the pH of the composition is 4.5.
- Pharmaceutical Composition 38 (PC 38): 1.5 mg/ml nicardipine hydrochloride, 9% sulfobutylether-β-cyclodextrin, and 30 mM sodium acetate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 39 (PC 39): 0.3 mg/ml nicardipine hydrochloride, and 30 mM sodium acetate, wherein the pH of the composition is 3.5.

21

Pharmaceutical Composition 40 (PC 40): 0.3 mg/ml nicarilpine hydrochloride, and 30 mM sodium acetate, wherein the pH of the composition is 4.0.

Pharmaceutical Composition 41 (PC 41): 0.3 mg/ml nicardipine hydrochloride, and 30 mM sodium acetate, 3 wherein the pH of the composition is 4.5.

Pharmaceutical Composition 42 (PC 42): 0.3 mg/ml nicardipine hydrochloride, 1.8% sulfobutylether-β-cyclodextrin, 30 mM sodium acetate, and 110 mM NaCl, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 43 (PC 43): 0.3 mg/ml nicardipine hydrochloride, 1.8% sulfobutylether-fi-cyclodextrin, 0.3% propylene glycol, 30 mM sodium acetata, and 85 mM NaCl, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 44 (PC 44): 0.3 mg/ml nicantipine hydrochloride, 1.8% sulfolartylether-β-cyclodeutrin, 30 mM sodium acetate, and 110 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 45 (PC 45): 0.3 mg/ml nica-20 mlipine hydrochloride, 1.8% sulfabutylether-B-cyclodextrin, 30 mM sodium acetate, and 200 mM dextrose, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 46 (PC 46): 0.3 mg/ml nicardipine hydrochloride, 0.75% sulfobutylether-β-cyclodentrin, 30 mM sodium acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 47 (PC 47); 0.3 mg/ml nicardipine hydrochloride, 1.0% sulfobutylether-β-cyclodextrin, 30 mM sodium acetste, and 125 mM NaCl, 30 wherein the pH of the composition is 4.5.

Pharmaceutical Composition 48 (PC 48): 0.3 mg/ml nicardipine hydrochloride, 3.4% surbitol, and 50 mM sodium succinate, wherein the pH of the composition is 5.6.

Pharmaceutical Composition 49 (PC 49): 0.3 mg/ml nicardipine hydrochloride, 1.3% propylene glycol, and 50 mM sodium acetate, wherein the pH of the composition is 5.6.

Pharmaceutical Composition 50 (PC 50): 0.3 mg/ml nicardipine hydrochlorids, 1.8% sulfobutylether-β-cyclodextrin, 30 mM sodium acetate, and 110 mM NaCl, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 51 (PC 51): 0.3 mg/ml nicardipine hydrochloride, 0.75% sulfobutylether-β-cyclodextrin, 30 mM sodium acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 52 (PC 52); 0.3 mg/ml nicardipine hydrochloride, 1.0% sulfobutylether-β-cyclodextrin, 30 mM sedium acetate, and 125 mM NsCl, 50 wherein the pH of the composition is 4.5.

Pharmaceutical Composition 53 (PC 53): 0.3 mg/ml nicardipine hydrochluride, 0.5% sorbitol, 0.3% propylene glycol, 30 mM sodium acetate, and 90 mM NaCl, wherein the pH of the composition is 5.2.

Pharmsceutical Composition 54 (PC 54): 0.3 mg/ml nicardipine hydrochloride, 1.0% sulfobutylether-β-cyclodextrin, 30 mM sodium acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 55 (PC 55): 0.3 mg/ml nicasor rdipine hydrochloride, 0.75% sulfobutylether-β-cyclodextrin, 30 mM sodium acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 56 (PC 56): 0.3 mg/ml nicardipine hydrochloride, 0.5% sorbitol, 0.3% propylene 65 glycol, 50 mM sodium acetate, and 90 mM NaCl, wherein the pH of the composition is 5.2. 22

The excipient concentration in the control formulation (CF) is identical to the commercial product formulation (CPF), Cardene 1.V (ampul). However, the concentration of active ingredient in the commercial and control formulations is different. In the commercial product formulation (CPF), the concentration of nicardipine hydrochloride in the amoul is 2.5 mg/mL before dilution, and 0.1 mg/ml after dilution with appropriate IV fluids before administration. The control fornrulation (CP), which is designed for premixed ready-to-use intravenous bags such that no further dilution with intravenous fluids is required, has a nicardipine hydrochloride concentration of 0.3 mg/mL. The purpose of the control formulation was to help assess the degradation propensity of the evaluated formulations. Comparable degradation profiles at stressed conditions is indicative of comparable formulation stability.

Example 8

Vial Stability Data with Sorbitol and Propylene Glycol Formulations

The stability in vials of pharmaceutical compositions of the present invention comprising a co-solvent and a buffering agent were compared to the control formulation and the commercial product formulation. Stability was determined by comparing the drug concentration over time for the below compositions. Specifically, the below compositions were prepared according to the method in Example 7:

50 mM Na-acetate, pH 3.5. 4.1% sorbitol (PC 5),

50 mM Na-acetate, pH 3.5. 1.9% propylene glycol (PC 6), 50 mM Na-acetate, pH 4.5, 4.1% sorbitol (PC 7),

50 mM Na-acetate, pH 4.5, 1.8% propylene glycol (PC 8), 50 mM Na-acetate, pH 5.0, 3.7% sorbitol (PC 1),

50 mM Na-acetate, pH 5.0, 1.7% propylene glycol (PC 2), Control formulation: 0.3 mg/mL, 2.5 mM citrate, 5% sorbitol, pH 3.5 (CF), and

Commercial product formulation: 2.5 mg/ml, 2.5 mM citrate, 5% sorbitol, pH 3.5 (CPF).

These stability studies were performed in 2 ml glass vials and at elevated temperature conditions, in this case 45° C. Formulation stability was monitored by measuring the drug concentration by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, 7 days and 21 days, except for the commercial product formulation, which measurements were taken at the start of the experiment and 46 days. These measurements were than converted into a percentage in order to show the percentage of drug remaining after a period of time.

5				Drug Cont.		Drug Conc.	
	PC #	Drug Conc. (µg/ml) t=0	M Drug Remaining	(µg/ml) t = 7 days	M Drug Remaining	(µg/ml) t=21 days	% Drug Remaining
0	5	314 302	100 100	312 305	99 101	289 282	92
	7	304	100	303	100	283	93 93
	5	304 298	100 100	304 294	100 98	282 274	93 92
5	CF	290 302	100 100	302 301	104 100	264 277	91 92

5

23

-	у,	ı

PC#	Drug Cone. (µg/ml) t=0	54 Drug Remaining	Drug Conc. (ug/ml) 1 = 46 daya	% ilmg Rensining
CPF	2553	100	2265	20

The data show that the stability in vials, drug concentration over time, of the pharmaceutical compositions of the present invention that contain co-solvents are comparable to both the control formulation (CF) and the current product formulation (CPF). In addition, the compositions had no additional degradation products relative to the control formulation (data not shown).

Example 9

Vial Stability Data with SBBBCD Formulations

The stability in vials of pharmaceutical compositions of the present invention comprising a complexing agent and a buffering agent were compared to the control formulation and the commercial product formulation. Stability was determined 25 by comparing the drug concentration over time for the below compositions. Specifically, the below compositions were prepared according to the method in Example 7:

50 mM Na-acetate, 8.5% SBE-beta cyclodextrin, pH 5.0 (PC 13),

50 mM Na-citrats, 8.5% SBE-beta cyclodextrin, pH 5.5 (PC 14),

50 mM Na-succinate, 8.5% SBE-beta cyclodextrin, pH 5.5 (PC 11).

50 mM Na-succinate, 8.5% SBE-beta cyclodextrin, pH 6.0 35 (PC 12).

Control formulation: 0.3 mg/mL, 2.5 mM citrate, 5% sorbitol, pH 3.5 (CF), and

Commercial product formulation: 2.5 mg/ml, 2.5 mM citrate, 5% sorbitol, pH 3.5 (CPF).

These stability studies were performed in 2 ml glass vials and at vials and at elevated temperature conditions, in this case 45° C. Pomulation stability was monitored by measuring the drug concentration by RP-HPLC against a standard curve. The drug concentration measurements were taken at 45 the start of the experiment, 6 days, 13 days and 30 days, except for the commercial product formulation, which measurements were taken at the start of the experiment and 46 days. These measurements were then converted into a percentage in order to show a percentage of drug remaining after 50 a period of time.

The data from these stability studies are shown in the following Tables.

PC#	Drug Conc. (µg/ml) t=0	% Drug Remaining	Drug Cone. (ug/ml) t = 46-days	% Drug Remaining
CPF	2553	100	22.65	20

The data show that the stability in vials, drug concentration over time, of the pharmaceutical compositions of the present invention that contain SBEBCD are comparable to both the control formulation (CF) and the commercial product formulation (CFF). In addition, the compositions had no additional degradation products relative to the control formulation (data not shown). It is also worth noting that the target concentration of 0.2-0.3 mg/mL could be readily attained in the presence of sulfobutlyether-β-cyclodextrin.

Example 10

Intravenous Bag Stability Data with Sorbitol and Propylene Glycol Formulations

The stability in intravenous bags of pharmaceutical compositions of the present invention comprising a co-solvant and a buffering agent were compared to a control formulation. Stability was determined by comparing the drug concentration over time for the below compositions. Specifically, the below compositions were prepared according to the method in Example 7:

50 mM Na-acetate, pH 3.5. 4.1% sorbitol (PC 5),

50 mM Ne-acetate, pH 3.5. 1.9% propylene glycol (PC 6),

Control formulation: 0.3 mg/mL, 2.5 mM citrate, 5% sorbitol, pH.3.5 (CF).

These stability studies were performed in 50 ml intravenous bags and at elevated temperature conditions, in this case 45° C. Formulation stability was monitored by measuring the drug concentration by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, 7 days and 21 days. These measurements were then converted into a percentage in order to show the percentage of drug remaining after a period of time.

The data from these stability studies are shown in the Table below.

PC#	[Drug] (µg/ml) t=0	M Drug Remaining	[Daug] (µg/ml) t=6d	% Drug Remaining	[Dang] (µg/ml) t = 13 d	% Dmg Remaining	[Drug] (µg/ml) t = 30 d	M Drug Remaining
13	381	100	387	101	413	108	390	102
14	334	100	339	101	352	105	333	100
11	364	100	378	104	396	109	364	100
12	318	100	341	107	355	112	326	103
CF	339	100	352	104	363	107	338	100

25

25

PC #	Dmg Conc. (ug/ml) 1=0	% Daug Remaining	Daug Conc. (µg/ml) t=7 daya	% Drug Remaining	Drug Cone. (µg/ml) t = 21 days	% Drug Remaining
3	314	100	317	101	319	102
6	302	100	311	103	297	98
CF	302	100	276	92	264	88

The data show that the stability in intravenous bags, drug concentration over time, of the pharmaceutical compositions of the present invention that contain co-solvents are comparable to the control formulation. In addition, the compositions had no additional degradation products relative to the control formulation (data not shown). Finally, drug adsorption on the bag surface was minimal at pH 3,5.

Example 11

Intravenous Bag Stability Data with HPCD Formulations

The stability of a pharmaceutical composition of the present invention comprising a complexing agent and a buffering agent was evaluated in both vials and intravenous bags. Stability was determined by comparing the drug concentration over time for the below composition. Specifically, the below composition was prepared according to the method in Example 7:

50 mM Na-acctate, pH 5.0, 22.5% HPCD (PC 15).

These stability studies were performed in 50 ml intravenous bags and at elevated temperature conditions, in this case 40 45° C. The stability evaluations were done with a 10 mL fill volume in both the upright and inverted bag configurations. These evaluations were done relative to the same formulation in a 2 mL glass vial, as a control. Formulation stability was monitored by measuring the drug concentration by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, 1 day, 2 days, 6 days, 9 days and 16 days.

The data from these stability studies are shown in the Table 50 below.

26 ability

The data show that the stability, drug concentration over time, of the pharmaceutical composition of the present invention that contains complexing agent is more promising in the upright configuration of the bag. The date also show that the recovery of drug product was poorer in the inverted bag configuration.

In order to determine why the composition was more stable in upright intravenous bags compared to inverted intravenous to bags, additional experiments were conducted. The drop in drug concentration was not due to any new degradation product (date not shown). We believe that the drop in drug concentration was due to drug adsorption on the bag surface. For many hydrophobic drugs, adsorption on PVC surfaces is a commonly reported concern. Therefore, it is likely that we observed significant adsorption in the inverted configuration because the drug is in contact with PVC surfaces. These results suggest the use of non-PVC bags and/or the careful evaluation of the bag size (solution volume) as feasible options to minimize drug adsorption in order to achieve adequate drug product recovery.

Example 12

Intravenous Bag Stability Data with Sorbitol Formulations

The stability of a pharmaceutical composition of the present invention comprising a cosolvent and a buffering agent was evaluated in both vials and intravenous bags. Stability was determined by comparing the drug concentration over time for the below composition. Specifically, the below composition was prepared according to the method in Example 7:

50 mM Na-acetate, pH 5.0, 3.7% sorbitol (PC 1).

These stability studies were performed in 50 ml intravenous bags and at elevated temperature conditions, in this case 45° C. The stability evaluations were done with both 10 and 50 ml. fill volumes in both the upright and inverted bag configurations. These evaluations were done relative to the same formulation in a 2 ml. glass vial, as a control. Formulation stability was monitored by measuring the drug concentration by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, 1 day, 2 days, 5 days, 9 days and 16 days.

The data from these stability studies are shown in the below Table.

	Drug Cone. (µg/ml) t = 0	Drag Cone. (µg/ml) t=1 day	Drug Conc. (ug/ml) t = 2 days	Drug Conc. (ug/ml) t = 6 days	Daug Come. (µg/ml) t = 9 days	Drug Conc. (ag/ml) t = 16 days
Vial	271	271	263	260	269	274
Upright Bag	271	266	244	264	270	301
Inverted Hag	271	233	203	175	172	150

	Drug Cone. (ug/ml) t=0	Drug Conc. (μg/π/) t = 1 day	Drug Conc. (µg/ml) t = 2 days	Drug Conc, (µg/ml) 1 = 6 days	Cone. (µg/ml) t=9 days	Drug Cenc. (ug/ml) t=16 days
Vial	100	102	100	110	104	106
Upright Bag 10 mi	100	93	89	98	85	87
Upright Beg 50 ml	100	98	96	114	97	80
Inverted Bag 10 ml	100	46	43	38	21	13
Inverted Bag 50 ml	100	89	87	102	86	25

The data show that the stability, drug concentration over time, of the pharmaceutical composition of the present invention that contains cosolvent is more promising in the upright configuration of the bag. The data also show that the recovery of drug product was poorer in the inverted bag configuration.

In order to determine why the composition was more stable in upright intravenous bags compared to inverted intravenous bags, additional experiments were conducted. The drop in drug concentration was not due to any new degradation product (data not shown). We believe that the drop in drug concentration was due to drug adsorption on the bag surface. For many hydrophobic drugs, adsorption on PVC surfaces is a commonly reported concern. Therefore, it is likely that we observed significant adsorption in the inverted configuration because the drug is in contact with PVC surfaces. This belief is further supported by the fact that we observed poorer recovery of the drug in the 10 mL fill configuration relative to the 50 mL fill configuration, although this poorer recovery may be partly due to the fact that the 10 mL fill configuration has a higher surface area to volume ratio, which adversely impacts 40 drug adsorption and recovery. In conclusion, these results suggest the use of non-PVC bags and/or the careful evaluation of the bag size (solution volume) as feasible options to minimize drug adsorption in order to achieve adequate drug product recovery.

All publications, patents, patent applications and other documents cited in this application are hereby incorporated by reference in their entireties for all purposes to the same extent as if each individual publication, patent, patent application or other document were individually indicated to be 50 incorporated by reference for all purposes.

While various specific embodiments have been illustrated and described, it will be appreciated that various changes can be made without departing from the spirit and scope of the invention(s).

What is claimed is:

- 1. A pharmaceutical composition for parenteral administration comprising a pre-mixed squeous solution with a pH from about 3.6 to about 4.7 comprising:
 - from about 0.1 to 0.4 mg/mL nicardipine hydrochloride; a tonicity agent selected from (i) about 4.5% to about 5% dextrose or (ii) about 0.8% to about 0.9% sodium chloride; and
 - buffer in an amount to maintain pH from about 3.6 to about 4.7;

- the aqueous solution contained in a pharmaceutically acceptable container such that the solution does not come into contact with polar polymers;
- the aqueous solution when stored in the container for at least one year at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine hydrochloride and (ii) a total impurity formation of less than about 3%.
- The composition of claim 1, further comprising at least one pH adjuster selected from the group consisting of hydrochloric acid, sodium hydroxide and a mixture thereof.
- The composition of claim 1, further comprising from about 1 mg/ml to about 4 mg/ml sorbitol.
- The composition of claim 1, wherein the container comprises copolyester, polyethylene or polyelefin.
 - 5. A pharmaceutical composition for parenteral administration comprising a pre-mixed aqueous solution with a pH from about 3.6 to about 4.7 comprising:
 - from about 0.1 to about 0.2 mg/mL nicardipine hydrochloride:
 - a tonicity agent selected from (i) about 46 to about 50 mg/mL dextrose or (ii) about 8.3 to about 9 mg/mL sodium chloride; and
 - a buffer in an amount to maintain pH from about 3.6 to about 4.7;
 - the aqueous solution contained in a pharmacentically acceptable container comprising copolyester, polyethylene or polyoletin;
 - the aqueous solution when stored in the container for at least one year at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine hydrochloride and (ii) a total impurity formation of less than about 3%.
 - 6. A pharmaceutical composition for parenteral administration comprising a pre-mixed aqueous solution comprising: from about 0.1 to about 0.2 mg/mL nicardipine hydrochloride:
 - a tonicity agent selected from (i) about 46 to about 50 mg/mL dextrose or (ii) about 8.3 to about 9 mg/mL sodium chloride;
 - from 0 mg/mL to about 4 mg/mL sorbitol; and
 - a buffer in an amount to maintain pH from about 3.6 to about 4.7;
 - the aqueous solution contained in a pharmaceutically acceptable container comprising copolyester, polyethylene or polyelefin;

29

- the aqueous solution when stored in the container for at least one year at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine hydrochloride and (ii) a total impurity formation of less than about 3%.
- 7. A pharmaceutical composition for parenteral administration comprising a pre-mixed aqueous solution comprising: from about 0.1 to about 0.2 mg/mL nicardipine hydrochlonide:
 - a tenicity agent selected from (i) about 46 to about 50 10 mg/mL dextrose or (ii) about 8.3 to about 9 mg/mL sodium chloride;
 - from 0 mg/mL to about 4 mg/mL sorbitol; and
 - a buffer in an amount to maintain pH from about 3.6 to about 4.7:
 - the aqueous solution contained in a pharmaceutically acceptable container comprising copolyester, polyethylone or polyolefin.
- 8. The pharmacentical composition for parenteral administration of claim 7, wherein the aqueous solution when stored 20 in the container for three months at room temperature exhibits less than a 10% decrease in the concentration of nicardipine hydrochlorids.

30 composition for

- 9. The phannaccutical composition for parenteral administration of claim 7, wherein the aqueous solution when stored in the container for three months at room temperature exhibits a total impurity formation of less than about 3%.
- 10. The pharmaceutical composition for parenteral administration of claim 7, wherein the aquaous solution when stored in the container for one year at room temperature exhibits less than a 10% decrease in the concentration of nicardipine hydrochloride.
- 11. The pharmaceutical composition for parenteral administration of claim?, wherein the aqueous solution when stored in the container for one year at room temperature exhibits a total impurity formation of less than about 3%.
- 12. The pharmaceutical composition for parenteral admin-15 istration of claim 1, wherein the buffer is citric acid.
 - 13. The pharmaceptical composition for parenteral administration of claim 5, wherein the buffer is citric acid.
 - 14. The pharmaceutical composition for parenteral administration of claim 6, wherein the buffer is citric acid.
 - 15. The pharmaceutical composition for parenteral administration of claim 7, wherein the buffer is citric acid.

* * 8 4 9

EXHIBIT B

(12) United States Patent Duncan et al.

(10) Patent No.:

US 7,659,291 B2

(45) Date of Patent:

Feb. 9, 2010

(54) METHODS OF TREATMENT WITH PRE-MIXED, READY-TO-USE PHARMACEUTICAL COMPOSITIONS

(75) Inventors: Michelle Renee Duncan, Glenview, IL. (US); Supriya Gupta, Sunnyvale, CA (US); David Hartley Haas, Fremont, CA (US); Norma V. Stephens, Skokie, IL (US); Camellia Zamiri, Fremont, CA (US)

(73) Assignee: EKR Therapeutles, Inc., Bedminster, NJ (US)

Subject to any disclaimer, the term of this (*) Notice: patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: 12/407,557

Mar. 19, 2009 (22) Filed:

Prior Publication Data (65)

> US 2009/0182018 A1 Jul. 16, 2009

Related U.S. Application Data

- Division of application No. 11/788,076, filed on Apr. 18, 2007, now Pat. No. 7,612,102.
- Provisional application No. 60/793,074, filed on Apr. 18, 2006.

(51) Int. CL A618 31/44 (2006.01)

Field of Classification Search None See application file for complete search history.

(56)References Cited

U.S. PATENT DOCUMENTS

3,985,758	A		10/1976	Munkami
4,711,902	A		12/1987	Semo
4,880,823	A	*	11/1989	Ogawa et al 514/35
4,940,556	A		7/1990	MacFarlane
5,079,237	A		1/1992	Husu et al.
5,164,405	A	ф	11/1992	McFarlane et al 514/35
5,198,226	A		3/1993	MacFariane
RE34,618	\mathbf{E}		5/1994	Ogawa
5,376,645	A		12/1994	Stella
5,519,012	A		5/1996	Fercej-Temeljatov
5,904,929	A		5/1999	Uekama.
6,595,926	BI		7/2003	Latagh
2007/0112041	Al		5/2007	Bhownick
2007/0244166	Al		10/2007	Gupta.
2007/0249689	Al		10/2007	-

FOREIGN PATENT DOCUMENTS

EP	0149475 B1	7/1985
Hb	0162705 B1	11/1985
GB	2228412 A	B/1990

WO 2001/07086 * 2/2001 WO

OTHER PUBLICATIONS

Kaiser, Barb, et al., Solutions to Health Care Waste: Life-Cycle Thinking and "green" purchasing, Environmental Health Perspectives, vol. 109, No. 3, Mar. 2001, pp. 1-4.*

Pomponio, R. et al., Photostability studies on nicardipinecyclodestrin complexes by capillary electrophoresis, Journal of Pharmacentical and Biomedical Analysis 35 (2004) 267-275.*

Yang et al., "Nicardiplue versus nitroprusside influsion as anilhypartensive therapy in hypertensive emergencies," J. Int Med. Research, vol. 32(2):118-123 (Mm.-Apr. 2004).

Atles et al., "The use of esmolol, nicardipine, or their combination to blunt hemodynamic changes after laryngoscopy and trachest intuba-tion," Anesth Analg, vol. 90:280-285 (Feb. 2000).

Aya et al., "Inhawanous nicardipine for severe hypertension in proeclampsia -- effects of an acute treatment on mother and foctue,"

Intensive Care Med., vol. 25(11):1277-1281 (Nov. 1999). Cheung et al., "Nicardipine intravenous bolus dozing for acutely decreasing arterial blood pressure during general accethesia for cardisc operations: pharmscolkinetics, pharmscodynamics, and associ-ated effects on left wentricular function," Anesth Analg, vol. 89:13 16-

Colson et al., "Haemodynamic beterogeneity and treatment with the calcium channel blocker nicardipine during phaeochromocytoma hungery," Act Ameesthesial Scand., vol. 42(9):1114-1119 (Oct. 1998). Elatrous et al., "Short-term treatment of severe hypertansian of pregnancy: prospective comparison of nicardipine and laberalel," Intensiye Care Med., vol. 28(9):1281-1286 (7ti. 26, 2002). Pernandes et al., "Physiochemical characterization and in vitro dis-

solution behavior of nicardipine-cycloderarius inclusion compounds," Bur. J. of Phanna. Sei. 15; pp. 79-88, 2002.

Flynn et al., "Intravenous nicardipine for treatment of severe hypertension in children," J Podiatr., vol. 139(1):38-43 (Jul. 2001).

Kwak et al., "Comparison of the effects of nicardipine and sodium nitrogramide for control of increased blood pressure after coronary artery bypass graft surgery," J Int Med Res, vol. 32:342-350 (Jul.-Aug. 2004).

Vincent et al., "Intravenous nicardipme in the treatment of postopentive arterial hypottension," J Cardiothorac Vasc Anesth, vol. 11(2):160-164 (Apr. 1997).

Non Final Office Action for U.S. Appl. No. 11/737,067, dated Oct. 29, 2008.

PDL Biopharms, Isc.; "Cardene IV (nicardipine hydrochloride)," Product Insert, Jan. 2006, USA.

Sweetens and Akers, "Solubility principles and practices for parenteral drug dosage form development," PDAJ Pharmaceutical Science & Technology, 50(5):330-342 (1996).

Zhang et al., "The use of nicardipine for electroconvulsive therapy: a dose-ranging study," Anesth Analg, vol. 100:378-381 (Feb. 2005). Endoh et al., "Effects of nicardipine-, nitroglycerin-, and prostaglandin E1-induced hyperanties on human corebrovascular carbon diexide reactivity during propoful-fentanyl anesthesis," I Cliz Anesth, vol. 11(7):545-549 (Nov. 1999).

Primary Examiner—Robert A Wax Assistant Examiner-Lyndsey Beckhardt (74) Attorney, Agent, or Firm-Lowenstein Sandler PC

ABSTRACT (57)

Provided herein are ready-to-use premixed pharmaceutical compositions of nicerdipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

12 Claims, 5 Drawing Sheets

Page 2

OTHER PUBLICATIONS

Bernard et al., "Long-term hypotensive technique with meandipine

nemera et al., "Long-term hypotensive technique with nicerdipine and nitroprusside during isoffurane anesthesia for spinal surgery," Anesth Analy., vol. 75(2):179-185 (Aug. 1992). Chen et al., "The comparative potentry of intravenous nicerdipine and verspamil on the cardiovascular response to tracheal intubation," Acta Anaesthesiol Sin., vol. 34(4):197-202 (Dec. 1996). Song et al., "Optimal dose of nicardipine for maintenance of

hemodynamic stability after tractical intubation and akin incision," Anasta Analg, vol. 85:1247-1251 (Dec. 1997).

Cheung et al., "Acute pharmacokinetic and hemodynamic effects of intravenous boins down of nicaedipine," Am Heart J., vol. 119(2 Pt 2):438-442 (Feb, 1990).

Yalkowsky et al., "Formulation-related problems associated with intravenous drug delivery," J Pharm Sciences, vol. 87(7):787-796

Mauria et al., "Solubilization of nicardipine hydrochloride via complexation and salt formation," J Pharm Sciences, vol. 83(10):1418-1420 (Oct. 1994).

* cited by examiner


U.S. Patent

Feb. 9, 2010

Sheet 1 of 5

US 7,659,291 B2

FIG. 1





U.S. Patent

Feb. 9, 2010


Sheet 2 of 5


US 7,659,291 B2







U.S. Patent Feb. 9, 2010 Sheet 3 of 5 US 7,659,291 B2





U.S. Patent Feb. 9, 2010 Sheet 4 of 5 US 7,659,291 B2







U.S. Patent

Feb. 9, 2010

Sheet 5 of 5

US 7,659,291 B2





METHODS OF TREATMENT WITH PRE-MIXED, READY-TO-USE PHARMACEUTICAL COMPOSITIONS

1. CROSS REFERENCE TO RELATED **APPLICATIONS**

This application is divisional of U.S. patent application Ser. No. 11/788,076, filed Apr. 18, 2007, and claims benefit under 35 U.S.C. §119(e) to U.S. Provisional application Ser. 10 No. 50/793,074, filed Apr. 18, 2005, the contents of both of which are incorporated herein by reference.

2. BACKGROUND

Nicardipine hydrochloride ((±)-2-(henzyl-methyl amino) ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3, 5-pyridinedicarboxylate mono hydrochloride) is a calcium ion influx inhibitor useful for the treatment of cardiovascular 758). Nicardipine hydrochloride is currently sold in capsule form and in an injectable intravenous form. The capsule form is marketed as CARDENE® and is available as an immediate release oral capsule and as an extended release oral capsule. The injectable intravenous form of CARDENE® is marketed 25 in glass ampuls suitable for intravenous administration following dilution in a compatible intravenous fluid, such as dextrose or sodium chloride (CARDENE® I.V.). Each milli-Hier of a CARDENE® I.V. ampul contains 2.5 mg nicardipine hydrochloride in water, 48.0 mg sorbitol, buffered to pH 3.5 30 with 0.525 mg citric acid monohydrate and 0.09 mg sodium hydroxide. For infusion, each milliliter of the diluted formulation contains 0.1 mg of nicardipine hydrochloride, with a variable pH due to the diluent selected by the end user. United States Reissue Patent No. RE. 34,618 (a reissue, of U.S. Pat. 35 No. 4,880,823) describes an injectable composition of nicardipine hydrochloride that is stored in a light resistant brown ampul. U.S. Pat. No. 5,164,405 describes a buffered pharmacentical composition containing nicerdipine designed for parenteral administration, that is also stored in an ampul.

The requirement for diluting CARDENE® I.V. before use is associated with a number of disadvantages. One disadvantage is that the diluted solution is only stable for 24 hours at room temperature. Another disadvantage is that the pH of the diluted formulation varies depending on the choice of diluent. 45 Since CARDENE® I.V. can be used under emergency conditions to control blood pressure, dilution of the concentrated ampul formulation consumes valuable time that could be used to treat a patient. Other disadvantages associated with the dilution step include the potential for contamination, dosage 50 errors, and safety hazards associated with the use of glass

The pharmaceutical compositions and methods described herein overcome these disadvantages. In particular, the readyto-use, injectable formulations described herein are stable, 55 allow medical personal to use prepared containers containing an injectable formulation off the shelf without additional preparation, avoid potential contamination problems, and eliminate dosage errors.

3. SUMMARY

Described herein are ready-to-use, premixed pharmacentical compositions of nicerdipine or pharmaceutically acceptable salts thereof, which are suitable for continuous intravenous infusion. By providing ready-to-use, premixed pharmaceutical compositions with a buffered pH, these phar-

maceutical compositions are stable at room temperature for at least one year. When stored at room temperature, the pharmaceutical compositions exhibit between 0% to about 15% loss of drug and between 0% to about 3% (w/w) total impurity 5 formation over an eighteen to twenty four month period.

Additional benefits of the pre-mixed, ready-to-use, injectable pharmaceutical compositions include convenience and ease of use as compared to an ampul formulation, improved safety for patients due to elimination of dosage errors and solution contamination, reduction of medical waste, and case of administration in emergency situations

The present disclosure relates to premixed pharmacoutical compositions comprising nicardipine or pharmaceutically acceptable salts thereof, one or more tonicity agents, and a buffer. In some embodiments, the compositions optionally comprise one or more cosolvents. Nicardipine hydrochloride can be present at concentrations between about 0.05 mg/ml to about 15 mg/ml. Typically, the concentration range for nicardipine hydrochloride is between about 0.1 mg/ml to about and carebrovascular disorders (see, e.g., U.S. Pat. No. 3,985, 20 0.2 mg/ml. Optionally, the pharmaceutical compositions can comprise acids and bases.

> The pharmaceutical compositions described herein require no dilution prior to administration and typically have a pH within the range from about 3.6 to about 4.7. The compositions can be administered by parenteral routes, including, subcutaneous, intramuscular, intravenous, intra-atrial, or intra-arterial continuous infusion to a patient. The compositions are suitable for the short-term treatment of hypertension when oral therapy is not feasible or desirable.

Methods for making a premixed nicardipine hydrochloride formulation suitable for intravenous administration comprise the steps of providing an effective amount of meardinine hydrochloride in a solution comprising one or more tonicity agents, a buffer, and optionally, one or more cosolvents. Sufficient water is added to make up the final volume. If required, the pH of the solution can be adjusted using a suitable pH adjuster. The compositions are dispensed in pharmaceutically acceptable containers for storage and direct administration to patients.

4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 provides a diagrammatic illustration of the effect of various diluents on the pH and stability of an ampul formulation post dilution over a twenty four hour period at room temperature.

FIGS. 2A and 2B provide a diagrammatic illustration of the effect of pH on drug loss (FIG. 2A) and total impurity formstion (FIG. 2B) in a pranticed non-sorbitol formulation comprising 0.1 mg/ml nicardipine bydrochloride, 0.1 mM citric acid and 5% dextrose at 40° C.;

FIGS. 3A and 3B provide a diagrammetic illustration of the effect of pH on drug loss (FIG. 3A) and total impurity formstion (FIG. 3B) in a premixed non-sorbitol formulation comprising 0.1 mg/ml nicardipine hydrochloride, 0.1 mM citric acid and 0.9% saline at 40° C.;

FIGS. 4A and 4B provide a diagrammatic illustration of the effect of nicardipine concentration on impurity formation in 60 non-sorbital destrose formulations comprising 0.1 mg/ml nicerclipine hydrochloride, 0.1 mM citrate, 5% dextrose, or 0.2 mg/ml nicardipine hydrochloride, 0.2 mM citrate and 5% destrose after six months at 40° C. (FIG. 4A); and, in nonsorbitol saline formulations comprising 0.1 mg/ml nicardipine hydrochloride, 0.1 mM citrate, 0.9% saline, or 0.2 mg/ml nicardipine hydrochloride, 0.2 mM citrate and 0.9% saline after 3 months at 40° C. (FIG. 4B); and

3

FIGS. 5A and 5B provide a diagrammatic illustration of the effect of incompatible (FIG. 5A) and compatible (FIG. 5B) plastic film composition on product stability at 40° C. in a premixed non-sorbital formulation comprising 0.2 mg/ml nicardipins HCL, 0.2 mM citric acid, 5% dextrose, at a pH of 54.0 to 4.2.

5. DETAILED DESCRIPTION

The premixed pharmaceutical compositions described 10 herein comprise nicardipine or a pharmaceutically acceptable salt thereof as the active ingradient, at least one tonicity agent and a buffer. As used herein, the term "pre-mixed" refers to a pharmaceutical composition that does not require reconstitution or dilution before administration to a patient. In contrast to ampul formulations comprising recardipine hydrochloride that must be diluted prior to use in a diluent and container selected by hospital personnel, the premixed pharmaceutical compositions provided herein are stable at room temperature for 6 months or longer due to the inclusion of a buffer capable 20 of maintaiping the pH within an optimal pH range, which is typically between 3.6 to about 4.7. In some embodiments, suitable pH adjusters and/or cosolvents are added to the pharmaceutical compositions.

5.2 Premixed Pharmaceutical Compositions

The production of stable, ready-to-use, premixed pharmaceutical compositions comprising nicardipine and/or its pharmaceutically acceptable salts as the active ingredient presents different development hurdles than does the development of the concentrated amoul product sold commercially as 30 CARDENB® I.V. As shown in FIG. 1, the percent of nicardipine remaining in solution decreases as function of pH over a twenty-four hour period. The percent decrease in nicardipine varies with the diluent and container chosen by the hospital staff.

As described in the Examples, pH (see, also, e.g., FIGS. 2A, 2B, 3A and 3B), the concentration of the active ingredient (see, also, e.g., FIGS. 4A and 4B), and the composition of the container material (see, also, e.g., FIGS. 5A and 5B) affect the stability of the active ingredient and the formation of impurities. Thus, the development of a stable, ready-to-use premixed pharmacautical composition requires simultaneous optimization of pH and nicardipine hydrochloride concentration, as well as selection of a pharmaceutically compatible container. The ready-to-use pharmaceutical compositions 45 described berein exhibit 0% to 15% drop in drug concentration and 0% to 3% formation of impurities when maintained at room temperature for 6 to at least 24 months. Typically, the pharmaceutical compositions are stable when maintained at room temperature for at least 6 months, at least 12 months, at 50 least 18 months, and at least 24 months. The compositions are also stable over extended periods of time when maintained at temperatures from about 2° to 8° C. The term "stable", as used herein, means remaining in a state or condition that is suitable for administration to a patient.

Compounds for use according to the compositions and methods described herein that can contain one or more asymmetric centers can occur as racemates, racemic mixtures, and as single enautiomers. Accordingly, the compositions and methods described herein are meant to comprehend all isomatic forms of such compounds.

The premixed pharmaceutical compositions described herein comprise nicardipine and/or its pharmaceutically acceptable salts. Nicardipine, its pharmaceutically acceptable salts, preparation, and use are known in the art (see, e.g., 65 U.S. Pat. No. 3,985,758, incorporated herein by reference in its entirety). Examples of pharmaceutically acceptable salts

of nicardipine include hydrochlorides, sulfates, phosphates, acetates, firmarates, maleates and tartrates.

Typically, the premixed pharmaceutical compositions comprise 0.05-15 mg/ml nicardipine or a pharmaceutically acceptable salt thereof. For example, suitable concentrations of nicardipine or a pharmaceutically acceptable salt thereof, include, but are not limited to: 0.05-0.1 mg/ml, 0.1-25 mg/ml, 0.1-10 mg/ml, 0.1-5 mg/ml, 0.1-3.0 mg/ml, 0.1-2.0 mg/ml, 0.1-1.0 mg/ml, 0.9 mg/ml, 0.8 mg/ml, 0.7 mg/ml, 0.6 mg/ml, 0.5 mg/ml, 0.4 mg/ml, 0.5 mg/ml, 0.4 mg/ml, 0.3 mg/ml, 0.2 mg/ml or 0.1 mg/ml.

In some embodiments, the premixed pharmaceutical compositions comprise nicardipine hydrochloride as the active ingredient at a concentration sufficient to penult intravenous administration at a concentration between 0.1 mg/ml to 0.2 mg/ml. In some embodiments, the concentration of micardipine hydrochloride suitable for use in the compositions and methods described herein includes, but is not limited to, at least about 0.1 mg/ml. In other embodiments, the concentration of nicardipine hydrochloride suitable for use in the compositions and methods described herein includes, but is not limited to, at least about 0.2 mg/ml.

In some embodiments, the premited formulation comprises, in addition to nicardipine and/or its pharmacoutically acceptable salts, a buffer that has sufficient buffering capacity to maintain the desired pH range throughout the shelf-life of the product. As shown in FIGS, 2A and 2B, pH is important for the long term stability of nicardipine in the premixed pharmaceutical compositions. Although the pH of the premixed pharmaceutical compositions can range from between about 3.0 to about 7.0, pharmaceutical compositions having a pH within the range of about 3.6 to about 4.7 exhibit a lower percentage of drug degradation and total impurities (See FIGS, 2A, 2B, 3A and 3B). Accordingly, suitable pH ranges for use in the premixed plasmacoutical compositions include, 35 but are not limited to, pH range of at least about 3.0, at least about 3.1, at least about 3.2, at least about 3.3, at least about 3.4, at least about 3.5, at least about 3.6, at least about 3.7, at least about 3.8, at least about 3.9, at least about 4.0, at least about 4.1, at least about 4.2, at least about 4.3, at least about 4.4, at least about 4.5, at least about 4.6, at least about 4.7, at least about 4.8, at least about 4.9, at least about 5.0, at least about 5.2, at least about 5.5, at least about 6.0, at least about 6.5, at least about 7.0.

In some embodiments, the pH of the premixed pharmaceutical compositions is between about 3.0 to about 5.0. In other embodiments, the pH of the premixed pharmaceutical compositions is between about 3.6 to about 4.7. In other embodiments, the pH of the premixed pharmaceutical compositions is between about 4.0 to about 4.4. In yet other embodiments, the pH of the premixed pharmaceutical compositions is 4.2.

Buffers suitable for use in the pharmaceutical compositions described herein include, but are not limited to, pharmaccutically acceptable salts and acids of acetate, glutamate, citrate, tartrate, benzonte, laciate, histidine or other amino 55 acids, gluconate, phosphate, malate, succinate, formate, propionate, and carbonate. "Pharmaceutically acceptable" is used herein in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Accordingly, the term "pharmaceutically acceptable salt" references salt forms of the active compounds which are prepared with counter ions which are nontoxic under the conditions of use and are compatible with a stable formulation. The concentration of the buffer in the formulation can be expressed in mg/ml, g/L or as a molar concentration. In typical embodiments, from about 0.0001 mg/ml to about 100 mg/ml of a suitable buffer is present in the pharmaceutical compositions. Thus, the premixed pharma4

ceutical compositions can comprise from about 0.001 to about 0.001 mg/ml of a suitable buffer, from about 0.001 to about 0.01 mg/ml of a suitable buffer, from about 0.01 to about 0.1 mg/ml of a suitable buffer, from about 0.1 to 1 mg/ml of a suitable buffer, from about 1 to about 5 mg/ml of a suitable buffer, from about 5 to about 10 mg/ml of a suitable buffer, from about 10 to about 15 mg/ml of a suitable buffer, from about 20 mg/ml of a suitable buffer, from about 25 to about 25 mg/ml of a suitable buffer, from about 50 to about 25 mg/ml of a suitable buffer, from about 50 mg/ml of a suitable buffer, from about 50 mg/ml of a suitable buffer, from about 50 mg/ml of a suitable buffer, from about 75 to about 100 mg/ml of a suitable buffer.

Alternatively, the buffer concentration can be expressed as molar concentrations. In typical embodiments, from about 0.1 to 100 mM of a suitable buffer is present in the pharmaceutical compositions. Thus, the premixed pharmaceutical compositions can comprise a suitable buffer having a concentration from about 0.1 to about 100 mM, from about 0.1 to about 5 mM, from about 1.0 to about 5 mM, from about 1.0 to about 5 to about 10 mM, from about 1.0 to about 15 mM, from about 15 to about 25 mM, from about 25 to about 50 mM, from about 75 mM, and from about 75 to about 100 mM.

In some embodiments, the premixed pharmaceutical compositions further comprise a pH adjuster. Suitable pH adjust- 25 ers typically include at least an acid or a salt thereof, and/or a base or a salt thereof. Acids and bases can be added on an as needed basis in order to achieve a desired pH. For example, if the pH is greater than the desired pH, an acid can be used to lower the pH to the desired pH. Acids suitable for use in 30 premixed pharmaceutical compositions include, but are not limited to, hydrochloric acid, phosphoric acid, citric acid, ascorbic acid, acetic acid, sulphuric acid, carbonic acid and mitric acid. In some embodiments, hydrochloric acid is used to adjust the pH. By way of another example, if the pH is less as than the desired pH, a base can be used to adjust the pH to the desired pH. Bases suitable for use in premixed pharmaceutical compositions include, but are not limited to, sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, sodium citrate, sodium acetate, and magnesium 40 hydroxide. In some embodiments, sodium hydroxide is used to adjust the nH.

In some embodiments, the premixed pharmaceutical compositions further comprise one or more tonicity agents. Typically, tonicity agents are used to adjust the osmolality of the
premixed pharmaceutical compositions to bring it closer to
the osmotic pressure of body fluids, such as blood or plasma.
In some embodiments the tonicity of the premixed formulation can be modified by adjusting the concentration of buffer
and/or other components present in the premixed formulation.

Provided that the compositions are physiologically compatible, the compositions do not require any particular osmolality. Thus, the compositions can be hypotonic, isotonic or hypertonic. Typically the premixed pharmaceutical compositions have a tonicity between about 250 to about 350 mOsm/kg.

Suitable tonicity agents for use in the premixed pharmaceutical compositions include, but are not limited to, anhydrous or hydrous forms of sodium chloride, dextrose, sucrose, xylital, fructose, glycerol, sorbital, mannital, potassium chloride, mannose, calcium chloride, magnesium chloride and other inorganic salts. The quantity of the tonicity agent in the formulation can be expressed in mg/ml or in g/L. In typical embediments, the tonicity agent(s) is present from about 1 mg/ml to about 90 mg/ml. Thus, the premixed pharmaceutical compositions can comprise one or more tonicity agents at

about 1-5 mg/ml, at about 5-10 mg/ml, at about 10-15 mg/ml, at about 15-25 mg/ml, at about 25-50 mg/ml, at about 50-60 mg/ml, at about 60-70 mg/ml, at about 70-80 mg/ml, and at about 80 to 90 mg/ml, as well as combinations of the above ranges.

Alternatively, the tonicity agent concentration is measured in weight/volume percent. In typical embodiments, the tonicity agent(s) is present from about 0.1% to about 10%. For example, suitable tonicity agent concentrations include, but are not limited to, from about 0.1% to about 0.2%, from about 0.2% to about 0.4%, from about 0.4% to about 0.4%, from about 0.5%, from about 0.5%, from about 0.7% to about 0.6%, from about 0.6% to about 0.7%, from about 0.9% to about 1%, from about 0.9% to about 1%, from about 0.9% to about 3%, from about 3% to about 4%, from about 4% to about 5%, from about 5% to about 5%, from about 6% to about 7%, from about 5% to about 5%, from about 5% to about 5%, from about 6% to about 5%, from about 5% to about 5%, from about 6% to about 5%, from about 5% to about 5%, from about 8% to about 9%, and from about 9% to about 10%, as well as combinations of the above ranges.

In some embodiments, the tenicity agent is dextrose. Typically, the concentration of dextrose suitable for use in the premixed pharmacoutical compositions is between about 2.5% (w/v) to about 7.5%. By way of example, suitable dextrose concentrations include, but are not limited to, from about 2.5% to about 3%, from about 3% to about 3.5%, from about 3.5% to about 4% (which is equivalent to about 4.0 mg/ml), from about 4.5% from about 4.5% from about 5.5% in about 5.5% from about 5.5% to about 5.5%, from about 6% to about 6.5%, from about 6.5%, from about 6.5% about 6.5% to about 6.5% to about 6.5% to about 6.5% about 6.

In some embodiments, the tonicity agent is sodium chloride. Typically, the concentration of sodium chloride suitable for use in the premixed pharmaceutical compositions is between about 0.1% (w/v) to about 1.8%. By way of example, suitable sodium chloride concentrations include, but are not limited to, from about 0.1% to about 0.2%, from about 0.2% to about 0.3%, from about 0.3% to about 0.4%, from about 0.4% from about 0.4% to about 0.6%, from about 0.6% to about 0.6% to about 0.7%, from about 0.7% to about 0.8% to about 0.9% (which is equivalent to 8 mg/ml), from an 0.8% to about 0.9% (which is equivalent to 9 mg/ml), from about 0.9% to about 1.0%, from about 1.9% to about 1.2%, from 1.2% (which is equivalent to 12 mg/ml) to about 1.4%, from about 1.4% to about 1.6%, and from about 1.6% to about 1.8%.

In some embodiments, the premixed pharmsceutical compositions comprise two, three, four, or more tonicity agents. In these embodiments, the concentration of each tonicity agent is typically less than the concentration that is used when only a single agent is present in the premixed formulation. For example, if the premixed formulation comprises sorbitol at 1.92 mg/ml, a suitable concentration of sodium chloride is 8.6 mg/ml. By way of another example, if the premixed formulation comprises 1.92 mg/ml sorbitol, a suitable concentration of dectrose is 48 mg/ml.

In some embodiments, the premixed pharmaceutical compositions further comprise one or more coscivents. A "cosolvent" is a solvent which is added to the aqueous formulation
in a weight amount which is less than that of water and assists
in the solubilization of nicardipline and/or a pharmaceutically
acceptable salt thereof, enhances stability of the premixed
formulation, and/or adjusts the osmolality of the premixed
pharmaceutical compositions. Cosoivents suitable for use in
the premixed pharmaceutical compositions include, but are

7

not limited to, glycols (e.g., polyethylene glycol, propylene glycol), ethanol, and polyhydric alcohols (e.g., sorbitol, mannitol, xylitol).

The quantity of the cosolvent used in the formulation can be expressed in mg/ml or in g/L. In typical embodiments, the cosolvent(s) is present from about 1 mg/ml to about 100 mg/ml. Thus, the premixed pharmaceutical compositions can comprise one or more cosolvent(s) at about 1 to about 2 mg/ml, at about 2 to about 3 mg/ml, at about 3 to about 4 mg/ml, at about 4 to about 5 mg/ml, at about 5 to about 10 mg/ml, at about 10 to about 15 mg/ml, at about 50 to about 25 mg/ml, at about 25 to about 70 mg/ml, at about 70 to about 80 mg/ml, at about 50 to about 80 mg/ml, at about 50 to about 80 mg/ml, at about 50 to about 60 mg/ml, at about 70 to about 90 to 100 mg/ml, as well as combination of the above ranges.

Alternatively, the cosolvent concentration is measured in weight/volume percent. In typical embodiments, the cosolvent(s) is present from about 0.1 % to about 25%. For example, suitable cosolvent concentrations include, but are not limited to, at least about 0.1% to 0.3%, from about 0.3% to about 0.5%, from about 0.5% to about 0.7%, from about 0.7% to about 0.9%, from about 0.9% to about 1%, from about 1% to about 3%, from about 3% to about 5% from about 5% to about 7%, from about 5% to about 1%, from about 11% to about 9% to about 11%, from about 11% to about 13% from about 13% to about 15%, from about 11% to about 20%, and from about 20% to about 25%, as well as combination of the above ranges.

In some embodiments, the premixed phermaceutical compositions further comprise one or more cyclodextrins. Due to 36 their structure, cyclodextrins have the ability to form complexes, or inclusion complexes, with a variety of organic and inorganic molacules. Complexes of nicardipine with cyclodextrins have been described (see, e.g., U.S. Pat. No. 5,079, 237 which describes an inclusion complex of nicardipine or 35 its hydrochloride with alpha-cyclodextrin, beta-cyclodextrin or gamma-cyclodextrin; U.S. Pat. No. 5,519,012 which describes inclusion complexes of dihydropyridines, including nicardipine, with hydroxy-alkylated-β-cyclodentrins; and, U.S. Pai. No. 5,904,929 which describes numerous drogs in a pharmaceutical composition with per-C2-18 acylated cyclodextrins). None of the above references discloses a dihydropyridine in combination with a cyclodestrin comprising a sulfate group. An example of a commercially available sulfated cyclodextrin is CAPTISOLO. CAPTISOLO is a polyanionic β-cyclodextrin derivative with a sodium sulfonate salt that is separated from the lipophilic cavity by a butyl other spacer group, or sulfobutylether. Methods for making the sulfoalkyl ether cyclodextrin derivatives are well known in the art and are sought in U.S. Pat. No. 5,376,645. Methode for 50 forming complexes of the derivatives with a drug are also well known in the art as disclosed in U.S. Pat. No. 5,376,645.

The cyclodextrin concentration can be measured in weight/volume percent. In typical embodiments, cyclodextrin(s) is present from about 0.1% to about 25%. For example, suitable 55 cyclodextrin(s) concentrations include, but are not limited to, at least about 0.1% to 0.3%, from about 0.3% to about 0.5%, from about 0.5% to about 0.5%, from about 0.5% to about 0.9%, from about 1% to about 3%, from about 1% to about 3%, from about 5% to about 7%, 60 from about 7% to about 9%, from about 9% to about 11%, from about 11% to about 13% from about 13% to about 15%, from about 15% to about 20%, and from about 20% to about 25%.

Examples of stable, premixed pharmaceutical compositions comprising the active ingredient, a tonicity agent, a buffer and optionally, a cosolvent are shown in Table 1. TABLE 1

3	Active Ingradient	Tonicity Agent(s) (mg/ml)	Buffer (mg/ml)	Cosolvant (mg/ml)	pΞ
	nicardipina hydrocklorida (0.1 mg/ml)	NaCi (8.6 mg/ml)	Citric anid, anhydrous (0.0)92 mg/ml)	Sorbitol (1.92 aug/mi)	3.6-4,7
10	nicardipine bydrochloride (0.1 mg/ml)	Destrose, hydrous (48 mg/ml)	Citrio acid, anhydrous (0.0192 mg/ml)	Sorbitol (1,92 mg/ml)	3.6-4.7
	nicardigine hydrochlorida	NaCl (9 mg/mi)	Citric sold, anhydrons	None	3.6-4.7
15	(0.1 mg/m) nicardiphe hydrochlonide	Destione, hydrour	(0.0192 mg/ml) Citric acid, anhydrons	None	3.6-4.7
	(0.1 mg/ml) nicardipine hydrochloride	(50 <i>mg/ml</i>) NaCi (9 mg/ml)	(0.0192 mg/ml) Citric sold, anhydrous	None	3.6-4.7
20	(0.2 mg/ml) nicardipine hydrochloride	Destrose, hydroue	(0.0314 mg/ml) Citric sold, subydrous	None	3.6-4.7
	(0.2 mg/ml) nicardigine hydrockleride (0.2 mg/ml)	(50 mg/ml) NaCi (8,3 mg/ml)	(0.0384 mg/ml) Citric sold, sultydrour (0.0384 mg/ml)	Sorbital (3.84 mg/ml)	3.6-4.7
25	nicerdipine hydrochlorida (0.2 mg/ml)	Desirose, hydrone (46 mg/ml)	Ciric soid, anhydrous (0.0384 mg/ml)	Sorbitol (3.84 mg/ml)	3,5-4.7

In some embodiments, the pharmacentical compositions are any as described in U.S. Provisional Application Ser. No. 60/793,084, filed Apr. 18, 2006, which is incorporated herein by reference.

5.3 Methods

The order in which various components comprising the compositions is added to the buffered solution is not critical. provided that the resulting compositions are stable and are suitable for continuous intravenous infusion. Accordingly, the compositions described herein can be made by prepared in a number of different ways. For example, in some embodiments, the compositions can be prepared by adding buffer, a tonicity agent and/or a cosolvent to water; adding nicardipine to the buffered water solution; adding an pH adjuster to achieve the desired pH; and then adding sufficient water to make up the final volume. If necessary, the pH can be readjusted to achieve the desired pH range. By way of another example, the compositions can be prepared by adding buffler and nicardipine or a pharmaceutically acceptable salt thereof to water; adding a tenicity agent and/or cosolvent, adjusting the pH to achieve the desired pH range; and then adding sufficient water to make up the final volume. By way of another example, a cosolvent can be added prior to the addition of nicardipine or a pharmaceutically acceptable sait thereof, and a tonicity agent can be added after the addition of nicerdipine or a phermaceutically acceptable salt thereof. By way of another example, a tonicity agent can be added prior to the addition of nicardipine or a pharmaceutically acceptable salt thereof, and a cosolvent can be added after the addition of nicardiplne or a pharmaceutically acceptable salt thereof, Hy way of another example, the compositions can be prepared by adding buffer, tonicity agent and/or cosolvent to water; adjusting the pH to a first pH range suitable for dissolving nicardipine (for example, less than pH 3.6); adding nicardipine or a pharmaceutically acceptable salt thereof; adjusting the nH to achieve the desired final pH range; and then adding sufficient water to make up the final volume.

In some embodiments, pharmacentical compositions comprising nicardipine hydrochloride, dextrose, and citric buffer at pH 3.6-4.7 can be prepared by adding citric acid to water, ø

adding dextrose to the buffered water, adding nicardiplne hydrochloride to the buffered water solution, adjusting the pH if necessary to the range 3.6-4.7, and adding sufficient water to make up the final volume. If necessary, the pH can be readjusted to between about 3.6 to about 4.7.

In some embodiments, pharmaceutical compositions comprising nicardipine hydrochloride, acdium chloride, and citrate buffer at pH 3.6 to about 4.7 can be prepared by adding citric acid to water, adding nicardipine to the buffered water solution, adding sodium chloride to the buffered water solution, adjusting the pH to between about 3.6 to about 4.7, and adding sufficient water to make up the final volume. If sorbital is included in the formulation, sorbitol is added at the same time as the citric acid.

In some embodiments, the pharmaceutical compositions 15 can be prepared by adding nicardipine or a pharmaceutically acceptable salt thereof to an acidic solution having a pH less than 5.0. For example, the acidic solution can be prepared by adding an acidic component of a buffer system. A buffer, one or more tonicity agents, and/or cosolvents can be added to the 20 acidic solution before or after dissolving the nicardipine. Sufficient water is then added to make up the final volume, If necessary, the pH of the composition can be adjusted to between about 3.6 to about 4.7.

In some embodiments, the pharmacentical compositions can be made by adding nicardipine or a pharmacentically acceptable salt thereof to a solution that has been heated to a temperature greater than 35° C.; adding buffer, one or more tonicity agents and/or cosolvents to the acidic solutions; and adding sufficient water to make up the final volume. If necessary, the pH of the composition can be adjusted to between about 3.6 to about 4.7.

The pharmaceutical compositions can be packaged for use in a variety of containers. The compositions are preferably packaged in a pharmaceutically acceptable container, such as an intravenous bag or bottles. Due to the light sensitivity of nicardipina, packages can be used that reduce the amount of light which can reach the composition. For example, in some embodiments, the container may, optionally, further comprise a light barrier, such as an aluminum overpouch or a 40 carton.

In some embodiments, the premixed pharmaceutical compositions are dispensed in intravenous bags, such as pre-mix bags and admix bags. Intravenous bags are well known in the art and commercially available. Examples of intravenous 45 bags include, but are not limited to: GALAXY®, INTRAVIA®, SOLOMIX®, STRDIM® 71, STRDIM® 100, VIAFLEX®, EXCEL®, VISIV®, VIAFLO™, ADDEASE®, ADD-VANTAGE®, DUPLEX™, FIRST CHOICE™, PROPYFLEX™ and BFS™.

In some embodiments, the components of the bag that come into contact with the pharmaceutical compositions should not contain polar polymers, such as polyvinyl chloride (PVC) and ethylene vinyl scetate (BVA). Examples of bags that do not contain polar polymers and thus, are suitable for 55 use in these embodiments, include, but are not limited to, GALAXY®, EXCEL®, VISIV®, and VIAFLO™.

Procedures for filling pharmaceutical compositions in pharmaceutically acceptable containers, and their subsequent processing are known in the art. These procedures can be used to produce sterile pharmaceutical drug products often required for health care. See, e.g., Center for Drug Evaluation and Research (CDRR) and Center for Veterinary Medicine (CVM), "Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products", (November 1994). Examples of suitable procedures for producing sterile

10

pharmacentical drug products include, but are not limited to, terminal moist heat sterilization, ethylene oxide, radiation (i.e., gamma and electron beam), and aseptic processing techniques. Any one of these sterilization procedures can be used to produce the sterile pharmaceutical compositions described basely.

In some embodiments, sterile pharmaceutical compositions can be prepared using aseptic processing techniques. Sterility is maintained by using sterile materials and a controlled working environment. All containers and appearatus are sterilized, preferably by heat sterilization, prior to filling. Then, the container is filled under aseptic conditions, such as by passing the composition through a filter and filling the units. Therefore, the compositions can be sterile filled into a container to avoid the host stress of terminal sterilization.

In some embodiments, the compositions are terminally sterilized using moist heat. Terminal sterilization can be used to destroy all viable microorganisms within the final, scaled container containing the pharmaceutical composition. An antoclave is typically used to accomplish terminal heat-sterilization of drug products in their final packaging. Typical autoclave cycles in the pharmaceutical industry to achieve terminal sterilization of the final product are 121° C. for st least 10 minutes.

The pharmaceutical compositions described herein can be used for prevention or treatment of scute elevations of blood pressure in a human patient in need thereof. In some embodiments, the patients being treated may be volume-restricted due to a co-existing medical condition and thus can benefit from the administration of higher concentration and lower fluid volume of nicardipine. Examples of medical conditions in which it would be advantageous to administer low volume formulations include, renal failure, ascites, cerebral edema, congestive heart failure, liver failure, or a CNS injury. Dosages can be individualized depending upon the severity of hypertension and the response of the individual patient during dosing. Typically, the dosage is administered as a continuous infusion of a pre-mixed product. In some embodiments, the patient has an elevated blood pressure with a systolic equal to or greater than 150 mm Hg. In other embodiments, the subject has an elevated blood pressure with a diastolic value greater than or equal to 90 mm Hg.

In some embodiments, the pharmaceutical compositions can be used to prevent acute elevations of blood pressure associated with various medical procedures. Examples of medical procedures associated with acute elevations of blood pressure include, but are not limited to, electroconvulsive therapy (see, e.g., Avramov, et al., 1998, J. Clinical Anesthesia, 10:394-400), caretid endarteractumy (see, e.g., Dorman, et al., 2001, J. Clinical Anesthesia, 13:16-19, tracheal intubation (Song, et al., 2001, Anesth Analg., 85:1247-51) and akin incision (Song, et al., 2001, Anesth Analg., 85:1247-51).

In some embodiments, the pharmaceutical compositions can be used to treat acute elevations in blood pressure due to certain cardiovascular and cerebrovascular conditions. Examples of cardiovascular conditions that are associated with acute elevations of blood pressure include, but are not limited to, essential hypertension, angina, acute ischemia, systemic arterial hypertension, congestive heart failure, coronary artery disease, myocardial infarction, cardiac arrhythmias, cardiomyopathies and arteriosclurosis. Examples of cerebrovascular conditions are associated with acute elevations of blood pressure include, but are not limited to pulmonary hypertension, carebral insufficiency and migraine headache.

In some embodiments, the pharmaceutical compositions can be used to treat other conditions that cause hypertension

11

including, but not limited to, renal disorders (e.g., renal parenchymal disorders or renal vascular disease), coarctation of the sorts, pheochromocytoma, hyperthyroidism, metabolic syndrome, solid organ transplant and drug-related hypertension.

In some embodiments, the pharmaceutical compositions can be used to induce hypotension during surgical procedures including, but not limited to cardiothoracic surgery, spinal surgeries and head and neck surgeries.

6. ALTERNATIVE ASPECTS

In an alternative aspect, the present invention relates to pre-mixed, ready-to-use, injectable pharmacoutical compositions comprising a cardiac medication or a pharmacentically 15 acceptable salt thereof, and at least one of a co-solvent and a complexing agent, and a buffering agent. The composition may further comprise a tonicity agent. The compositions are preferably isotonic. The pH of the compositions is preferably between 3 and 7. The compositions are preferably packaged 20 in a pharmaceutically acceptable container, such as an intravenous bag, syringe or vial. Preferably, the compositions are used for the treatment of cardiovascular and cerebrovascular conditions. The present invention also relates to methods for preparing such compositions. In this other aspect, the term 25 "pre-mixed", as used herein, means a pharmaceutical composition that is already mixed from the point of manufacture and does not require dilution or further processing before administration. The term "pre-mixed" may also mean a pharmaceutical composition wherein the liquid solution and the 30 active pharmaceutical ingredient are separated from the point of manufacture and in storage, such as when the solution is stored in an intravenous bag and the active pharmaceutical ingredient is lyophilized and stored in a vial that is connected to the bag, but not in fluid contact with the solution until just 35 before administration to a patient. Preferably, the pharmaceatical compositions are aqueous solutions that are administered by injection. Alternatively, the pharmaceutical compositions may be lyophilized and then reconstituted in isotonic saline, for example, before intravenous administration.

In this alternative aspect, the pharmaceutical compositions of the present invention comprise a cardiac medication or a pharmacontically acceptable salt thereof. Examples of classes of cardiac medications include beta-blockers, calcium channel antagonists, angiotensin converting enzyme inhibi- 45 tors, diuretics, vasodilators, nitrates, anti-platelet medications and anti-coagulants. Preferably, the cardiac medication is a calcium channel antagonist or a pharmaceutically acceptable salt thereof. More preferably, the cardiac medication is a dihydropyridine derivative or a pharmaceutically acceptable 50 salt thereof. Most preferably, the cardiac medication is nicardipine or a pharmaceutically acceptable salt thereof. Examples of pharmaceutically acceptable salts of nicardipine are hydrochlorides, sulfates, phosphates, acetates, fumarates, maleates and tartarates. The preferred pharmaceutically 55 acceptable salt of nicardipine is nicardipine hydrochloride. The pharmaceutical compositions may comprise 0.05-1.5 mg/ml of nicardipine or a pharmaceutically acceptable salt thereof. Preferably, the pharmaceutical compositions comprise 0.15-0.35 mg/ml of nicardipine or a pharmaceutically so acceptable salt thereof. More preferably, the compositions comprise 0.2-0.3 mg/ml of nicardipine or pharmaceutically acceptable salt thereof. Nicardipine and its pharmaceutically acceptable salts, their preparation, and their use are known in the art. For example, they are disclosed in, among other 55 references, U.S. Pat. No. 3,985,758, which is incorporated herein by reference in its entirety.

In some embodiments, the pharmaceutical compositions comprise 0.1-15 mg/ml nicardipins or a pharmaceutically acceptable salt thereof. For example, suitable concentrations of nicardipine or a pharmaceutically acceptable salt thereof, include, but are not limited to: 0.1-15 mg/ml, 0.1-10 mg/ml, 0.1-5 mg/ml, 0.1-3.0 mg/ml, 0.1-2.0 mg/ml, 0.1-1.0 mg/ml, 0.9 mg/ml, 0.8 mg/ml, 0.7 mg/ml, 0.6 mg/ml, 0.5 mg/ml, 0.4

mg/ml, 0.3 mg/ml, 0.2 mg/ml or 0.1 mg/ml.

In this alternative aspect, the pharmaceutical compositions can be used to treat cardiac conditions. Preferably, the compositions can be used to treat conditions that are alleviated by the administration of calcium channel antagonists, such as cardiovascular and cerebrovascular conditions. Cardiovascular conditions that can be treated with the pharmaceutical compositions of the present invention include angina, ischemia, systemic arterial hypertension, congestive heart failure, coronary artery disease, myocardial infarction, cardiac arrhythmias, cardiomyopathies and arteriosclerosis. Cerebrovascular conditions that can be treated with the pharmaceutical compositions of the present invention include pulmonary hypertension, cerebral insufficiency and migraine. Preferably, the compositions are used to treat hypertension.

In this alternative aspect, the pharmaceutical compositions of the present invention also comprise at least one of a cosolvent and a complexing agent. Therefore, the compositions may comprise a cosolvent, a complexing agent, multiple cosolvents, multiple complexing agents, a cosolvent and a complexing agent, a cosolvent and multiple complexing agents, a complexing agent and multiple cosolvents, or multiple cosolvents and multiple cosolvents.

In this alternative aspect, Nicardipine and its pharmaceutically acceptable salts are only slightly soluble in water. Concivents and complexing agents help solubilize nicardipins in the acqueous solution of the pharmaceutical composition. Coscivents and complexing agents are especially beneficial when a high concentration of nicardipine is present, such as in the compositions of the present invention. An advantage of the compositions of the present invention is that they have a high concentration of nicardipine, which allows the composition to be administered using a lower volume of intravenous fluid. Such compositions can be a treatment option for a greater number of patients, especially volume restricted patients.

In this alternative aspect, patients and medical conditions that may benefit from a higher concentration and lower fluid volume of nicardipine include, but are not limited to, the following: acute congestive cardiac failure; pediatries; hypertensive crises in elderly patients where fluid overload is a major concern; all acute stroke areas including AIS, ICH and SAH to control blood pressure; controlled hypotension during surgical procedures including cardiothoracic surgery (CABG, coarctation of the acrta, etc.), spinal surgeries, and head and neck surgeries; and neurosurgery for the control of breakthrough hypertension post carotid endarterectomy, traumatic brain injury and potential treatment of hypertension and vascorosum.

In this alternative aspect, in addition to enhancing solubility, cosolvents and complexing agents enhance the stability of the pharmaceutical compositions. Furthermore, changes may be made to the concentration of cosolvents and complexing agents in the pharmaceutical compositions in order to adjust the tonicity of the pharmaceutical compositions. Pharmaceutically acceptable cosolvents are known in the art and are commercially available. Typical cosolvents include polyethylens glycol (PEG), propylene glycol (PG), ethanol and sorbitol. Preferably, the cosolvent concentration is 0.1-10% weight/volume percent, which will depend on the pH of the

13

composition. More preferably, the cosolvent concentration is 0.1-5%. Most preferably, the cosolvent concentration is 0.1-2%. Preferred cosolvents for the pharmaceutical compositions are propylene glycol and sorbitol. Preferably, the concentration of propylene glycol is 0.1-2%. More preferably, 5 the concentration of propylene glycol is 0.1-1%. Most preferably, the concentration of propylene glycol is 0.3%. A preferably, the concentration of sorbitol is 0.1-2%. An even more preferred concentration of sorbitol is 0.1-1%. A most preferred concentration of sorbitol is 0.5%.

In this alternative aspect, pharmaceutically acceptable complexing agents are known in the art and commercially available. Typical complexing agents include cyclodextrins, such as natural eyeodentrius and chemically modified cyclodextrins. Preferably, the complexing agent is a beta cyclodextrin. Preferred complexing agents for the pharmaceutical compositions are 2-hydroxypropyl-8-cyclodextrin (2HP-BCD) and sulfobutylether-β-cyclodextrin (SBEBCD). Preferably, the complexing agent concentration is 0.1-25% weight/volume percent. More preferably, the complexing 20 agent concentration is 0.1-10%. Most preferably, the complexing agent concentration is 0.1-5%. Preferably, the concentration of 2HPBCD is 15-25%. More preferably, the concentration of 2HPBCD is 20-25%. The preferred concentration of SBEBCD is 0.1-10%. An even more pre- 25 ferred concentration of SBEBCD is 0.1-5%. The most preferred concentration of SBEBCD is 0.75 to 1%.

In addition, the pharmaceutical compositions in this alternative aspect can comprise a buffering agent. However, the compositions may comprise multiple buffering agents. The pharmaceutical compositions of the present invention are preferably close to physiological pH in order to minimize the incidence of phlebitis upon administration. However, the pH of the pharmaceutical composition also affects the solubility and stability of nicardipine in the composition. Generally, as the pH of the pharmaceutical composition increases, it is additional to solubilize nicardipine close to physiological pH. In addition, the composition abould have sufficient buffering capacity such that the solution does not precipitate upon dilution with blood when administered.

In this alternative aspect, typical buffering agents include acctate, glutamate, citrate, tartrate, benzoate, lactate, histidine or other amino acids, gluconate, phosphate and succinate. The preferred buffering agents are acctate and succinate. A preferred buffering agent concentration is 1-100 mM. An even more preferred buffering agent concentration is 1-50 mM. An even more preferred buffering agent concentration is 25-35 mM.

In this alternative aspect, preferably, the pharmaceutical compositions of the present invention are isotonic, i.e., in the range of 270-328 mOsm/kg. However, the compositions may have a ronicity in the range of 250-350 mOsm/kg. Therefore, the compositions may be either alightly hypotonic, 250-269 mOsm/kg, or slightly hypertonic, 329-350 mOsm/kg. Preferably, the tonicity of the pharmaceutical compositions is rendered isotonic by adjusting the concentration of any one or more of cosolvent, complexing agent and buffering agent in the solution.

In this alternative aspect, the pharmaceutical compositions of the present invention may further comprise a toricity agent. However, the compositions may further comprise multiple tonicity agents. Tonicity agents are well known in the art and commercially available. Typical tonicity agents include sodium chloride and dextrose. The preferred tonicity agent is sodium chloride. A preferred tonicity agent concentration is

1-200 mM. A more preferred tonicity agent concentration is 75-125 mM. An even more preferred tonicity agent concentration is 90-110 mM.

The pharmaceutical compositions of the present invention are preferably packaged in pharmaceutically acceptable containers in this alternative aspect. Pharmaceutically acceptable containers include intravenous bugs, bottles, vials, and syringes. Preferred containers include intravenous bags and syringes, which are preferably polymer-based, and vials and intravenous bottles, which are preferably made of glass. It is also preferred that the components of the container that come into contact with the pharmaceutical composition do not contain polyvinylchloride (PVC). The most preferred container is an intravenous bag that does not have any PVC containing components in contact with the pharmaceutical composition. It is also desirable to protect the pharmaceutical compositions from light. Therefore, the container may, optionally, further comprise a light barrier. A preferred light barrier is an aluminum overpouch.

This alternative aspect also provides methods as described above for preparing the pharmaceutical compositions which are sterile.

7. EXAMPLES

Examples 1 through 6 are intended to be illustrative and not limiting as to the general disclosure. Examples 7 through 12 disclose specific embodiments of the pharmaceutical compositions that are principally illustrative of the alternative 30 aspects described herein.

Examples 1 Through 6

Example 1

Effect of Various Diluents on Stability of Concentrated CARDENE®I.V.

Stability results for the concentrated ampul product diluted to 0.1 mg/ml with various commonly used intravenous infusion fluids in an IV bag are shown in FIG. 1. pH after mixing was measured and is reported on the X-axis. Product stability was measured by monitoring the % drug remaining after duration of 24 hours by RP-HPLC and is shown on the Y-axis.

As shown in FIG. 1, the instability of nicardipine hydrochloride is related to the initial pH of the infusion fluid and to the final pH of the solution after mixing. The magnitude of drug loss post dilution increases as the final pH of the solution after mixing increases, for example, a very pronounced drug loss is obtained when the pH is above 4.5. Based on these findings, the product insert for the marketed ampul product requires product dilution be carried out using specific infusion fluids. Furthermore, the diluted product must be used within 24 hours.

Example 2

Effect of pH on Stability

Stability results for a 0.1 mg/mL nlcardipine HCl, 0.1 mM citric acid, and 5% dextrose formulation dispensed in a GAL-AXY® bag are shown in FIGS. 2A and 2B. Stability results for a 0.1 mg/ml. nicardipine HCl, 0.1 mM citric scid, 0.9% saline formulation dispensed in a GALAXY® bag are shown in FIGS. 3A and 3B. Stability assessments are done by measuring the % drug remaining and the total impurity formation as a function of time using RP-HPLC.

15

Stability testing was done at an accelerated temperature of 40° C. Based on published literature, activation energies for drug decompositions usually fall in the range of 12 to 24 Kcal/mol, with typical value of 19-20 Kcal/mol, Under these conditions (assumption Ea=19.4 Kcal/mol) 15 weeks storage at 40° C. corresponds to a product with approximately 18 months expiration at 25° C. (see, e.g., Connors, K. A., et al., Chemical Stability of Pharmaceuticals, A Handbook for Pharmacisis, John Wiley & Sons, 2d ed. 1986).

As shown in FIGS. 2A and 3A, loss in product potency (drop in % drug remaining) due to degradation and adsorption on to the bag surface increased as the formulation pH was increased. For example, after 6 months storage at 40° C. for the destrose formulations, a clear trend indicating increased drug loss for formulations at pH 4.4 and 4.7 can be observed. 15 At pH 3.3, the drop in % drug remaining is attributed to an increase in total impurities (FIGS. 2B and 3B), rather than drug loss due to adsorption. In addition to the observed drug loss, the formation of nicardipine-related impurities (FIGS. 2B and 3B) was also found to be strongly pH dependent. In 20 this case, however, the reverse trend was observed; as the pH was decreased, the total impurities increased.

The results from this study indicate that the formulation pH has a significant effect on stability of a ready-to-use diluted product. The findings of this study indicate that the optimal 25 formulation pH range is between about 3.6 to about 4.7. However, depending on the degree of acceptable drug degradation and/or total impurity formation, other pH ranges can be chosen.

Example 3

Effect of Nicardipine Concentration on Impurity Formation

The effect of nicardipine concentration on impurity formation in ready to use premixed compositions comprising 0.1 mg/ml. and 0.2 mg/ml non-sorbitol formulations with dextrose over 5 months at 40° C. is shown in FIG. 4A. The effect of nicardipine concentration on impurity formation in ready to use premixed compositions comprising 0.1 mg/ml and 0.2 mg/ml. non-sorbitol formulations with saline over 3 months at 40° C. is shown in FIG. 4B. The formulations are dispensed in GALAXY® bags. Stability assessments are done as described in Example 2.

As shown in FIGS. 4A and 4B, in addition to pH, product concentration is another factor that impacts product stability, in particular the formation of nicardipine-related impurities. The concentration dependence observed with respect to total impurity formation is minimized as the formulation pH is so increased. For example, in PIG. 4A and B, the effect of concentration is significant at pH 3.3 and is minimized as the pH approaches 4.7.

These results indicate that impurity formation is greater for the 0.1 mg/ml formulations as compared to the 0.2 mg/ml 55 formulations for both the dextrose and saline formulations. Simultaneous optimization of the drug concentration along with the viable formulation pH range is important in the development of ready-to-use premixed drug formulations.

Example 4

Stability Comparison of Sorbitol and Non-Sorbitol Formulations

A stability comparison of sorbitol and non-sorbitol formulations was conducted under accelerated conditions (4 weeks at 40° C.) using a 0.1 mg/mL nicardipine HCl, 1.92 mg/mL sorbitol, 48 mg/mL dextrose, 0.0192 mg/mL citric acid, pH 4.2 and a 0.1 mg/mL nicardipine HCl, 50 mg/mL dextrose, 0.0192 mg/mL citric acid, pH 4.0. Both formulations were dispensed in GALAXY® hags. Stability assessments were done by measuring the % drug remaining and total impurity formation as a function of time using RP-HPLC. The results

16

TABLE 2

are shown in Tables 2 and 3.

Destrous Formulation without Soction							
Time	% Drug Remaining	% Total Impuritor					
O	100,0	0.08 0.17					
	Time	% Drug Time Remaining					

TABLE 3

Destroye Formulation with Scabital

Time	K Dru Remaini		
0	100,0 96,4	NMT ¹ 0,05 0,13	

NMT refers to no more than.

As shown in Tables 2 and 3, minimal differences between the two formulations were observed in the measured parameters. Based on these results, as well as the results shown in Examples 1 and 2, the presence or absence of sorbitol is not predicted to alter the impact of formulation pH and drug concentration on the stability of the premixed pharmaceutical compositions comprising nicerdipine HCl and dextrose or sodium chloride.

Example 5

The Effect of Plastic Film Composition on Stability

The effect of plastic film composition on the stability of ready to use premixed compositions comprising 0.2 mg/ml. nicardipine HCl, 0.2 mM citrate, 5% decrease, pH 4.0-4.2 for "incompatible" bags and "compatible" bags is shown in FIGS. 5A and 5B respectively, "incompatible" bags contain polar polymers, such as polyvinyl chloride (PVC) and ethylene vinyl acetate (HVA). "Compatible" bags do not contain polar polymers.

Stability evaluations were done for the 0.2 mg/mL nonscribitol dextrose formulation in various commercially available IV infusion bag systems. EXCEL®, VIAPLEX®, VIA-FLO™, INTRAVIA®, and VISIV® bags were rinsed in water and covered with aluminum foil over pouches. The bags were filled with the above formulation and autoclaved at 105° C. for 21 minutes. STRDIM®71 and GALAXY® bags were assembled with the above formulation. Stability assessments were done by measuring the % drug remaining and total impurity formation (data not shown) as a function of time using RP-HPLC for samples incubated for up to 24 weeks at 40° C. The % drug remaining was calculated relative to the concentration measured post-mixing in tank.

As shown in FIG. 5A, various commercially available IV 55 bags were not compatible with nicardipine HCl. Significant loss in product potency was observed upon storage primarily due to product adsorption in bags that contained the polymer

17

PVC (e.g., VIAFLEX® and INTRAVIA®). Nicardipine was also incompatible with bags containing the polymer ethylenevinyl acetate (EVA) in the contact layer (e.g., STEDIM®71). PVC and EVA are examples are of polar plastic materials that are incompatible with nicardipine HCl. Because nicardipine 5 HCl is a weak base with a pKa of ~7.2, it is increasingly hydrophobic as the formulation pH increases, and therefore, compatibility with polymeric contact surfaces is dependent on surface charge-related properties.

As shown in FIG.5B, minimal drop in product potency was 10 observed with commercial bags comprising copolyester (e.g., EXCEL®), polyethylene (e.g., GALAXY®), and polyoletin blends (e.g., VISIV® and VIAFLO™).

Example 6

Reflect of CAPTISOL® on Product Stability

The effect of CAPTISOL® on the stability of ready to use premixed compositions comprising 0.3 mg/ml Nicardipine, 20 30 mM NaAcetate, 1.8% Captisol, 1.12 mM NaCl, pH 4.5 or 0.3 mg/ml Nicardipine, 30 mM NaAcetate, 1.8% Captisol, 3.7% Dextrose, pH 4.5 dispensed in 100 ml GALAXY® bags was monitored for 12 weeks at 5, 25 and 40° C. in (see, e.g., Table 4). Because the drug was stable at 5° C., the data is not 25 shown. In addition, the formulations were monitored at 45° C. in 2 mL glass vials (see, e.g., Table 5). All formulations were filled aseptically into the vials and bags by filtering the solution through a 0.22 µm filter.

TABLE 4

% Drug Remaining at 25° C. and 40° C. in GALAXY @ Bur							
	% Drug remai	ning at 25° C.	% Drug remai	ning at 40° U.			
Turaș (senaks)	NaCl Formulation	Destrone Formulation	NaCl Formulation	Dentrose Formulation			
Ð	100.00	100.00	100.00	100.00			
1	96.57	99.86	97.15	9B.86			
2	98.09	100.80	97.07	100.40			
4	99.45	104.01	98.46	102.56			
12	97.23	101.18	95.36	99.00			

TABLE 5

% Drug Remaining at 45° C. in Glass Vials % Drug Remaining							
Time. (weeks)	NaCl Formulation	Desirosè Formulation					
D	100.00	100.00					
2	107.69	105.78					
4	105.18	105.22					
14	192.22	102.80					

Pharmaceutical compositions comprising CAPITSOL® exhibited minimal drug loss and impurity formation (data not shown) as a function of time and temperature. Based on the accelerated stability data at 40° and 45° C., formulations comprising CAPTISOL®, dextrose or NACI should be stable 60 at room temperature for at least 12 months.

Examples 7 Through 12

Examples 7-12 illustrate experiments performed using 65 specific embodiments. The experiments in Examples 7-12 were performed at 45° C. in order to simulate stressed con-

ditions that cause sufficient product degradation in a relatively short period of time. Stability comparisons were done against the control formulation (CF) and/or the commercial product formulation (CFF) in order to sasses relative differences in their degradation profiles. The CFF is a marketed drug product arid, therefore, degradation behavior of the molecule is well understood as a function of temperature and time. Stability data are available for the marketed product up

The rationale used in this preliminary screening evaluation is that if the degradation kinetics of the evaluated formulation prototypes were comparable to the CPF at stressed temperatures, drug product stability would likely be comparable or better at room temperature. The current prototype formulation is stable for at least 18 months at 25° C., and therefore it is projected that the evaluated formulation prototypes can have comparable or better stability.

to 36 months at room temperature, 22-27° C., and 40° C.

Example 7

Formulation Preparation and Analysis

Appropriate buffers, such as acetate or succinate, containing the desired cosolvents, such as sorbitol or propylene glycol, and/or complexing agents, such as SBEBCD or 2HPBCD, were prepared. Appropriate tonicity agents, such as sodium chloride, were prepared and added to some of the pharmaceutical compositions. Based upon the final formulation volume and the target drug concentration, usually 0.2-0.3 30 mg/mL, nicardipine was weighed into an appropriate glass container and prepared buffer was added to dissolve the drug. Tonicity agent, if any, was then added. The solution was then sonicated for up to 45 minutes to facilitate drug dissolution. Following drug dissolution, the solution was filtered through 35 a 0.45 µm syringe filter (Acrodisc LC 13 mm Syringe filter, PVDF Membrane from Life Sciences, PN 4452T). When filtering, the first few drops were discarded and the remaining solution was collected into another glass container. The prepared formulations were subsequently dispensed into either 40 vials or intravenous bags.

The following isotonic pharmacentical compositions were made according to the above protocol:

Pharmaceutical Composition 1 (PC 1): 0.2-0.3 mg/ml nicanlipins bydrochloride, 3.7% sorbitol, and 50 mM Na-acetats, wherein the pH of the composition is 5.0.

Phermaccutical Composition 2 (PC2): 0.2-0.3 mg/ml nicardipine hydrochloride, 1.7% propylene glycol, and 50 mM Na-acetate, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 3 (PC3): 0.2-0.3 mg/ml nicardipine hydrochloride, 2.8% sorbitol, and 50 mM Na-succinate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 4 (PC 4): 0.2-0.3 mg/ml nicardipine hydrochloride, 1.1% propylene glycol, and 50 mM Na-succinate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 5 (PC 5): 0.2-0.3 mg/ml nicardipine hydrochloride, 4.1% sorbitol, and 50 mM Na-acetate, wherein the pH of the composition is 3.5.

Pharmaceutical Composition 6 (PC 6): 0.2-0.3 mg/ml nicardipins hydrochloride, 1.9% propylene glycol, and 50 mM Na-acetate, wherein the pH of the composition is 3.5.

Phermaceutical Composition 7 (PC7): 0.2-0.3 mg/ml nicardipine hydrochloride, 4.1% sorbitol, and 50 mM Na-acetate, wherein the pH of the composition is 4.5

Pharmaceutical Composition 8 (PC 8): 0.2-0.3 mg/ml nicardipine hydrochloride, 1.8% propylene glycol, and 50 mM Na-acetate, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 24 (PC 24): 0.3 mg/ml nicardipine hydrochlorida, 4.1% sorbitol, and 50 mM sodium acctate, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 9 (PC 9): 0.2-0.3 mg/ml nicardipine hydrochloride, 6.5% sulfibratylether-β-cyclodextrin, and 50 mM Na-succinate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 10 (PC 10): 0.2-0.3 mg/ml 5 rdipine nicardipine hydrochloride, 6.5% sulfolarlylether-p-cyclodextrin, and 50 mM Na-succinate, wherein the pH of the composition is 6.0.

Pharmaceutical Composition 11 (PC 11): 0.2-0.3 mg/ml nicardipine hydrochloride, 8.5% sulfobutylether-β-cyclo-dextrin, and 50 mM Na-succinate, wherein the pH of the exapposition is 5.5.

Pharmaceutical Composition 12 (PC 12): 0.2-0.3 mg/ml nicardipine hydrochloride, 8.5% sulfobutylether-β-cyclodextrin, and 50 mM Na-succinate, wherein the pH of the ¹⁵ composition is 6.0.

Pharmaceutical Composition 13 (PC 13): 0.2-0.3 mg/ml nicardipine hydrochloride, 8.5% sulfobutylether-β-cyclodextrin, and 50 mM Na-acetate, wherein the pH of the composition is 5.0.

Pharmscertical Composition 14 (PC 14): 0.2-0.3 mg/ml nicardipine hydrochloride, 8.5% sulfobitylether-β-cyclodextrin, and 50 mM Na-citrate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 15 (PC 15): 0.2-0.3 mg/ml nicardipine hydrochloride, 22.5% 2-hydroxypropyl-β-cyclodextrin, and 50 mM Na-acetate, wherein the pH of the composition is 5.0.

Phannaceutical Composition 16 (PC 16): 0.2-0.3 mg/ml ₃₀ nicardipine hydrochloride, 22.5% 2-hydroxypropyl-β-cyclodextrin, and 50 mM Ns-succinste, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 17 (PC 17): 0.2-0.3 mg/ml nicardipine hydrochloride, 17-5% 2-hydroxypropyl-β-syclodextrin, and 50 mM Na-acetate, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 18 (PC 18): 0.2-0.3 mg/ml nicardipine hydrochloride, 17.5% 2-hydroxypropyl-β-cyclodextrin, and 50 mM Na-succinate, wherein the pH of the 40 composition is 5.5.

Commercial Product (Ampul) Formulation (CPF): 2.5 mg/ml nicardipine hydrochloride, 2.5 mM citrate, and 5% sorbitol, wherein the pH of the composition is 3.5.

Control Formulation (CF): 0.3 mg/ml micardipine hydrochloride, 2.5 mM citrate, and 5% sorbitol, wherein the pH of the composition is 3.5.

Pharmaceutical Composition 19 (PC 19): 0.3 mg/ml nicardipine hydrochloride, 50 mM sodium acetate, 50 mM sodium citrate, and 50 mM disodium succinate, wherein the pH of the composition is 3.5.

Pharmaceutical Composition 20 (PC 20): 0.3 mg/ml nicardipine hydrochloride, 50 mM sodium scetate, 50 mM sodium citrate, and 50 mM disodium succinate, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 21 (PC 21): 0.3 mg/ml nicardipine hydrochloride, 50 mM sodium acetate, 50 mM sodium citrate, and 50 mM disodium succinate, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 22 (PC 22): 0.3 mg/ml nicardipine hydrochloride, 50 mM sodium acetate, 50 mM sodium citrate, and 25 mM disodium succinate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 23 (PC 23): 0.3 mg/ml nicardipine hydrochloride, 4.1 % sorbitol, and 50 mM sodium acetate, wherein the pH of the composition is 3.5. Pharmaceutical Composition 25 (PC 25): 0.3 mg/ml nicardipine hydrochloride, 3.7% sorbitol, and 50 mM sodium acetate, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 26 (PC 26): 0.3 mg/ml nicardipine hydrochloride, 2.8% sorbitol, and 50 mM sodium acetate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 27 (PC 27): 0.3 mg/ml nicardipine hydrochloride, 1.9% propylene glycol, and 50 mM sodium acetate, wherein the pH of the composition is 3.5.

Pharmaceutical Composition 28 (PC 28): 0.3 mg/ml nicardipine hydrochloride, 1.8% propylene glycol, and 50 mM sodium acetate, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 29 (PC 29): 0.3 mg/ml nicardipine hydrochloride, 1.7% propylene glycol, and 50 mM sodium acetate, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 30 (PC 30): 0.3 mg/ml nicardipine hydrochloride, 1.1% propylene glycol, and 50 mM sodium succinate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 31 (PC 31): 0.3 mg/ml nicandipine hydrochloride, 6.5% sulfobutylether-p-cyclodextria, and 50 mM sodium succinate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 32 (PC 52): 0.3 mg/ml sicardipine hydrochlorida, 6.5% sulfobutylether-β-cyclodextrin, and 50 mM sodium succinate, wherein the pH of the composition is 6.0.

Pharmaceutical Composition 33 (PC 33): 0.3 mg/ml nicardipine hydrochloride, 22.5% 2-hydroxypropyl-β-cyclodextrin, and 50 mM sodium scetate, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 34 (PC 34): 0.3 mg/ml nicardipine hydrochloride, 17% 2-hydroxypropyl-β-cyclodestrin, and 50 mM disodium succinate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 35 (PC 35): 0.3 mg/ml nicardipine hydrochloride, 0.3% propylene glycol, 0.5% sorbitol, 30 mM sodium acetate, and 90 mM NaCl, wherein the pH of the composition is 5.2.

Pharmaceutical Composition 36 (PC 36): 0.3 mg/ml nicardipine hydrochloride, 0.3% propylene glycol, 2.0% authitol, 30 mM sodium acetate, 45 mM NaCl, wherein the pH of the composition is 5.2.

Pharmaceutical Composition 37 (PC 37): 1.5 mg/ml nicardiplne hydrochloride, 9% sulfobutylether-\$-cyclodextrin, and 30 mM sodium acetate, wherein the pH of the composition is 4,5.

Pharmaceutical Composition 38 (PC 38): 1.5 mg/ml nicardipine hydrochloride, 9% sulfobutylether-β-cyclodeutrin, and 30 mM sodium acetate, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 39 (PC 39): 0.3 mg/ml micardipine hydrochloride, and 30 mM sodium acetate, wherein the pH of the composition is 3.5.

Pharmaceutical Composition 40 (PC 40): 0.3 mg/ml nicardipinc hydrochloride, and 30 mM sodium acetate, wherein the pH of the composition is 4.0.

Pharmaceutical Composition 41 (PC 41): 0.3 mg/ml nicardipine hydrochloride, and 30 mM sodium acetate, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 42 (PC 42): 0.3 mg/ml nicardipine hydrochloride, 1.8% sulfobutylether-β-cyclodeutrin, 30 mM sodium acestate, and 110 mM NaCl, wherein the pH of the composition is 5.0.

20

stability.

2

Pharmaceutical Composition 43 (PC 43): 0.3 mg/ml nicardipine hydrochloride, 1.8% sulfobutylether-β-cyclodextrin, 0.3% propylene glycol, 30 mM sodium acetate, and

85 mM NaCl, wherein the pH of the composition is 5.0. Pharmaceutical Composition 44 (PC 44): 0.3 mg/ml nicastripine hydrochloride, 1.8% sulfobutylether-β-cyclodextrin, 30 mM sodium acetate, and 110 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 45 (PC 45): 0.3 mg/ml nicardipine hydrochloride, 1.8% sulfobutylether-β-cyclodextrin, 10 30 mM sodium acetate, and 200 mM dextrose, wherein the pH of the composition is 4.5.

Phannacsutical Composition 46 (PC 46): 0.3 mg/ml nicarcipine hydrochloride, 0.75% sulfobutylether-β-cyclodextrin, 30 mM sodium acctate, and 125 mM NaCl, wherein the 15 pH of the composition is 4.5.

Pharmaceutical Composition 47 (PC 47): 0.3 mg/ml nicardipine hydrochloride, 1.0% sulfabutylether-β-cyclodextrin, 30 mM sodium acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 48 (PC 48): 0.3 mg/ml nicardipine hydrochloride, 3.4% sorbitol, and 50 mM sodium succinete, wherein the pH of the composition is 5.6.

Pharmaceutical Composition 49 (PC 49): 0.3 mg/ml nicardipine hydrochloride, 1.3% propylene glycol, and 50 mM 25 bitol, pH 3.5 (CF), and sodium acetate, wherein the pH of the composition is 5.6. Commercial product

Pharmaceutical Composition 50 (PC 50): 0.3 mg/ml nicardipine hydrochloride, 1.8% sulfobutylether-β-cyclodextrin, 30 mM sodium acetate, and 110 mM NaCl, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 51 (PC 51): 0,3 mg/ml nicardipine hydrochloride, 0.75% sulfobutylether-fi-cyclodextrin, 30 mM sodium acceste, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 52 (PC 52): 0.3 mg/ml nicardipine hydrochloride, 1.0% sulfobutylether-β-cyclodextrin, 30 mM sodium acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 53 (PC 53): 0.3 mg/ml nicardipine hydrochloride, 0.5% sorbitol, 0.3% propylene glycol, 40 30 mM sodium acetate, and 90 mM NaCl, wherein the pH of the composition is 5.2.

Pharmaceutical Composition 54 (PC 54): 0.3 mg/ml nicantipine hydrochloride, 1.0% sulfobutylether-8-cyclodextrin, 30 mM sodium acctate, and 125 mM NaCl, wherein the pH of 45 the composition is 4.5.

Pharmaceutical Composition 55 (PC 55): 0.3 mg/ml nicardipine hydrochloride, 0.75% sulfabutylether-β-cyclodextrin, 30 mM sadium scetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 56 (PC 56): 0.3 mg/ml nicardipine hydrochloride, 0.5% sorbitol, 0.3% propylens glycol, 50 mM sodium acetate, and 90 mM NaCi, wherein the pH of the composition is 5.2.

The excipient concentration in the control formulation (CIP) is identical to the commercial product formulation (CIP), Cardene® I.V (ampul). However, the concentration of active ingredient in the commercial and control formulations is different. In the commercial product formulation (CIP), the concentration of nicardipine hydrochloride in the ampul is 60 2.5 mg/mL before dilution, and 0.1 mg/ml after dilution with appropriate IV fluids before administration. The control formulation (CIP), which is designed for premixed ready-to-use intravenous bags such that no further dilution with intravenous fluids is required, has a nicardipine hydrochloride concentration of 0.3 mg/mL. The purpose of the control formulation was to help assess the degradation propensity of the

evaluated formulations. Comparable degradation profiles at stressed conditions is indicative of comparable formulation

Example 8

Vial Stability Data with Sorbitol and Propylene Glycol Formulations

The stability in vials of pharmaceutical compositions of the present invention comprising a co-solvent and a buffering agent were compared to the control formulation and the commercial product formulation. Stability was determined by comparing the drug concentration over time for the below compositions. Specifically, the below compositions were prepared according to the method in Example 7:

50 mM Ns-acetate, pH 3.5, 4.1% sorbitol (PC 5), 50 mM Ns-acetate, pH 3.5, 1.9% propylene glycol (PC 6), 50 mM Ns-acetate, pH 4.5, 4.1% sorbitol (PC 7), 50 mM Ns-acetate, pH 4.5, 1.8% propylene glycol (PC 8),

50 mM Na-acetate, pH 5.0, 3.7% sorbitol (PC 1), 50 mM Na-acetate, pH 5.0, 1.7% propylene glycol (PC 2), Control formulation: 9.3 mg/mL, 2.5 mM citrate, 5% sor-

Control formulation: 0.3 mg/mL, 2.5 mM citrate, 5% sorbitol, pH 3.5 (CF), and

Commercial product formulation: 2.5 mg/ml, 2.5 mM citrate, 5% surbitol, pH 3.5 (CPF).

These stability studies were performed in 2 ml glass visits and at elevated temperature conditions, in this case 45° C. Promulation stability was monitored by measuring the drug concentration by RP-HPLC against a standard corve. The drug concentration measurements were taken at the start of the experiment, 7 days and 21 days, except for the commercial product formulation, which measurements were taken at the start of the experiment and 46 days. These measurements were then converted into a percentage in order to show the percentage of drug remaining after a period of time.

io	PC #	Drug Conc. (ug/ml) t=0	% Drug Remaining	Drug Cone, (µg/ml) t=7 days	% Daug Remaining	Ding Cone. (ug/ml) t=21 days	% Drug Remeining
5	5	314	100	312	99	289	92
	6	302	100	305	101	282	93
	7	304	100	303	100	283	93
	В	304	100	304	100	282	93
	1	298	100	294	98	274	92
_	2	290	100	302	104	264	91
0	Œ	302	100	301	100	111	92

j	PC#	Drug Cono, (µg/m?) 1=0	% Drug Remaining	Drug Conn. (ug/ml) 1—46 days	% Drug Remaining
	CPF	2553	100	2265	89

The data show that the stability in vials, drug concentration over time, of the pharmaceutical compositions of the present invention that contain co-solvents are comparable to both the control formulation (CF) and the current product formulation (CPF). In addition, the compositions had no additional degradation products relative to the control formulation (data not shown).

23 Example 9

Vial Stability Date with SBEBCD Formulations

The stability in vials of pharmaceutical compositions of the 5 present invention comprising a complexing agent and a buffering agent were compared to the control formulation and the commercial product formulation. Stability was determined by comparing the drug concentration over time for the below compositions. Specifically, the below compositions were prepared according to the method in Example 7:

50 mM Na-acetate, 8.5% SBE-beta cyclodextrin, pH 5.0 (PC 13),

50 mM Na-citrata, 8.5% SBH-beta cyclodextrin, pH 5.5 (PC 14),

50 mM Na-succinate, 8.5% SBE-beta cyclodextrin, pH 5.5 (PC 11),

50 mM Na-succinate, 8.5% SBE-beta cyclodextrin, pH 6.0 (PC .12).

Control formulation: 0.3 mg/mL, 2.5 mM citrate, 5% sor- 20 bitol, pH 3.5 (CF), and

Commercial product formulation: 2.5 mg/ml, 2.5 mM citrate, 5% surbitol, pH 3.5 (CPF).

These stability studies were performed in 2 ml glass vials and at vials and at elevated temperature conditions, in this case 45° C. Formulation stability was monitored by measuring the drug concentration by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, of days, 13 days and 30 days, except for the commercial product formulation, which measurements were taken at the start of the experiment and 46 days. These measurements were then converted into a percentage in order to show a percentage of drug remaining after a period of time.

The data from these stability studies are shown in the 35 following Tables.

24

lation (CPF). In addition, the compositions had no additional degradation products relative to the control formulation (data not shown). It is also worth noting that the target concentration of 0.2-0.3 mg/mL could be readily attained in the presence of sulfabutly ether- β -cyclodextrin.

Example 10

Intravenous Bag Stability Data with Sorbitol and Propylene Glycol Formulations

The stability in intravenous bags of pharmaceutical compositions of the present invention comprising a co-solvent
and a buffering agent were compared to a control formulation.
Stability was determined by comparing the drug concentration over time for the below compositions. Specifically, the
below compositions were prepared according to the method
in Example 7:

50 mM Na-acetate, pH 3.5. 4.1% sorbitol (PC 5),

50 mM Na-acetate, pH 3.5. 1.9% propylene glycol (PC 6), and Control formulation: 0.3 mg/mL, 2.5 mM citrate, 5% scribitol, pH 3.5 (CF).

These stability studies were performed in 50 ml intravenous bags and at elevated temperature conditions, in this case 45° C. Formulation stability was monitored by measuring the drug concentration by RP-HPLC against a standard curve, The drug concentration measurements were taken at the start of the experiment, 7 days and 21 days. These measurements were then converted into a percentage in order to show the percentage of drug remaining after a period of time.

The data from these stability studies are shown in the Table below.

PC#	[Daug] (µg/ml) t=0	% Drug Remaining	[Daug] (µg/ml) i = 6 d	% Drug Remaining	[Drug] (µg/ml) t=13 d	Drug Retnaining	[Drug] (µg/ml) t≈30 d	Manusining
13	381	100	387	101	413	108	390	102
14	334	100	339	101	3,52	105	333	10D
11	364	100	378	104	396	109	364	100
12	318	100	943	107	355	112	326	103
CF	339	100	352	104	363	107	338	190

PC#	Drug Conc. (µg/ml) 1 = 0	% Drug Remaining	Dang Conc (µg/ml) t = 46 days	% Drug Remaining
CPF	2553	100	2265	89

The data show that the stability in vials, drug concentration over time, of the pharmaceutical compositions of the present invention that contain SHEBCD are comparable to both the control formulation (CF) and the commercial product formu-

60	PC #	Drug Conte. (µg/ml) t=0	% Drag Remaining	Drug Cone. (pg/ml) t = 7 days	% Drug Remaining	Drug Cone, (µg/ml) 1=21 days	M Drug Remaining
	5	314	100	317	101	319	102
	6	302	100	311	103	297	98
65	CF	302	100	276	92	264	88

35

The data show that the stability in intravenous bags, drug concentration over time, of the pharmaceutical compositions of the present invention that contain co-solvents are comparable to the control formulation. In addition, the compositions had no additional degradation products relative to the control 5 formulation (data not shown). Finally, drag adsorption on the bag surface was minimal at pH 3.5.

Example 11

Intravenous Bag Stability Data with HPCD Formulations

The stability of a pharmaceutical composition of the eriog agent was evaluated in both vials and intravenous bags. Stability was determined by comparing the drug concentration over time for the below composition. Specifically, the below composition was prepared according to the method in Exemple 7:

50 mM Na-acetate, pH 5.0, 22.5% HPCD (PC 15).

These stability studies were performed in 50 ml intravenous bags and at elevated temperature conditions, in this case 45° C. The stability evaluations were done with a 10 mL fill volume in both the upright and inverted bag configurations. These evaluations were done relative to the same formulation in a 2 mL glass vial, as a control. Formulation stability was monitored by measuring the drug concentration by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, 1 day, 2 days, 6 days, 9 days and 16 days.

The data from these stability studies are shown in the Table

	Drug Cone, (µg/ml) t=0	Drug Cons. (µg/mi) t=1 day	Drug Conc. (pg/ml) t=2 deys	Datag Cone. (µg/ml) t = 6 dayz	Drug Cone. (ug/ml) t=9 days	Drug Cone. (ag/ml) 1=16 daya	44
Vial Uprigkt Bag	271 271	271 266	263 244	260 264	269 270	274 301	•
Inverted Bag	271	233	203	175	172	150	45

The data show that the stability, drug concentration over time, of the phermaceutical composition of the present invention that contains complexing agent is more promising in the 50 upright configuration of the hag. The data also show that the recovery of drug product was poorer in the inverted bag configuration.

In order to determine why the composition was more stable in upright intravenous bags compared to inverted intravenous 55 bags, additional experiments were conducted. The drop in drug concentration was not due to any new degradation product (data not shown). We believe that the drop in drug concentration was due to drug adsorption on the bag surface. For many hydrophobic drugs, adsorption on PVC surfaces is a 60 commonly reported concern. Therefore, it is likely that we observed significant adsorption in the inverted configuration because the drug is in contact with PVC surfaces. These results suggest the use of non-PVC bags and/or the careful evaluation of the bag size (solution volume) as feasible 65 options to minimize drug adsorption in order to achieve adequate drug product recovery.

26

Example 12

Intravenous Bag Stability Data with Sorbitol **Pormulations**

The stability of a pharmaceutical composition of the present invention comprising a cosolvent and a buffering agent was evaluated in both vials and intravenous bags. Stability was determined by comparing the drug concentration over time for the below composition. Specifically, the below composition was prepared according to the method in Example 7:

50 mM Na-acetate, pH 5.0, 3.7% sorbitol (PC 1).

These stability studies were performed in 50 ml intravepresent invention comprising a complexing agent and a buff. 15 nous bags and at elevated temperature conditions, in this case 45° C. The stability evaluations were done with both 10 and 50 mL fill volumes in both the upright and inverted bag configurations. These evaluations were done relative to the same formulation in a 2 mL glass vial, as a control. Formulation stability was monitored by measuring the drug concentration by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, 1 day, 2 days, 5 days, 9 days and 16 days.

The data from these stability studies are shown in the below 25 Table.

)	Dang Cone. (pg/ml) t=0	Drug Conc. (µg/ml) 1 = 1 day	Daug Cone, (µg/ml) t=2 days	Drug Cunc. (µg/ml) 1 = 6 days	Drug Conc. (µg/ml) 1 = 9 days	Drug Conc. (µg/ml) 1 = 16 days
Vial Upright Beg	100 100	102 93	100	110 98	104 85	106 87
10 ml Upright Bag 50 ml	100	98	96	114	97	98
Invested Rag 10 ml	100	46	43	38	21	13
Inverted Hag 50 ml	100	89	87	102	86	85

The data show that the stability, drug concentration over time, of the pharmaceutical composition of the present invention that contains cosolvent is more promising in the unright configuration of the bag. The data also show that the recovery of drug product was poorer in the inverted bag configuration.

In order to determine why the composition was more stable in upright intravenous bags compared to inverted intravenous bags, additional experiments were conducted. The drop in drug concentration was not due to any new degradation prodnot (data not shown). We believe that the drop in drug concentration was due to drug adsorption on the bag surface. For many hydrophobic drugs, adsorption on PVC surfaces is a commonly reported concern. Therefore, it is likely that we observed significant adsorption in the inverted configuration because the drug is in contact with PVC surfaces. This belief is further supported by the fact that we observed poorer recovery of the drug in the 10 mL fill configuration relative to the 50 mL fill configuration, although this poorer recovery may be partly due to the fact that the 10 mL fill configuration has a higher surface area to volume ratio, which adversely impacts drug adsorption and recovery. In conclusion, these results suggest the use of non-PVC bags and/or the careful evalua27

tion of the bag size (solution volume) as feasible options to minimize drug edscription in order to achieve adequate drug product recovery.

All publications, patents, patent applications and other documents cited in this application are hereby incorporated 5 by reference in their entireties for all purposes to the same extent as if each individual publication, patent, patent application or other document were individually indicated to be incorporated by reference for all purposes.

While various specific embodiments have been illustrated 10 and described, it will be appreciated that various changes can be made without departing from the spirit and scope of the invention(s).

What is claimed is:

- 1.A method for treating scate elevations of blood pressure in a human subject in need thereof, said method comprising parenterally administering a composition comprising from about 0.1 to 0.4 mg/mL nicardipine or a pharmaceutically acceptable salt thereof; a tonicity agent; and a buffer, wherein the composition requires no dilution before administration and has a pH from about 3.6 to about 4.7, the composition when stored in container for at least three months at room when atored in container for at least three months at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine or pharmaceutically acceptable salt thereof and (ii) a total impurity formation of less than 25 about 3%.
- 2. A method for inducing hypotension in a human subject in need thereof, said method comprising parameterally administering a composition comprising from about 0.1 to 0.4 mg/ml. nicardipine or a pharmaceutically acceptable sait 30 thereof; a tonicity agent; and a buffer; wherein the composition requires no dilution before administration and has a pH from about 3.6 to about 4.7, the composition when stored in a container for at least three months at room temperature exhibiting (i) less than a 10% decrease in the concentration of 35 nicardipine or pharmaceutically acceptable salt thereof and (ii) a total impurity formation of less than about 3%.
- 3. A method for treating acute elevations of blood pressure in a human subject in need thereof, said method comprising parametrally administering to a subject in need thereof, a 40 pre-mixed aqueous solution with a pH from about 3.6 to about 4.7 comprising:
 - from about 0.1 to 0.4 mg/mL nicardipine hydrochloride; a tonicity agent selected from (i) about 4.5% to about 5% dextrose or (ii) about 0.8% to about 0.9% sodium chlo-4s ride; and

from about 0.01 to about 0.1 mg/mL citric acid;

the aqueous solution contained in a pharmaceutically acceptable container such that the solution does not come into contact with polar polymers;

the aqueous solution when stored in the container for at least one year at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine bydrochloride and (ii) a total impurity formation of less than about 3%; wherein the administering does not comprise diluting the aqueous solution prior to administration.

4. The method of claim 3, further comprising at least one pH adjuster selected from the group consisting of hydrochloric soid, sodium hydroxide and a mixture thereof.

 The method of claim 3, further comprising from about 1 mg/ml to about 4 mg/ml sorbitol.

6. The method of claim 3, wherein the container comprises copolyester, polyethylene or polyolefin.

7. The method of claim 3, wherein the pre-mixed aqueous solution comprises:

from about 0.1 to about 0.2 mg/mL nicardipine hydrochlotide;

a tonicity agent selected from (i) about 46 to about 50 mg/mL dextrose or (ii) about 8.3 to about 9 mg/mL sodium chloride; and

from about 0.0192 to about 0.0384 mg/mL citric acid.

8. A method for inducing hypotension in a human subject in need thereof said method comprising parenterally administering to a subject in need thereof, a pre-mixed aqueous solution with a pH from about 3.6 to about 4.7 comprising:

from about 0.1 to 0.4 mg/mL nicardipine hydrochloride;

a tonicity agent selected from (i) about 4.5% to about 5% dextrose or (ii) about 0.8% to about 0.9% sodium chloride; and

from about 0.01 to about 0.1 mg/mL citric acid;

the aqueous solution contained in a pharmaceutically acceptable container such that the solution does not come into contact with polar polymers;

the aqueous solution when stored in the container for at least one year at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine hydrochloride and (ii) a total impurity formation of less than about 3%;

wherein the administering does not comprise diluting the aqueous solution prior to administration.

- 9. The method of claim 8, further comprising at least one pH adjuster selected from the group consisting of hydrochloric acid, sodium hydroxide and a mixture thereof.
- 10. The method of claim 8, further comprising from about 1 mg/ml to about 4 mg/ml sorbitol.
- The method of claim 8, wherein the container comprises copolyester, polyethylene or polyeiefin.
- The method of claim B, wherein the pre-mixed aqueous solution comprises:
 - from about 0.1 to about 0.2 mg/mL nicardipine hydrochloride:
 - a tonicity agent selected from (i) about 46 to about 50 mg/mL destrose or (ii) about 8.3 to about 9 mg/mL sodium chloride; and

from about 0.0192 to about 0.0384 mg/mL citric acid.

EXHIBIT C

US008455524B2

(12) United States Patent Duncan et al.

(10) Patent No.:

(45) Date of Patent:

US 8,455,524 B2

*Jun. 4, 2013

(54) METHODS OF TREATMENT WITH PRE-MIXED, READY-TO-USE PHARMACEUTICAL COMPOSITIONS

(75) Inventors: Michelle Renee Duncan, Glenview, IL (US); Supriya Gupta, Smnyvale, CA (US); David Hartley Ham, Frement, CA (US); Norma V. Stephens, Skolcie, IL (US); Camellia Zamiri, Fremont, CA (US)

(73) Assignee: EKR Theraportics, Inc., Cary, NC (US)

U.S.C. 154(b) by 254 days.

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35

This patent is subject to a terminal dis-

claimer. (21) Appl. No.: 12/971,684

(22)Filed: Dec. 17, 2010

(65)Prior Publication Date

> US 2011/0086892.A1 1/0086892.A1 Apr. 14, 2011 Related U.S. Application Data

- (60) Continuation of application No. 12/407,557, filed on Mar. 19, 2009, now Pat. No. 7,659,291, which is a division of application No. 11/788,076, filed on Apr. 18, 2007, now Pat. No. 7,512,102,
- (60) Provisional application No. 60/793,074, filed on Apr. 18, 2006.

(51) Int. CL A61K 31/44

(2006.01)

(52) U.S. CL USPC

514/354; 424/400

(58) Field of Claudification Search See application file for complete search history.

(56)References Cited

U.S. PATENT DOCUMENTS

3,985,758 A	10/1976	Mingilcami
4,711,902 A	12/1987	
4,880,823 A	11/1989	Ogava
4,940,556 A	7/1990	
5,079,237 A	1/1992	Hum et al.
5,164,405 A	11/1992	McParlene
5,198,226 A	3/1993	MacFadage
RE34,618 E	5/1994	Ogazora.
5,376,645 A	12/1994	Stella
5,519,012 A	5/1996	Fercej-Terneljotov
5,904,929 A	5/1999	Udcama
6,595,926 BI	7/2003	Lamgh
7,612,102 B2	11/2009	Duncan et al.
7,659,290 B2	2/2010	Duncan et al.
7,659,291 B2	2/2010	Duncan et al.
2002/0160942 A1	10/2002	Larow et al.
2007/0112041 A1		Bhowmick
2007/0244166 A1	10/2007	Gupta
2007/0249689 A1	10/2007	Duncan

FORRIGN PATENT DOCUMENTS

呼	0143305 A1	6/1985
砰	0149475 B1	7/1985
EP	0162705 B1	11/1985
GB	2228412 A	8/1990
WO	01/07086	2/2001

OTHER PUBLICATIONS

VarV, Destrose Injection Solution, (Agr. 2007), pp. 1-6.* Honey, Shannon et al., Anosth Analg: 84, (1997), pp. 1-239-1244.* Viron, Joseph, et al., Internet Scientific Publications (Oct. 1996), pp. 1-12.*

1-12.*
Zoidler, C., Compatibility of various drugs used in intensive care medicine in polyethylene, FVC and glass inflution containers, European Hospital Pharmacy, 5(3), (Sep. 1999), pp. 106-110.*
Kaise, B., et al., "Solutions to Health Care Waste; Life-Cycle Thinking and "Graen" Parchasing", Environmental Health Perspectives, vol. 109, No. 3, Mar. 2001, pp. 1-4.
Tomponio, R., et al., "Photostubility Studies on Nicardipine-Cycledestria Complexes by Capillary Hectroposais", Journal of Pharmacottical and Biomedical Analysis, vol. 35, 2004, pp. 267-275.
Basake, M., et al., "Stability of Nicardipine Hydrocheride in Intravenous Solutions", Am J Realth-Syst Pharm, vol. 53, Jul. 15, 1996, pp. 701-1795. gp. 1701-1705.

venous Solitions", Am J. Health-Syst Plains, vol. 33, Jul. 15, 1995, ypp. 1701-1705.

Kawano, K., et al., "The Effect of the Drip Condition (Container Materials, Concentration, Drip Rate) on the Sorption of Nicardipine Hydrochloride from Injection in the Intravenous Infusion Set", Jps. J. Hosp. Pharm., 18(5), 491-495 (1992) with English translation.

Kawano, K., et al., "The Sorption of Nicardipine Hydrochloride from the Solutions into the Administration Set", Jps. J. Hosp. Pharm., 18(3), 182-186 (1992) with English translation.

Yang et al., "Nicardipine versus nitropresside infusion as antihypentensive therapy in hybertensive emergencies," J. Inf Med Rasserch, vol. 32(2):18-123 (Mer. Apr. 2004).

Affect al., "The use of esmolol, nicardipine, or their combination to blust hemodynamic charges after laryngoscopy and tracheal infubation," Amedi Analg, vol. 90-280-285 (feb. 2000).

Aya et al., "Intravenous alcardipine for severe hypertension in preschappine...effects of an acute treatment on mother and focus," Intensive Care Med., vol. 25(11):1277-1281 (Nov. 1999).

Cheung et al., "Nicardipine infravenous bohm doxing for acutely decreasing arisenta blood pressure during general anothesia for cardiac operations: pharmacolinetics, pharmacolynamics, and associated affects on left ventricular function," Amedi Analg, vol. 89:1116-1123 (Nov. 1999).

1123 (Nov. 1999).

and outputs on less vermentair amenton, "Aneum Anag, vol. 69:11161123 (Nov. 1999).

Colson et al., "Basmodynamic heterogeneity and treatment with the calcium, channel blocker nicamipine during phasochromocytoma surgery," Act Anaasthesiol Scand., vol. 42(9):1114-1119 (Oct. 1998).

Riberour et al., "Short-term treatment of vewer hyperhealton of pregnancy: grouppetive comparison of akardioine and labelatol," Intensive Care Micd., vol. 28(9):1281-1286 (Jul. 26, 2002).

Perozardes et al., "Physiochemical characterization and in vitro dissolution behavior of nicardipine-cyclodestrias inclusion computads," Eur. J. of Pharms. Sci. 15: pp. 79-88, 2002.

Hyun et al., "Intravenous nicardipine for treatment of severe hypertension in children," J Pediatr., vol. 339(1):38-43 (Jul. 2001).

Kwak et al., "Comparison of the effacts of nicardipine and actium abroproused for control of increased blood pressure after carrioary artery bypear graft surgery," J Int Mod Res., vol. 32:342-350 (Jul. Ang. 2004).

Vincent et al., "Intravenous micardipine in the treatment of postoperative arterial hypertension," J Cardiothome Vasc Aneuth, vol. 11(2):160-164 (Apr. 1997).

International Preliminary Report on Patentability for PCT/US2007/066897, justicided.

International Search Report for PCT/US2007/066897, published Feb. 19, 2009.

Written Opinion of the International Searching Anthority for PCT/ US2007/066897, mailed Nov. 24, 2008.

International Preliminary Report on Patentability for PCT/US2007/ 009549, issued Oct. 22, 2008

International Search Report for PCT/US2007/009549, published Jan. 3, 2008.

(Continued)

Primary Examiner - Scott Long Assistant Examiner -- Lyndsey Beckhardt (74) Attorney, Agent, or Firm - Lowenstein Sandler LLP

ABSTRACT

Provided herein are ready-to-use premixed planmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

28 Claims, 5 Drawing Sheets

US 8,455,524 B2

Page 2

OTHER PUBLICATIONS

Written Opinion of the International Searching Authority for PCT/ US2007/009549 (date not indicated),

Non Final Office Action for U.S. Appl. No. 11/737,067, deted Oct. 29, 2008.

PDL Biophanna, Inc.; "Cantese IV (nicenfipine hydrochloride);" Product Insert, Jan. 2006, USA.

International Search Report and Written Opinion of the International Searching Authority from PCT/US2007/009549, dated Nov. 9, 2007. Sweetana and Alcers, "Solubility principles and practices for parenteral drug douge imm development," PDA J Pharmacoulical Science & Technology, 50(5):330-342 (1996).

Zhang et al., "The use of nicavilgine for electroconvulsive therapy: a dose-ranging study," Anesth Analg, vol. 100:378-381 (Feb. 2005). Hadob et al.. "Effects of nicavilgines, nitrophycerins, and prostaglandin III-induced hypotasalon on hauman percentaguardin discide reactivity during proposid-featurely anesthesia," J Clin Anesth. vol. 11(7):545-549 (Nov. 1999)

Berand et al., "Long-term hypotensive technique with nicardipine and nitroputsaide during isoflurane anesthesis for spinal nargery,"

Anesth Angle., vol. 75/2):179-185 (Ang. 1992).

Anesth Analg, vol. 75(2):179-185 (Aug. 1992).

Chea et al., "The comparative potentry of intervenous nicardiplue and verspamil on the cardiovascular response to trucked infulation."

Acta Anaesthedol Sin., vol. 34(4):197-202 (Dec. 1996).

Song et al., "Optimal does of aisardipine for maintenence of hemodynamic stability after tracheal intubation and stin incision," Anesth Analg, vol. 85:1247-1251 (Dec. 1997).

Cheung et al., "Acute pharmacokinetic and hemodynamic effects of intravenous bolus dosing of nicardipine," Am Heart J., vol. 119(2 Pt 2):438-442 (Feb. 1990).

Yallanwalcy at al., "Formulation-related problems associated with intravenous drug delivery," J Pharm Sciences, vol. 87(7):787-796 (ful. 1998).

Maurin et al., "Solubilization of nicardigine hydrochloride via complexation and salt famoution," J Pharm Sciences, vol. 83(10):1418-1420 (Oct. 1994).

U.S. Appl. No. 12/977,965—Response/Amendment dated Feb. 28, 2013.

U.S. Appl. No. 12/977,965-Non-Final Rejection dated Nov. 30, 2012

U.S. Appl. No. 12/645,169—Response/Amendment dated Feb. 6, 2013.

U.S. Appl. No. 12/645,169--Non-Final Rejection dated Sep. 6, 2012.


* cited by examiner

U.S. Patent

Jun. 4, 2013

Sheet 1 of 5

US 8,455,524 B2





U.S. Patent

Jun. 4, 2013


Sheet 2 of 5


US 8,455,524 B2







U.S. Patent Jun. 4, 2013 Sheet 3 of 5 US 8,455,524 B2







U.S. Patent Jun. 4, 2013 Sheet 4 of 5 US 8,455,524 B2





U.S. Patent Jun. 4, 2013 Sheet 5 of 5 US 8,455,524 B2





1

METHODS OF TREATMENT WITH PRE-MIXED, READY-TO-USE PHARMACEUTICAL COMPOSITIONS

1. CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/645,169, filed Dec. 22, 2009 which is a continuation of U.S. Pat. No. 7,659,291, filed Mar. 19, 2009 which is a divisional of U.S. Pat. No. 7,612,102, filed Apr. 18, 2007, and claims beaufit under 35 U.S.C. §119(e) to U.S. Provisional application Ser. No. 60/793,074, filed Apr. 18, 2006, the contents of all of which are incorporated herein by reference.

2. BACKGROUND

Nicardipine hydrochloride ((2)-2-(benzyl-methyl amino) ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3, 20 5-pyridinedicarboxylate monohydrochloride) is a calcium ion influx inhibitor medial for the treatment of cardiovascular and cerebrovascular disorders (sec, e.g., U.S. Pat. No. 3,985, 758). Nicardipine hydrochloride is currently sold in capsule form and in an injectable intravenous form. The capsule form 25 is marketed as CARDENE® and is available as an immediate release arel capsule and as an extended release arel capsule. The injectable intravenous form of CARDENE® is marketed in glass ampula suitable for intravenous administration following dilution in a compatible intravenous fluid, such as 30 dextrose or sodium chloride (CARDENE® LV.). Each milliliter of a CARDENE® I.V. ampul contains 2.5 mg micardipine hydrochloride in water, 48.0 mg sorbitol, buffered to pH 3.5 with 0.525 mg vitric acid monohydrate and 0.09 mg sodium hydroxide. For influsion, each milliliter of the diluted formu- 35 lation contains 0.1 mg of nicardipine hydrochloride, with a variable pH due to the diluent selected by the end user, U.S. Reissue Pat. No. RH. 34,618 (a reissue of U.S. Pat. No. 4,880,823) describes an injectable composition of nicardipine hydrochloride that is stored in a light resistant brown 40 ampul. U.S. Pat. No. 5,164,405 describes a buffered pharmaceutical composition containing nicardipine designed for parenteral administration, that is also stored in an ampul.

The requirement for diluting CARDENE® I.V. before use is associated with a number of disadvantages. One disadvantage is that the diluted solution is only stable for 24 hours at room temperature. Another disadvantage is that the pH of the diluted formulation varies depending on the choice of dilutent. Since CARDENIS® I.V. can be used under emergency conditions to control blood pressure, dilution of the concentrated ampul formulation consumes valuable time that could be used to treat a patient. Other disadvantages associated with the dilution step include the potential for contamination, desage errors, and safety hazards associated with the use of glass ampuls.

The pharmaceutical compositions and methods described herein overcome these disadvantages. In particular, the ready-to-use, injectable formulations described herein are stable, allow medical personal to use prepered containers containing an injectable formulation off the shelf without additional 60 preparation, avoid potential contamination problems, and aliminate dosage errors.

3. SUMMARY

Described herein are ready-to-use, premixed pharmaceutical compositions of nicardipine or pharmaceutically acceptable salts thereof, which are suitable for continuous intravenous inflation. By providing ready-to-use, premixed
pharmaceutical compositions with a buffered pH, these pharmaceutical compositions are stable at room temperature for at
least one year. When stored at moon temperature, the pharmaceutical compositions exhibit between 0% to about 15%
loss of drag and between 0% to about 3% (w/w) total impurity
formation over an eighteen to twenty four month period.

Additional benefits of the pre-mixed, resdy-to-use, injectable pharmaceutical compositions include convenience and case of use as compared to an ampul formulation, improved safety for patients due to elimination of dosage errors and solution contamination, reduction of medical waste, and ease of administration in emergency situations.

The present disclosure relates to premixed pharmaceutical compositions comprising pleardipine or pharmaceutically acceptable salts thereof, one or more tonicity agents, and a buffer. In some embodiments, the compositions optionally comprise one or more conductate. Nicardipine hydrochloride can be present at concentrations between about 0.05 mg/ml to about 15 mg/ml. Typically, the concentration range for nicardipine hydrochloride is between about 0.1 mg/ml to about 0.2 mg/ml. Optionally, the pharmaceutical compositions can comprise acids and bases.

The pharmaceutical compositions described herein require no dilution prior to administration and typically have a pH within the range from about 3.6 to about 4.7. The compositions can be administered by parentaral routes, including, subcutaneous, intransuscular, intravenous, intra-strial, or intra-strend continuous infusion to a patient. The compositions are suitable for the short-term treatment of hypertension when and therapy is not feasible or desirable.

Methods for miking a premixed nicardipine hydrochloride formulation suitable for intravenous administration comprise the steps of providing an effective amount of nicardipine hydrochloride in a solution comprising one or more tonicity agents, a buffer, and optionally, one or more conolvents. Sufficient water is added to make up the final volume. If required, the pH of the solution can be adjusted using a suitable pH adjuster. The compositions are dispensed in pharmaceutically acceptable containers for storage and direct administration to patients.

4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 provides a diagrammatic illustration of the effect of various diluents on the pH and stability of an ampul formulation post dilution over a twenty four hour period at room temperature.

FIGS. 2A and 2B provide a diagrammatic illustration of the effect of pH on drug loss (FIG. 2A) and total impurity formation (FIG. 2B) in a premixed non-sorbital formulation comprising 0.1 mg/ml nicardipine hydrochloride, 0.1 mM citric acid and 5% destrose at 40° C₃

FIGS. 3A and 3B provide a diagrammatic libraration of the effect of pH on drug loss (FIG. 3A) and total impurity formation (FIG. 3B) in a premixed non-sorbital formulation comprising 0.1 mg/ml nicardipine hydrochloride, 0.1 mM citric acid and 0.9% saline at 40° C.;

FIGS. 4A and 4B provide a diagrammatic illustration of the effect of picardipine concentration on impurity formation in non-sorbitol destrose formulations comprising 0.1 mg/ml mentipine hydrochloride, 0.1 mM citrate, 5% destrose, or 0.2 mg/ml nicardipine hydrochloride, 0.2 mM citrate and 5% destrose after six menths at 40° C. (FIG. 4A); and, in non-sorbitol saline formulations comprising 0.1 mg/ml nicardipine hydrochloride, 0.1 mM citrate, 0.9% saline, or 0.2

3

mg/ml nicardipine hydrochloride, 0.2 mM citrate and 0.9% valine after 3 months at 40° C, (FIG, 4B); and

FIGS. 5A and 5B provides diagrammatic illustration of the effect of incompatible (FIG. 5A) and compatible (FIG. 5B) plastic film composition on product stability at 40° C. in a 3 premixed non-sorbital formulation comprising 0.2 mg/ml nicardipine HCL, 0.2 mM citric acid, 5% dectrose, at a pH of 4.0 to 4.2.

5. DETAILED DESCRIPTION

The premixed pharmaceutical compositions described berein comprise nicardipine or a pharmaceutically acceptable salt thereof as the active ingredient, at least one tonicity agent and a buffer. As used herein, the term "pre-mixed" refers to a 15 pharmaceutical composition that does not require reconstitution or dilution before administration to a patient. In contrast to ampul formulations comprising nicardipine hydrochloride that must be diluted prior to use in a diluent and container selected by hospital personnel, the premixed pharmaceutical 20 compositions provided herein are stable at room temperature for 6 months or longer due to the inclusion of a buffer capable of maintaining the pH within an optimal pH range, which is typically between 3.6 to about 4.7. In some embodiments, ruitable pH adjusters and/or cosolvents are added to the phar- 25 maceutical compositions.

5.2 Premixed Pharmaceutical Compositions

The production of stable, ready-to-use, premixed pharmacentical compositions comprising nicardipine and/or its pharmaceutically acceptable salts as the active ingredient presents 30 different development hurdles than does the development of the concentrated simpul product sold commercially as CARDENEO I.V. As shown in FIG. 1, the percent of nicardipine remaining in solution decreases as function of pH over dipine varies with the diluent and container chosen by the hospital staff.

As described in the Examples, pH (see, also, e.g., FIGS. 2A, 2B, 3A and 3B), the concentration of the active ingredient (see, also, e.g., FIGS. 4A and 4B), and the composition of the 40 container material (see, also, e.g., FIGS, 5A and 5B) affect the stability of the active ingredient and the formation of impurities. Thus, the development of a stable, ready-to-use premixed pharmaceutical composition requires simultaneous optimization of pH and nicardipine hydrochloride concentration, as well as selection of a pharmaceutically compatible container. The ready-to-use pharmaceutical compositions described herein exhibit 0% to 15% drop in drug concentration and 0% to 3% formation of impurities when maintained at room temperature for 6 to at least 24 months. Typically, the so pharmaceutical compositions are stable when maintained at room temperature for at least 6 months, at least 12 months, at least 18 months, and at least 24 months. The compositions are also stable over extended periods of time when maintained at herein, means remaining in a state or condition that is suitable for administration to a patient,

Compounds for use according to the compositions and methods described herein that can contain one or more asymmetric centers can occur as reconstes, recente mixtures, and 60 as single enantioners. Accordingly, the compositions and methods described herein are meant to comprehend all isomeric forms of such compounds.

The premixed pharmaceutical compositions described herein comprise nicerdipine and/or its pharmacentically 65 acceptable salts. Nicardipine, its pharmaceutically acceptable salts, preparation, and use are known in the art (see, e.g.,

U.S. Pat. No. 3,985,758, incorporated herein by reference in its entirety). Examples of pharmacentically acceptable salts of nicerdinine include hydrochlorides, sulfates, phosphates, acetates, fumerates, maleates and tartrates.

Typically, the premixed pharmaceutical compositions comprise 0.05-15 mg/ml nicardipine or a pharmacentically acceptable salt thereof. For example, suitable concentrations of nicardipine or a pharmaceutically acceptable salt thereof, include, but are not limited to: 0.05-0.1 mg/ml, 0.1-15 mg/ml, 10 0.1-10 mg/ml, 0.1-5 mg/ml, 0.1-3.0 mg/ml, 0.1-2.0 mg/ml, 0.1-1.0 mg/ml, 0.9 mg/ml, 0.8 mg/ml, 0.7 mg/ml, 0.6 mg/ml, 0.5 mg/ml, 0.4 mg/ml, 0.3 mg/ml, 0.2 mg/ml or 0.1 mg/ml.

In some embodiments, the premixed phermaceutical compositions comprise nicardipine hydrochloride at the active ingredient at a concentration sufficient to permit intravenous administration at a concentration between 0.1 mg/ml to 0.2 mg/ml In some embodiments, the concentration of nicardipine hydrochloride suitable for use in the compositions and methods described herein includes, but is not limited to, at least about 0.1 mg/ml. In other embodiments, the concentration of nicerdipine hydrochloride suitable for use in the compositions and methods described herein includes, but is not limited to, at least about 0,2 mg/ml.

In some embodiments, the premixed formulation comprises, in addition to nicardipine and/or its pharmaceutically acceptable salts, a buffer that has sufficient buffering capacity to maintain the desired pH range throughout the shelf-life of the product. As shown in FIGS. 2A and 2B, pH is important for the long term stability of nicardipine in the premixed pharmaceutical compositions. Although the pH of the premixed pharmaceutical compositions can range from between about 3.0 to about 7.0, pharmaceutical compositions having a pH within the range of about 3.6 to about 4.7 exhibit a lower percentage of drug degradation and total impurities (See a twenty-four hour period. The percent decrease in nicar- 35 FIGS. 2A, 2B, 3A and 3B). Accordingly, suitable pH ranges for me in the premitted pharmaceutical compositions include, but are not himsed to, pH range of at least about 3.0, of least about 3.1, at least about 3.2, at least about 3.3, at least about 3.4, at least about 3.5, at least about 3.6, at least about 3.7, at least about 3.8, at least about 3.9, at least about 4.0, at least about 4.1, at least about 4.2, at least about 4.3, at least about 4.4, at least about 4.5, at least about 4.6, at least about 4.7, at least about 4.8, at least about 4.9, at least about 5.0, at least about 5,2, at least about 5.5, at least about 6.0, at least about 6,5, at least about 7.0.

In some embodiments, the pH of the premixed pharmaceutical compositions is between about 3.0 to about 5.0. In other embodiments, the pH of the premixed pharmaceutical compositions is between about 3.6 to about 4.7. In other embodiments, the pH of the premixed pharmaceutical compositions is between about 4.0 to about 4.4. In yet other embodiments, the pH of the premixed pharmaceutical compositions is 42.

Buffers suitable for use in the pharmaceutical compositions described herein include, but are not limited to, phartemperatures from about 2° to 8° C. The term "stable", as used 55 maceutically acceptable salts and acids of accente, glutamate, citrate, tertrate, benzoate, lectate, histidine or other amino acids, gluconate, phosphate, malate, succinate, formate, propionate, and carbonate. "Pharmaceutically acceptable" is used herein in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Accordingly, the term "phatmaceutically acceptable salt" references salt forms of the active compounds which are prepared with counter ions which are nontoxic under the conditions of use and are compatible with a stable formulation. The concentration of the buffer in the formulation can be expressed in mg/ml, g/L or as a molar concentration. In typical embodiments, from about 0.0001

mg/ml to about 100 mg/ml of a mitable buffer is present in the pharmaceutical compositions. Thus, the premixed pharmacentical compositions can comprise from about 0.0001 to about 0.001 rog/ml of a suitable buffer, from about 0.001 to about 0.01 mg/ml of a suitable buffer, from about 0.01 to about 0.1 mg/ml of a suitable buffer, from about 0.1 to 1 rag/ml of a mitable buffer, from about 1 to about 5 rag/ml of a suitable buffer, from about 5 to about 10 mg/ml of a suitable buffer, from about 10 to about 15 mg/ml of a mitable buffer, from about 15 to about 20 mg/ml of a suitable buffer, from 10 about 20 to about 25 mg/ml of a suitable buffer, from about 25 to about 50 mg/ml of a suitable buffler, from about 50 to about 75 mg/ml of a suitable huffer, and from about 75 to about 100 mg/ml of a suitable buffer.

Alternatively, the buffer concentration can be expressed as 15 molar concentrations. In typical embodiments, from about 0.1 to 100 mM of a suitable buffer is present in the pharmscentical compositions. Thus, the premixed pharmaceutical compositions can comprise a suitable buffer baving a concentration from about 0.1 to about 100 mM, from about 0.1 to 20 about 0.5 mM, from about 0.5 to about 1.0 mM, from about 1.0 to about 5 mM, from about 5 to about 10 mM, from about 10 to about 15 mM, from about 15 to about 25 mM, from about 25 to about 50 mM, from about 50 to about 75 mM, and from about 75 to about 100 mM.

In some embodiments, the premitted pharmaceutical compositions further comprise a pH adjuster. Suitable pH adjusters typically include at least an acid or a salt thereof, and/or a base or a salt thereof. Acids and bases can be added on an as the pH is greater than the desired pH, an acid can be used to lower the pH to the desired pH. Acids suitable for use in premixed pharmaceutical compositions include, but are not limited to, hydrochloric acid, phosphoric acid, citric acid, ascorbic acid, acetic acid, sulphuric acid, carbonic acid and 35 nitric acid. In some embodiments, hydrochloric acid is used to adjust the pH. By way of another example, if the pH is less than the desired pH, a base can be used to adjust the pH to the desired pH. Pases suitable for use in premixed pharmaceutical compositions include, but are not limited to, sodium 40 hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, sodium citrate, sodium acetate, and magnesium hydroxide. In some embodiments, sodium hydroxide is used to adjust the pH.

In some embodiments, the premitted pharmaceutical com- 45 positions further comprise one or more tonicity agents. Typically, tonicity agents are used to adjust the osmolality of the premixed pharmaceutical compositions to bring it closer to the exmetic pressure of body fluids, such as blood or plasma. in some embodiments the tonicity of the premixed formula- 50 tion can be modified by adjusting the concentration of buffer and/or other components present in the premixed formula-

Provided that the compositions are physiologically compatible, the compositions do not require any particular osmo- 55 latity. Thus, the compositions can be hypotonic, isotonic or hypertonic. Typically the premixed pharmaceutical compositions have a tonicity between about 250 to about 350 mOsm/

Suitable tonicity agents for use in the premixed pharma- 60 certical compositions include, but are not limited to, anhydrons or hydrous forms of sodium chloride, dectrose, sucrose, sylital, fructose, glycorol, sorbital, mannital, potassium chloride, mannose, calcium chloride, magnesium chloride and other inorganic salts. The quantity of the tonicity agent in the 65 formulation can be expressed in mg/ml or in g/L. In typical embodiments, the tonicity agent(s) is present from about 1

mg/ml to about 90 mg/ml. Thus, the premixed pharmaceutical compositions can comprise one or more tonicity agents at about 1-5 mg/ml, at about 5-10 mg/ml, at about 10-15 mg/ml, at about 15-25 mg/ml, at about 25-50 mg/ml, at about 50-60 mg/ml, at about 60-70 mg/ml, at about 70-80 mg/ml, and at about 80 to 90 mg/ml, as well as combinations of the above

Alternatively, the tonicity agent concentration is measured in weight/volume percent. In typical embodiments, the tonicity agent(s) is present from about 0.1% to about 10%. For example, suitable tonicity agent concentrations include, but are not limited to, from about 0.1% to about 0.2%, from about 0.2% to about 0.3%, from about 0.3% to about 0.4%, from about 0.4% to about 0.5%, from about 0.5% to about 0.6%, from about 0,6% to about 0.7%, from about 0.7% to about 0.8%, from about 0.8% to about 0.9%, from about 0.9% to about 1%, from about 1% to about 2%, from about 2% to about 3%, from about 3% to about 4%, from about 4% to about 5%, from about 5% to about 6%, from about 6% to about 7%, from about 7% to about 8%, from about 8% to about 9%, and from about 9% to about 10%, as well as combinations of the above ranges.

In some embodiments, the tonicity agent is dextrose. Typically, the concentration of dextrose suitable for use in the 25 premitted pharmaceutical compositions is between about 2.5% (w/v) to about 7.5%. By way of example, suitable destrose concentrations include, but are not limited to, from about 2.5% to about 3%, from about 3% to about 3.5%, from about 3.5% to about 4% (which is equivalent to about 40 needed basis in order to achieve a desired pH. For example, if 30 mg/ml), from about 4% to about 4.5%, from about 4.5% to about 5% (which is aquivalent to about 50 mg/ml), from about 5% to about 5.5%, from about 5.5% to about 6% (which is equivalent to about 60 mg/ml), from about 6% to about 6.5%, from about 6.5% to about 7%, as well as combinations of the above ranges.

In some embodiments, the tonicity agent is sodium chloride. Typically, the concentration of sodium chloride suitable for use in the premixed pharmaceutical compositions is between about 0.1% (w/v) to about 1.8%. By way of example, suitable sodium chloride concentrations include, but are not limited to, from about 0.1% to about 0.2%, from about 0.2% to about 0.3%, from about 0.3% to about 0.4%, from about 0.4% to about 0.5%, from about 0.5% to about 0.6%, from about 0.6% to about 0.7%, from about 0.7% to about 0.8% (which is equivalent to 8 mg/ml), from out 0.8% to about 0.9% (which is equivalent to 9 mg/ml), from about 0.9% to about 1.0%, from about 1% to about 1.2%, from 1.2% (which is equivalent to 12 mg/ml) to about 1.4%, from about 1.4% to about 1.6%, and from about 1.6% to about 1.8%.

In some embodiments, the premixed pharmaceutical compositions comprise two, three, four, or more tonicity agents. In these embodiments, the concentration of each tonicity agent is typically less than the concentration that is used when only a single agent is present in the premixed formulation. For example, if the premixed formulation comprises surbitol at 1.92 mg/ml, a suitable concentration of sodium chloride is 8.6 mg/ml. By way of another example, if the premixed formulation comprises 1.92 mg/ml sorbitol, a suitable concentration of dextrose is 48 mg/ml.

In some embodiments, the premixed pharmaceutical compositions further comprise one or more cosolvents. A "cosolvent" is a solvent which is added to the aqueous formulation in a weight amount which is less than that of water and assists in the solubilization of nicerdipine end/or a pharmaceutically acceptable sait thereof, enhances stability of the premixed formulation, and/or adjusts the osmolality of the premixed pharmaceutical compositions. Cosolvents suitable for use in

7

the premised pharmaceutical compositions include, but are not limited to, glycols (e.g., polyethylene glycol, propylene glycol), ethanol, and polyhydric alcohols (e.g., sorbitol, mannitol, xylitol).

The quantity of the cosolvent used in the formulation can be expressed in mg/ml or in g/L. In typical embodiments, the cosolvent(s) is present from about 1 mg/ml to about 100 mg/ml. Thus, the premixed pharmaceutical compositions can comprise one or more cosolvent(s) at about 1 to about 2 mg/ml, at about 2 to about 3 mg/ml, at about 3 to about 4 mg/ml, at about 4 to about 5 mg/ml, at about 5 to about 10 mg/ml, at about 10 to about 15 mg/ml, at about 50 to about 25 mg/ml, at about 50 to about 50 mg/ml, at about 50 to about 50 mg/ml, at about 50 to about 60 mg/ml, at about 80 to 90 mg/ml, at about 90 to 100 mg/ml, as well as combination of the above ranges.

Alternatively, the cosolvent concentration is measured in weight/volume percent. In typical embodiments, the cosolvent(s) is present from about 0.1% to about 25%. For a example, suitable cosolvent concentrations include, but are not limited to, at least about 0.1% to 0.3%, from about 0.3% to about 0.5%, from about 0.5% from about 0.7%, from about 0.7% to about 19%, from about 19% to about 3%, from about 3% to about 5%, from about 5% to about 5%, from about 5% to about 5%, from about 5% to about 11% from about 11% to about 11% from about 11% to about 13% from about 13% to about 15%, from about 15% to about 20%, and from about 20% to about 25%, as well as combination of the above ranges.

In some embodiments, the premixed phermaceutical compositions further comprise one or more cyclodectrins. Due to their structure, cyclodextrins have the ability to form complenes, or inchasion complexes, with a variety of organic and 35 inorganic molecules. Complexes of nicardipine with cyclodextrins have been described (see, e.g., U.S. Pat. No. 5,079, 237 which describes an inclusion complex of nicardipine or its hydrochloride with sipha-cyclodextrin, beta-cyclodextrin or gamma-cyclodextrin; U.S. Pat. No. 5,519,012 which 40 describes inclusion complexes of dihydropyridines, including nicardipine, with hydroxy-alkylated-\$-cyclodextrins; and, U.S. Pat. No. 5,904,929 which describes numerous drugs in a pharmaceutical composition with per C2-18 acylated cyclodestrins). None of the above references discloses a dihy- 45 dropyridine in combination with a cyclodestrin comprising a sulfate group. An example of a commercially available sulfated cyclodextrin is CAPTISOL®, CAPTISOL® is a polyanionic β-cyclodestrin derivative with a sodium sulfonate salt that is separated from the lipophilic cavity by a butyl other 50 spacer group, or sulfobutylether. Methods for making the sulfoalkyl ether cyclodextrin derivatives are well known in the art and are taught in U.S. Pat. No. 5,376,645. Methods for forming complexes of the derivatives with a drug are also well known in the art as disclosed in U.S. Pat. No. 5,376,645.

The cyclodestrin concentration can be measured in weight/volume percent. In typical embodiments, cyclodestrin(s) is present from about 0.1% to about 25%. For example, suitable cyclodestrin(s) concentrations include, but are not limited to, at least about 0.1% to 0.3%, from about 0.3% to about 0.5%, so from about 0.5% to about 0.7%, from about 0.7% to about 0.9%, from about 1% to about 3%, from about 5% to about 3%, from about 5% to about 7%, from about 7% to about 1%, from about 5% to about 1%, from about 11% to about 11%, from about 11% to about 13% from about 13% to about 15%, 65 from about 15% to about 15%, and from about 20% to about 25%.

Examples of stable, premixed pharmaceutical compositions comprising the active ingredient, a tonicity agent, a buffer and optionally, a consolvent are shown in Table 1.

TABLE 1

	Active Ingredient	Tomicity Appent(e) (mg/ml)	Bulker (mg/ml)	Cosolvent (mg/ml)	pН
10	zicardipite żychockleride (0,1 ma/ml)	NaCi (8.6 mg/ml)	Citric acid, anhydrous (0.0192 mg/ml)	Sorbitol (1.92 mg/ml)	3.6-4.7
	nicardipine hydrochloride (0.1 mg/ml)	Destrone, hydrone (48 mg/ml)	Cimic scid, asleydrous (0.0192 mg/zd)	Sorbital (1.92 mg/ml)	3.64.7
15		NoCl (9 mg/ml)	Citric acid, anhydrous (0.0192 mg/ml)	None	3.6-4.7
	nioudipins hydrochlorida (0.1 mg/ml)	Destrois, hydron (50 mg/ml)	Clinic azid, anleydrous (0.0192 mg/ml)	Name	3.6-4.7
20	niordicine hydrochlorida (0.2 mg/ml)	bjaCi (9 mg/mi)	Citric sold, anhydrous (0.0384 mg/ml)	Nune	3.5-4.7
	nicardipine hydrochioride (0.2 mg/ml)	Destrose, hydrotes (50 mg/ml)	Citrio said, unkydrous (0.0384 mg/ml)	None	3.6-4.7
25	nlosodiplac hydrochloside (0.2 ma/ml)	NaCl (8.3 mg/ml)	Chric sold, anhydrous (0.0384 market)	Societal (3,54 mg/ml)	3,6-4,7
	nicerdipite hydrochloride (0.2 mg/ml)	Destroes, hydrons (46 mg/ml)	Citric acid, anhydrous (0.0384 mg/ml)	Sorbitol (3.44 mg/ml)	1647

In some embodiments, the pharmaceutical compositions are any as described in U.S. Provisional Application Ser. No. 60/793,084, filed Apr. 18, 2006, which is incorporated herein by reference.

5.3 Methods

The order in which various components comprising the compositions is added to the buffered solution is not critical, provided that the resulting compositions are stable and are mitable for continuous intravenous infusion. Accordingly, the compositions described herein can be made by prepared in a number of different ways. For example, in some embodiments, the compositions can be prepared by adding buffer, a tonicity agent and/or a cosolvent to water, adding nicardipine to the buffered water solution; adding an pH adjuster to achieve the desired pH; and then adding sufficient water to make up the final volume. If necessary, the pH can be readjusted to achieve the desired pH range. By way of another example, the compositions can be prepared by adding buffer and nicardipine or a pharmaceutically acceptable salt thereof to water, adding a traicity agent and/or cosolvent, adjusting the old to achieve the desired pH range; and then adding sufficient water to make up the final volume. By way of another example, a cosolvent can be added prior to the addition of nicardipine or a pharmaceutically acceptable salt 55 thereof, and a tonicity agent can be added after the addition of nicardipine or a pharmaceutically acceptable salt thereof. By way of another example, a tonicity agent can be added prior to the addition of nicardipine or a pharmaceutically acceptable salt thereof, and a cosolvent can be added after the addition of nicardipine or a pharmaccutically acceptable salt thereof. By way of snother example, the compositions can be prepared by adding buffer, tonicity agent and/or cosolvent to water; adjusting the pH to a first pH range suitable for dissolving nicardipine (for example, less than pH 3.6); adding nicardipine or a pharmaccutically acceptable salt thereof; adjusting the pH to achieve the desired final pH range; and then adding sufficient water to make up the final volume.

In some embodiments, pharmaceutical compositions comprising nicardipine hydrochloride, destrose, and citric buffer at pH 3.6-4.7 can be prepared by adding citric acid to water, adding dextrose to the buffered water, adding nicerdipine hydrochloride to the buffered water solution, adjusting the pH 5 if necessary to the range 3.6-4.7, and adding sufficient water to make up the final volume. If necessary, the pH can be readjusted to between about 3.6 to about 4.7.

In some embodiments, pharmaceutical compositions comprising nicardipine hydrochloride, sodium chloride, and cit- 10 rate buffer at pH 3.6 to about 4.7 can be prepared by adding citric acid to water, adding nicardipine to the buffered water solution, adding sodium chloride to the buffered water solution, adjusting the pH to between about 3.6 to about 4.7, and adding sufficient water to make up the final volume. If sorbi- 15 tol is included in the formulation, sorbitol is added at the same time as the citric soid.

In some embodiments, the planmacentical compositions can be prepared by adding micardipine or a pharmaceutically acceptable salt thereof to an acidic solution having a pH less 20 than 5.0. For example, the acidic solution can be prepared by adding an acidic component of a buffer system. A buffer, one or more tonicity agents, and/or cosolvents can be added to the acidic solution before or after dissolving the nicardipine. Sufficient water is then added to make up the final volume. If 25 necessary, the pH of the composition can be adjusted to between about 3.6 to about 4.7.

In some embodiments, the pharmaceutical compositions can be made by adding nicardipine or a pharmacentically acceptable salt thereof to a solution that has been heated to a 30 temperature greater than 35° C.; adding buffer, one or more tonicity agents and/or cosolvents to the scidic solutions; and adding sufficient water to make up the final volume. If necessary, the pH of the composition can be adjusted to between about 3.6 to about 4.7.

The pharmaceutical compositions can be packaged for use in a variety of containers. The compositions are preferably packaged in a pharmaceutically acceptable container, such as an intravanous bag or bottles. Due to the light sensitivity of nicardiplus, packages can be used that reduce the amount of 40 light which can reach the composition. For example, in some embodiments, the container may, optionally, further comprise a light barrier, such as an aluminum overpouch or a

positions are dispensed in intravenous bags, such as pre-mix bags and admix bags. Intravenous bags are well known in the art and commercially available. Examples of intravenous bays include, but are not limited to: GALAXY®, INTRA-VIAO, SOLOMIKO, SIBDIMO 71, SIBDIMO 100, 50 VIAFLOTK VIAFLEXO, EXCEL®. VISIV®, ADDEASED. ADD-VANTAGEO, DUPLEXTM, FIRST CHOICEM, PROPYFLEXIM and BESTM.

In some embodiments, the components of the bag that come into contact with the pharmaceutical compositions 35 should not contain polar polyment, such as polyvinyl chloride (PVC) and ethylene vinyl acetate (EVA). Examples of lags that do not contain polar polymers and thus, are suitable for use in these embodiments, include, but are not limited to, GALAXY®, EXCEL®, VISIV®, and VIAFLOTM.

Procedures for filling pharmaceutical compositions in pharmaceutically acceptable containers, and their subsequent processing are known in the art. These procedures can be used to produce sterile pharmaceutical drug products often required for health care. See, e.g., Center for Drug Evaluation 65 and Research (CDER) and Center for Veterinary Medicine (CVM), "Guidance for Industry for the Submission Docu-

mentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products", (November 1994). Examples of suitable procedures for producing sterile phermaceutical drug products include, but are not limited to. terminal moist heat sterilization, ethylene cride, radiation (i.e., gamma and electron beam), and aseptic processing techniques. Any one of these starifization procedures can be used to produce the sterile pharmaceutical compositions described

In some embodiments, sterile pharmaceutical compositions can be prepared using asceptic processing techniques. Sterility is maintained by using sterile materials and a controlled working environment. All containers and apparatus are sterilized, preferably by heat sterilization, prior to filling. Then, the container is filled under assptic conditions, such as by passing the composition through a filter and filling the units. Therefore, the compositions can be sterile filled into a container to avoid the heat stress of terminal sterilization.

In some embodiments, the compositions are terminally sterilized using moist heat. Terminal sterilization can be used to destroy all viable microorganisms within the final, realed container containing the pharmaceutical composition. An autoclave is typically used to accomplish terminal heat-sterilization of drug products in their final packaging. Typical autoclave cycles in the pharmaceutical industry to achieve terminal sterilization of the final product are 121° C for at least 10 minutes.

The pharmaceutical compositions described herein can be used for prevention or treatment of acute elevations of blood pressure in a human patient in need thereof. In some embodiments, the patients being treated may be volume-restricted due to a co-existing medical condition and thus can benefit from the administration of higher concentration and lower fluid volume of nicardipine. Examples of medical conditions in which it would be advantageous to administer low volume formulations include, renal failure, ascites, cerebral edema, congestive heart failure, liver failure, or a CNS injury. Dosages can be individualized depending upon the severity of hypertension and the response of the individual patient during dosing. Typically, the dosage is administered as a continuous infusion of a pre-mixed product. In some embodiments, the petient has an elevated blood pressure with a systolic equal to In some embodiments, the premitted pharmaceutical com- 45 or greater than 150 mm Hg. In other embodiments, the subject has an elevated blood pressure with a diastolic value greater than or equal to 90 mm Hg.

In some embodiments, the pharmaceutical compositions can be used to prevent acute elevations of blood pressure associated with various medical procedures. Examples of medical procedures associated with acute elevations of blood pressure include, but are not limited to, electroconvulsive therapy (see, e.g., Avramov, et al., 1998, J. Clinical Anesthesia, 10:394-400), carotid endarterectumy (see, e.g., Dorman, et al., 2001, J. Clinical Anesthesia, 13:16-19, tracheal intubation (Song, et al., 2001, Anesth Analg., 85:1247-51) and skin inciaion (Song, et al., 2001, Anesth Analg., 85:1247-51).

In some embodiments, the planmaceutical compositions can be used to treat acute elevations in blood pressure due to certain cardiovascular and cerebrovascular conditions. Examples of cardiovascular conditions that are associated with some elevations of blood pressure include, but are not limited to, essential hypertension, angina, acute ischemis, systemic arterial hypertension, congestive heart failure, coronary artery disease, myocardial infarction, cardiac arrhytimins, cardiomyopathies and arteciosclerosis. Examples of cerebrovescular conditions are associated with acute cleva-

11

tions of blood pressure include, but are not limited to pulmonary hypericusion, cerebral insufficiency and migraine headache

In some embodiments, the pharmaceutical compositions can be used to treat other conditions that cause hypertension 5 including, but not limited to, renal disorders (e.g., renal parenchymal disorders or renal vascular disease), coerciation of the aorta, pheochromocytoma, hyperthyroidism, metabolic syndrome, solid organ transplant and drug-related hypertension.

In some embodiments, the pharmaceutical compositions can be used to induce hypotension during surgical procedures including, but not limited to cardiothoracic surgery, spinal surgeries and bend and neck surgeries.

6. ALTERNATIVE ASPECTS

In an alternative aspect, the present invention relates to pre-mixed, ready-to-use, injectable pharmaceutical compositions comprising a cardiac medication or a pharmaceutically 20 acceptable salt thereof, and at least one of a co-solvent and a complexing agent, and a buffering agent. The composition may further comprise a tonicity agent. The compositions are preferably isotomic. The pH of the compositions is preferably in a pharmaceutically acceptable container, such as an intravenous bag, syringe or vial. Preferably, the compositions are used for the treatment of cardiovascular and cerebrovascular conditions. The present invention also relates to methods for preparing such compositions. In this other aspect, the term 30 "pre-mixed", as used herein, means a pharmaceutical composition that is already mixed from the point of manufacture and does not require dilution or further processing before administration. The term "pre-mixed" may also mean a pharinscentical composition wherein the liquid solution and the 35 active pharmaceutical ingredient are separated from the point of manufacture and in storage, such as when the relution is stored in an intravenous bag and the active pharmaceutical ingredient is lyophilized and stored in a vial that is connected to the bag, but not in fluid contact with the solution until just 40 before administration to a patient. Preferably, the pharmacentical compositions are aqueous solutions that are administered by injection. Alternatively, the pharmaceutical compositions may be lyophilized and then reconstituted in isotomic saline, for example, before intravenous administration.

In this alternative aspect, the pharmaceutical compositions of the present invention comprise a cardiac medication or a pharmaceutically acceptable salt thereof. Examples of clauses of cardiac medications include beta-blockers, calcium channel antagonists, angiotensin conventing enzyme inhibi- so tors, diaretics, vasodilators, nitrates, anti-platelet medications and anti-congulants. Preferably, the cardiac medication is a calcium channel antagonial or a pharmaceutically acceptable salt thereof. More preferably, the cardiac medication is a dihydropyridine derivative or a pharmaceutically acceptable 55 walt thereof. Most preferably, the cardiac medication is nicardipine or a pharmaceutically acceptable salt thereof. Examples of pharmaceutically acceptable salts of nicardipine are hydrochlorides, sulfates, phosphates, acetates, fumarates, maleates and tartarates. The preferred pharmaceutically acceptable salt of nicardipine is nicardipine hydrochloride. The pharmaceutical compositions may comprise 0.05-1.5 mg/ml of nicardipine or a pharmaceutically acceptable salt thereof. Preferably, the pharmaceutical compositions comprise 0.15-0.35 mg/ml of meandipine or a pharmaceutically 65 acceptable salt thereof. More preferably, the compositions comprise 0.2-0.3 ang/ml of nicardipine or pharmaceutically

acceptable salt thereof. Nicardipine and its pharmaceutically acceptable salts, their preparation, and their use are known in the art. For example, they are disclosed in, among other references, U.S. Pat. No. 3,985,758, which is incorporated herein by reference in its entirety.

la some embodiments, the plannaceutical compositions comprise 0.1-15 mg/ml nicardipine or a pharmaceutically acceptable salt thereof. For example, suitable concentrations of nicardipine or a pharmaceutically acceptable salt thereof, 10 include, but are not limited to: 0.1-15 mg/ml, 0.1-10 mg/ml, 0.1-5 mg/ml, 0.1-3.0 mg/ml, 0.1-2.0 mg/ml, 0.1-1.0 mg/ml, 0.9 mg/ml, 0.8 mg/ml, 0.7 mg/ml, 0.6 mg/ml, 0.5 mg/ml, 0.4 mg/ml, 0.3 mg/ml, 0.2 mg/ml or 0.1 mg/ml.

In this alternative aspect, the pharmaceutical compositions 15 can be used to treat cardisc conditions. Preferably, the compositions can be used to trent conditions that are alleviated by the administration of calcium channel antegonists, such as cardiovascular and cerebrovascular conditions. Cerdiovascular conditions that can be treated with the pharmaceutical compositions of the present invention include angina, ischemia, systemic arterial hypertension, congestive heart failure, coronary artery disease, myocardial inferction, cardiac amhythmias, cardiomyopathies and arteriosclerosis. Cerebrovacular conditions that can be treated with the pharbetween 3 and 7. The compositions are preferably packaged 25 maceutical compositions of the present invention include pulmonary hypertension, cerebral insufficiency and migraine. Preferably, the compositions are used to treat hypertension.

In this alternative aspect, the pharmaceutical compositions of the present invention also comprise at least one of a cosolvant and a complexing agent. Therefore, the compositions may comprise a cosolvent, a complexing agent, multiple cosolvents, multiple complexing agents, a cosolvent and a complexing agent, a cosolvent and multiple complexing agents, a complicting agent and multiple cosolvents, or multiple concivents and multiple completing agents.

In this alternative aspect, Nicardipine and its pharmacentically acceptable salts are only slightly soluble in water. Considerate and complexing agents help solubilize nicardipine in the acqueous solution of the pharmaceutical composition. Cosolvents and complexing agents are especially beneficial when a high concentration of nicardipine is present, such as in the compositions of the present invention. An advantage of the compositions of the present invention is that they have a high concentration of nicardipine, which allows the composition to be administered using a lower volume of intravenous fluid. Such compositions can be a treatment option for a greater number of patients, especially volume restricted patients.

In this alternative aspect, patients and medical conditions that may benefit from a higher concentration and lower fluid volume of nicardipine include, but are not limited to, the following: acute congestive cardiac failure; pediatrics; hypertensive crises in elderly patients where fluid overload is a major concern; all acute stroke areas including AIS, ICH and SAH to control blood pressure; controlled hypotension during surgical procedures including cardiothoracic surgery (CABG, coarctation of the sorts, etc.), spinal surgeries, and head and neck surgeries; and neurosurgery for the control of breakthrough hypertension post carolid endanterectomy, traumatic brain injury and potential treatment of hypertension and vasosassm.

In this alternative aspect, in addition to enhancing solubility, cosolvents and complexing agents enhance the stability of the pharmaceutical compositions. Furthermore, changes may he made to the concentration of cosolvents and complexing agents in the pharmaceutical compositions in order to adjust the tonicity of the pharmaceutical compositions. Pharmaceu-

13

tically acceptable cosolvents are known in the art and are commercially available. Typical cosolvents include polyethylene glycol (PRG), propylene glycol (PR), ethanol and sorbitol. Preferably, the cosolvent concentration is 0.1-10% weight/volume percent, which will depend on the pRI of the 5 composition. More preferably, the cosolvent concentration is 0.1-3%. Most preferably, the cosolvent concentration is 0.1-2%. Preferred cosolvents for the pharmaceutical compositions are propylene glycol and sorbitol. Preferably, the concentration of propylene glycol is 0.1-2%. More preferably, 10 the concentration of propylene glycol is 0.1-1%. Most preferably, the concentration of propylene glycol is 0.3%. A preferred concentration of sorbitol is 0.1-2%. An even more preferred concentration of sorbitol is 0.5-1%. A most preferred concentration of sorbitol is 0.5%.

In this alternative aspect, pharmaceutically acceptable complexing agents are known in the art and commercially available. Typical complexing agents include cyclodextrins, such as natural cyclodextrins and chemically modified cyclodextrins. Preferably, the complexing agent is a beta cyclodex- 20 trin. Preferred complexing agents for the pharmaceutical compositions are 2-hydroxypropyl-6-cyclodextrin (2HP-BCD) and sulfobutylether-\$-cyclodextrin (SBEBCD). Preferably, the complexing agent concentration is 0.1-25% weight/volume percent. More preferably, the complexing 25 agent concentration is 0.1-10%. Most preferably, the complexing agent concentration is 0.1-5%. Preferably, the concentration of 2HPBCD is 15-25%. More preferably, the concentration of 2HPBCD is 20-25%. The preferred concentration of SBBBCD is 0.1-10%. An even more pre- 30 ferred concentration of SBEBCD is 0,1-5%. The most preferred concentration of SBEBCD is 0.75 to 1%.

In addition, the pharmaceutical compositions in this alternative aspect can comprise a buffering agent. However, the compositions may comprise multiple buffering agents. The 35 pharmaceutical compositions of the present invention are preferably close to physiological pH in order to minimize the incidence of phlebitis upon administration. However, the pH of the pharmaceutical composition also affects the solubility and stability of nicardipine in the composition. Generally, as 40 the pH of the pharmaceutical composition increases, the aqueous solubility of nicardipine decreases. As a result, it is difficult to solubilize nicardipine close to physiological pH. In addition, the composition abould have sufficient buffering capacity such that the solution does not precipitate upon 45 dilution with blood when administered.

In this alternative aspect, typical buffering agents include acetate, glutamate, citrate, tartrate, benzuate, lactate, histidine or other unino exids, gluconate, phosphate and succinate. The preferred buffering agents are acetate and succinate. So A preferred buffering agent concentration is 1-100 mM. A neven more preferred buffering agent concentration is 1-50 mM. An even more preferred buffering agent concentration is 25-35 mM.

In this alternative aspect, praferably, the pharmaceutical 55 compositions of the present invention are isotonic, i.e., in the range of 270-328 mOsm/kg. However, the compositions may have a tonicity in the range of 250-350 mOsm/kg. Therefore, the compositions may be either alightly hypotonic, 250-269 mOsm/kg, or slightly hypotonic, 329-350 mOsm/kg. Preferably, the tonicity of the pharmaceutical compositions is rendered isotonic by adjusting the concentration of any one or more of cosolvent, complexing agent and buffering agent in the solution.

In this alternative aspect, the pharmaceutical compositions 65 of the present invention may further comprise a tonicity agent. However, the compositions may further comprise mul-

tiple tonicity agents. Tonicity agents are well known in the art and commercially available. Typical tonicity agents include acdium chloride and dextrose. The preferred tonicity agent is sodium chloride. A preferred tonicity agent concentration is 1-200 mM. A more preferred tonicity agent concentration is 75-125 mM. An even more preferred tonicity agent concentration is 90-110 mM.

14

The pharmacentical compositions of the present invention. are preferably packaged in pharmaceutically acceptable containers in this alternative aspect. Pharmaceutically acceptable containers include intravenous bags, bottles, vials, and syringes. Preferred containers include intravenous bags and syringes, which are preferably polymer-based, and vials and intravenous bottles, which are preferably made of glass. It is also preferred that the components of the container that come into contact with the pharmaceutical composition do not contain polyvinylchloride (PVC). The most preferred container is an intravenous bag that does not have any PVC containing components in contact with the pharmaceutical composition. It is also desirable to protect the pharmaceutical compositions from light. Therefore, the container may, optionally, further comprise a light barrier. A preferred light barrier is an aluminum everpouch.

This alternative aspect also provides methods as described above for preparing the pharmaceutical compositions which are sterile.

7. EXAMPLES

Examples 1 through 6 are intended to be illustrative and not limiting as to the general disclosure. Examples 7 through 12 disclosure specific embodiments of the pharmaceutical compositions that are principally illustrative of the alternative aspects described herein.

Examples 1 Through 6

Example 1

Effect of Various Diluents on Stability of Concentrated CARDENEGI.V.

Stability results for the concentrated amoud product diluted to 0.1 mg/ml with various commonly used infravenous infusion fluids in an IV bag are shown in FIG. 1. pH after mixing was measured and is reported on the X-axis. Product stability was measured by monitoring the % drug remaining after duration of 24 hours by RP-HPLC and is shown on the V-axis.

As shown in FIG. 1, the instability of nicardipine hydrochloride is related to the initial pH of the infusion fluid and to the final pH of the solution after mixing. The magnitude of drug loss post dilution increases as the final pH of the solution after mixing increases, for example, a very pronounced drug loss is obtained when the pH is above 4.5. Based on these findings, the product insert for the marketed ampul product requires product dilution be carried out using specific infusion fluids. Furthermora, the diluted product must be used within 24 hours:

Example 2

Effect of pH on Stability

Stability results for a 0.1 mg/mL nicardipine HCl, 0.1 mM is citric acid, and 5% distrose formulation dispensed in a GAL-AXY@ bag are shown in FIGS. 2A and 2B. Stability results for a 0.1 mg/mL nicardipine HCl, 0.1 mM citric acid, 0.9%

15

saline formulation dispensed in a GALAXY® bag are shown in FIGS. 3A and 3B. Stability assessments are done by measuring the % drug remaining and the total impurity formation as a function of time using RP-HPLC.

Stability testing was done at an accelerated temperature of 40° C. Based on published literature, activation energies for drug decompositions usually fall in the range of 12 to 24 Kcal/mol, with typical value of 19-20 Kcal/mol. Under these conditions (assumption Ra=19.4Kcal/mol) 15 weeks storage at 40° C. corresponds to a product with approximately 18 months expiration at 25° C. (see, e.g., Connors, K. A., et al., Chemical Stability of Pharmaceuticals, A Handbook for Pharmacists, John Wiley & Sons, 2d ed. 1986).

As shown in FIGS. 2A and 3A, less in product potency (drop in % drug remaining) due to degradation and adsorption on to the beg surface increased as the formulation pH was increased. For example, after 6 months storage at 40° C. for the dextrose formulations, a clear trend indicating increased drug loss for formulations at pH 4.4 and 4.7 can be observed. At pH 3.3, the drop in % drug remaining is attributed to an increase in total impurities (FIGS, 2B and 3B), rather than 20 drug loss due to adsorption, in addition to the observed drug loss, the formation of nicardinine-related impurities (FIGS, 2B and 3B) was also found to be strongly pH dependent. In this case, however, the reverse trend was observed; as the pH was decreased, the total impurities increased.

The results from this study indicate that the formulation pH has a significant effect on stability of a ready-to-use diluted product. The findings of this study indicate that the optimal formulation pH range is between about 3.6 to about 4.7. However, depending on the degree of acceptable drug degradation and/or total impurity formation, other pH ranges can be chosen.

Example 3

Effect of Nicardipine Concentration on Impurity Formation

The effect of nicardipine concentration on impurity formation in ready to use premixed compositions comprising 0.1 mg/ml, and 0.2 mg/ml non-sorbital formulations with dextrose over 6 months at 40° C. is shown in FIG. 4A. The effect of nicardipine concentration on impurity formation in ready to use premixed compositions comprising 0.1 mg/ml and 0.2 mg/ml. non-sorbital formulations with saline over 3 months at 40° C. is shown in FIG. 4B. The formulations are dispensed in GALAXY® bags. Stability assessments are done as 45 described in Example 2.

As shown in FIGS. 4A and 4B, in addition to pH, product concentration is another factor that impacts product stability, in particular the formation of nicardipine-related impurities. The concentration dependence observed with respect to total impurity formation is minimized as the formulation pH is increased. For example, in PIGS. 4A and B, the effect of concentration is significant at pH 3.3 and is minimized as the pH approaches 4.7.

These results indicate that impurity formation is greater for the 0.1 mg/ml formulations as compared to the 0.2 mg/ml formulations for both the dextrose and saline formulations. Simultaneous optimization of the drug concentration along with the viable formulation pH range is important in the development of ready-to-use premixed drug formulations.

Example 4

Stability Comparison of Sorbitol and Non-Sorbitol Formulations

A stability comparison of sorbitol and non-sorbitol formulations was conducted under accelerated conditions (4 weeks 16

at 40° C.) using a 0.1 mg/mL nicerdipine HCl, 1.92 mg/mL surbitol, 48 mg/mL dextrose, 0.0192 mg/mL citric acid, pH 4.2 and a 0.1 mg/mL nicerdipine HCl, 50 mg/mL dextrose, 0.0192 mg/mL citric acid, pH 4.0. Both formulations were dispensed in GALAXY® bags. Stability assessments were done by measuring the % drug remaining and total impurity formation as a function of time using RP-HPLC. The results are shown in Tables 2 and 3.

TABLE 2

Descrete Remodution without Sorbital										
s	Timo	% Drug Remaining	% Total Impurities							
	0	100,0	0.08							
	4	98.1	0.17							

TABLE 3

Dextrose Formulation with Sorbital									
Time	% Drug Remaining	% Total Impurities							
Ò	100.0 96.4	NMT ¹ 0.05 0.13							

NOT refer to no more than

As shown in Tables 2 and 3, minimal differences between the two formulations were observed in the measured parameters. Based on these results, as well as the results shown in Examples 1 and 2, the presence or absence of sorbitol is not predicted to alter the impact of formulation pH and drug concentration on the stability of the premixed pharmaceutical compositions comprising hierardipine HCl and dextrose or sodium chloride.

Example 5

The Effect of Plastic Film Composition on Stability

The effect of plastic film composition on the stability of ready to use premixed compositions comprising 0.2 mg/mL nicardipine HCl, 0.2 mM citrate, 5% deartose, pH 4.0-4.2 for "incompatible" bags and "compatible" bags is shown in FIGS. \$A and 5B respectively. "Incompatible" bags contain polar polymers, such as polyvinyl chloride (PVC) and ethylene vinyl acetate (EVA). "Compatible" bags do not contain polar polymers.

Stability evaluations were done for the 0.2 mg/ml. nonsorbitol dexiruse formulation in various commercially available IV infusion bag systems. EXCEL®, VIAFLEX®, VIAFLOTM, INTRAVIA®, and VISIV® bags were rinsed in
water and covered with aluminum foil over pouches. The
bags were filled with the above formulation and autoclaved at
105° C. for 21 minutes. STEDIM®71 and GALAXY® bags
were asceptically filled with the above formulation. Stability
assessments were done by measuring the ¼ drug remaining
and total impurity formation (data not shown) as a function of
time using RP-HPLC for samples incubated for up to 24
weeks at 40° C. The ¾ drug remaining was calculated relative
to the concentration measured post-mixing in tank.

As shown in FIG. 5A, various commercially available TV is bags were not compatible with nicardipine HCl. Significant loss in product potency was observed upon storage primarily due to product adsorption in bags that contained the polymer

17

PVC (e.g., VIAFLEX® and INTRAVIA®). Nicardipine was also incompatible with bags containing the polymer ethylenevinyl acetate (EVA) in the contact layer (e.g., STEDIMO71). PVC and EVA are examples are of polar plastic materials that are incompatible with nicardipine HCI. Because nicardipine HCl is a weak base with a pKn of -7.2, it is increasingly hydrophobic as the formulation pH increases, and therefore, compatibility with polymeric contact surfaces is dependent on surface charge-related properties.

As shown in FIG. 5B, minimal drop in product potency was observed with commercial bags comprising copolyester (e.g., HXCHL®), polyethylene (e.g., GALAXY®), and polyolefin blends (e.g., VISIV® and VIAFLOTA).

Example 6

Effect of CAPTISOLO on Product Stability

The effect of CAPTISOL® on the stability of ready to use premitted compositions comprising 0,3 mg/ml Nilcardipine, 20 30 mM NaAcetate, 1.8% Ceptisol, 112 mM NaCl, pH 4.5 or 0.3 mg/ml Nicardipine, 30 mM NaAcetate, 1.8% Captisol, 3.7% Dextrose, pH 4.5 dispensed in 100 ml GALAXY® begs was monitored for 12 weeks at 5, 25 and 40° C. in (eee, e.g., shown. In addition, the formulations were monitored at 45° C. in 2 ml, glass vials (see, e.g., Table 5), All formulations were filled aseptically into the vials and bags by filtering the solution through a 0.22 µm filter.

TABLE 4

16.7	Ing Remaining	at 25° C. and 40	PC Is GALAX	Y D But	_
		Immeining		temajnjag	
Time (weeks)	NaCl Pomulation	Destroie Pommistion	NaCi Papenlation	Destros Population	
0	100,00	100,00	100,00	100.00	-
1	96.57	99,86	97.15	96,26	-
2	98.09	100.50	97.07	100.40	
4	99,45	104,01	92.46	102.55	
12	97.23	101.13	95.36	99.00	

TABLE 5

_	%	Drug Remaining at 4 % Drug Rec		_
	Tima (weeks)	NaCi Formulation	Destrose Formulation	5
	0	100,00	100.00	_
	2 4	107.69 105.18	105.78 105.22	
	14	100.27	102.80	5

Pharmaceutical compositions comprising CAPITSOL® exhibited minimal drug loss and impurity formation (data not shown) as a function of time and temperature. Based on the accelerated stability data at 40° and 45° C., formulations 60 comprising CAPTISOL®, dextrose or NACI should be stable at room temperature for at least 12 months.

Examples 7 Through 12

Examples 7-12 illustrate experiments performed using specific embodiments. The experiments in Examples 7-12

were performed at 45° C. in order to simulate stressed conditions that cause sufficient product degradation in a relatively abort period of time. Stability comparisons were done against the control formulation (CF) and/or the commercial product formulation (CPF) in order to assess relative differences in their degradation profiles. The CPF is a marketed drug product and, therefore, degradation belavior of the molecule is well understood as a function of temperature and time. Stability data are available for the marketed product up 10 to 36 months at room temperature, 22-27° C., and 40° C.

18

The rationals used in this preliminary screening evaluation is that if the degradation kinetics of the evaluated formulation prototypes were comparable to the CPF at stressed temperatures, drug product stability would likely be comparable or 15 better at room temperature. The current prototype formulation is stable for at least 18 months at 25° C., and therefore it is projected that the evaluated formulation prototypes can have comparable or better stability.

Example 7

Formulation Preparation and Analysis

Appropriate buffers, such as acetate or succinate, contain-Table 4). Because the drug was stable at 5° C., the data is not 25 ing the desired cosolvents, such as sorbitol or propylene glycol, and/or complexing agents, such as SHEBCD or 2HPBCD, were prepared. Appropriate tonicity agents, such as sodium chloride, were prepared and added to some of the pharmaceutical compositions. Based upon the final formulaso from volume and the target drug concentration, usually 0.2-0.3 mg/mL, nicardipine was weighed into an appropriate glass container and prepared buffer was added to dissolve the drug. Tonicity agent, if my, was then added. The solution was then sonicated for up to 45 minutes to facilitate drug dissolution. 35 Pollowing thug dissolution, the solution was filtered through a 0.45 µm syringe filter (Acrodisc LC 13 mm Syringe filter, PVDF Membrane from Life Sciences, PN 4452T). When filtering, the first few drops were discarded and the remaining solution was collected into another glass container. The pre-40 pered formulations were subscruently dispensed into either vials or intravenous bags.

The following isotonic pharmaceutical compositions were made according to the above protocol:

Pharmaceutical Composition 1 (PC 1): 0.2-0.3 mg/ml nicerdipine hydrochloride, 3.7% sorbitol, and 50 mM Naacetate, wherein the pH of the composition is 5.0.

Pharmacentical Composition 2 (PC 2): 0.2-0.3 mg/ml nicardipine hydrochloride, 1.7% propylene glycol, and 50 mM Na-acetate, wherein the pH of the composition is

Pharmaceutical Composition 3 (PC3): 0.2-0.3 mg/ml nicardipine hydrochloride, 2.8% sorbitol, and 50 mM Nasuccinate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 4 (PC 4): 0.2-0.3 mg/ml nicardipine hydrochiloride, 1.1% propylene glycol, and 50 mM Na-saccinate, wherein the pH of the composition is

Pharmaceutical Composition 5 (PC 5): 0.2-0.3 mg/ml nicardipine hydrochloride, 4.1% sorbitol, and 50 mM Naacetate, wherein the pH of the composition is 3.5.

Pharmaceutical Composition 6 (PC 6): 0.2-0.3 mg/ml nicardipine hydrochloride, 1.9% propylene glycol, and 50 mM Na-acctate, wherein the pH of the composition is

Pharmaceutical Composition 7 (PC 7); 0.2-0.3 mg/ml nicardipine hydrochloride, 4.1% sorbitol, and 50 mM Naacetate, wherein the pH of the composition is 4.5.

20 tion 25 (PC 23): 0.

- Pharmsceutical Composition 8 (PC 8): 0.2-0.3 mg/ml nicarclipine hydrochloride, 1.8% propylene glycol, and 50 mM Na-acetate, wherein the pH of the composition is 4.5.
- Pharmaceutical Composition 9 (PC 9): 0.2-0.3 mg/ml nicardipine hydrochloride, 6.5% sulfobutylether-β-cyclodeatrin, and 50 mM Na-succinate, wherein the pH of the
 composition is 5.5.
- Pharmacsutical Composition 10 (PC 10): 0.2-0.3 mg/ml nicardipine hydrocaloxide, 6.5% sulfobutylether-β-cyclodextrin, and 50 mM Na-aucrinste, wherein the pH of the composition is 6.0.
- Pharmacsurieal Composition 11 (PC 11): 0,2-0,3 mg/ml micardipine hydrochloxide, 8.5% salfobutylether-6-cy-clodextrin, and 50 mM Na-succinate, wherein the pH of the composition is 3.5.
- Pharmaceutical Composition 12 (PC 12): 0,2-0.3 mg/ml nicardipine hydrochloride, 8.5% sulfobutylether-6-cy-clodextrin, and 50 mM Na-succinate, wherein the pH of 20 the composition is 6.0.
- Pharmaceutical Composition 13 (PC 13): 0.2-0.3 mg/ml nicardipine hydrochloride, 8.5% sulfobutylether-β-cyclodextrin, and 50 mM Na-acetate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 14 (PC 14): 0.2-0.3 mg/ml nicardipine hydrochloride, 8.5% sulfobutylether-β-cyclodextrin, and 50 mM Na-citrate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 15 (PC 15): 0.2-0,3 mg/ml 30 nicardipine hydrochloride, 22.5% 2-hydroxypropyl-β-cyclodextria, and 50 mM Na-acetate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 16 (PC 16): 0.2-0.3 mg/ml nicardipine hydrochloride, 22.5% 2-hydroxypropyl-β- 35 cyclodextrin, and 50 mM Na-succinste, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 17 (PC 17): 0.2-0.3 mg/ml nicardipine hydrochloride, 17.5% 2-hydroxypropyl-B-cyclodextrin, and 50 mM Na-acetate, wherein the pH of 40 the composition is 5.0.
- Pharmaceutical Composition 18 (PC 18): 0.2-0.3 mg/ml nicardipine hydrochluride, 17.5% 2-hydroxypropyl-βcyclodextrin, and 50 mM Na-succinate, wherein the pH of the composition is 5.5.
- Commercial Product (Ampul) Formulation (CPF): 2.5 mg/ml meardipine hydrochloride, 2.5 mM citrate, and 5% sorbitol, wherein the pH of the composition is 3.5.
- Control Formulation (CF): 0.3 mg/ml nicerclipine hydrochloride, 2.5 mM citrate, and 5% sorbitol, wherein the 50 pH of the composition is 3.5.
- Pharmaceutical Composition 19 (PC 19): 0.3 mg/ml nicardipine hydrochloride, 50 mM acdium acetate, 50 mM sodium citrate, and 50 mM disodium succinate, wherein the pH of the composition is 3.5.
- Pharmacoutical Composition 20 (PC 20): 0.3 mg/ml nicardipine hydrochloride, 50 mM sodium sectate, 50 mM sodium citrate, and 50 mM disodium succinate, wherein the pH of the composition is 4.5.
- Pharmaceutical Composition 21 (PC 21): 0.3 mg/ml nicadipine hydrochloride, 50 mM sodium scetste, 50 mM sodium citrate, and 50 mM disodium succinate, wherein the nH of the composition is 5.0.
- Pharmaceutical Composition 22 (PC 22): 0.3 mg/ml nicantipine hydrochloride, 50 mM sodium acctate, 50 mM as sodium citrate, and 25 mM disodium succinate, wherein the pH of the composition is 5.5.

- Pharmacentical Composition 25 (PC 23): 0.3 mg/ml nicardipine hydrochloride, 4.1% sorbitol, and 50 mM sodium acetate, wherein the pH of the composition is 3.5.
- Pharmaceutical Composition 24 (PC 24): 0.3 mg/ml nicardipine hydrochloride, 4.1% sorbitel, and 50 mM sodium acetate, wherein the pH of the composition is 4.5.
- Pharmaceutical Composition 25 (PC 25): 0.3 mg/ml nicardipine hydrochloride, 3.7% scribini, and 50 mM acdum acetate, wherein the pH of the composition is
- Framecentical Composition 26 (PC 25): 0.3 mg/ml nicerdigine hydrochloride, 2.8% sorbitol, and 50 mM sodium sectate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 27 (PC 27): 0.3 mg/ml nicardipine hydrochloride, 1.9% propylene glycol, and 50 mM sodium acetate, wherein the pH of the composition is 3.5.
- Pharmaceutical Composition 28 (PC 28): 0.3 mg/ml nicardipine hydrochloride, 1.3% propylene glycol, and 50 mM sodium acetate, wherein the pH of the composition is 4.5.
- Pharmaceutical Composition 29 (PC 29); 0.3 mg/ml nicandipine hydrochloride, 1.7% propylene glycol, and 50 mM sodium acetate, wherein the pH of the composition is 5.0
- Pharmaceutical Composition 30 (PC 30): 0.3 mg/ml nicamipine hydrochloride, 1.1% propylene glycol, and 50 mM sodium succinate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 31 (PC 31): 0.3 mg/ml nicardipine hydrochloride, 6.5% sulfabutylether-6-cyclodentrin, and 50 mM sodium succinate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 32 (PC 32): 0.3 mg/ml nicardipine hydrochloride, 6.5% sulfobutylether-8-cyclodestrin, and 50 mM sodium succinate, wherein the pH of the composition is 6.0.
- Pharmaceutical Composition 33 (PC 33): 0.3 mg/ml nicardipine hydrochloride, 22.5% 2-hydroxypropyl-β-cyclodextrin, and 50 mM sodium acetate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 34 (PC 34): 0.3 mg/ml nicardipine hydrochloride, 17% 2-hydroxypropyl-B-cyclodentrin, and 50 mM disodium succinate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 35 (PC 35): 0.3 mg/ml nicardipine hydrochloride, 0.3% purpylene glycol, 0.5% sorbitol, 30 mM sodium acetate, and 90 mM NaCl, wherein the pH of the composition is 5.2.
- Pharmaceutical Composition 36 (PC 36): 0.3 mg/ml nicardipine hydrochloride, 0.3% propylene glycol, 2.0% sorbitol, 30 mM sodium scetate, 45 mM NaCl, wherein the pH of the composition is 5.2.
- Pharmaccutical Composition 37 (PC 37): 1.5 mg/ml nicardinine hydrochloride, 9% suffobutylether-β-cyclodertrin, and 30 mlM sodium acetate, wherein the pH of the composition is 4.5.
- Pharmaceutical Composition 38 (PC 38): 1.5 mg/ml nicardipine hydrochloride, 9% antiobutylether-6-cyclodextrin, and 30 mM sodium acctate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 39 (PC 39): 0.3 mg/ml nicardipine hydrochloride, and 30 ml/l sodium acetate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 40 (PC 40): 0.3 mg/ml nicardipine hydrochloride, and 30 mM sodium acetate, wherein the pH of the composition is 4.0.

Pharmaceutical Composition 41 (PC 41): 0.3 mg/ml nicantipine hydrochloride, and 30 mM sodium scetate, 5 wherein the pH of the composition is 4.5.

Pharmaceutical Composition 42 (PC 42): 0.3 mg/ml micantipine hydrochleride, 1.8% sulfobutylether-β-cyclodextrin, 30 mM sodium scetate, and 110 mM NaCl, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 43 (PC 43): 0.3 mg/ml nicardipine hydrochloride, 1.8% sulfobutylether-B-cyclodextrin, 0.3% propylene glycol, 30 mM sodium acetate,

85 mM NaCl, wherein the pH of the composition is 5.0. Pharmaceutical Composition 44 (PC 44); 0.3 mg/ml nicardipine hydrochloride, 1.8% sulfobutylether-6-cyclodextrin, 30 mM sodium acetate, and 110 mM NaCl, wherein the pH of the composition is 4.5,

Pharmaceutical Composition 45 (FC 45): 0.3 mg/ml nica- 20 rdipine hydrochloride, 1.8% sulfobutylether-fl-cyclodeatrin, 30 mM sodium acetate, and 200 mM deatrose, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 46 (PC 46): 0.3 mg/ml nicadestrin, 30 mM sodium acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 47 (PC 47): 0.3 mg/ml nicazdipine hydrochloride, 1.0% sulfobutylether-p-cyclodextrin, 30 mM sodium acetate, and 125 mM NaCl, 30 wherein the pH of the composition is 4.5.

Pharmacentical Composition 48 (PC 48): 0.3 mg/ml nicerdipine hydrochloride, 3.4% sorbitol, and 50 mM sodium succurate, wherein the pH of the composition is

Pharmaceutical Composition 49 (PC 49): 0.3 mg/ml nicurdipine hydrochloride, 1.3% propylene glycol, and 50 mM sodium acutate, wherein the pH of the composition

Pharmaceutical Composition 50 (PC 50): 0.3 mg/ml nics- 40 rdipine hydrochloride, 1.8% sulfobutylether-β-cyclodestrin, 30 mM sodium acetete, and 110 mM NaCl, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 51 (PC 51): 0.3 mg/ml nicardipine hydrochloride, 0.75% sulfobutylether-B-cyclodestrin, 30 mM sodium acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 52 (PC 52): 0.3 mg/ml nicardipine hydrochloride, 1.0% sulfobutylether-B-cyclodextrin, 30 mM sodium acetate, and 125 mM NaCl, so wherein the pH of the composition is 4.5.

Pharmaceutical Composition 53 (PC 53): 0.3 mg/ml nicerdipine hydrochloride, 0.5% sorbitol, 0.3% propylene giyeol, 30 mM sodium spetate, and 90 mM NaCl, wherein the pH of the composition is 5.2.

Pharmaceutical Composition 54 (PC 54): 0.3 mg/ml picardipine hydrochloride, 1.0% sulfobatylether-β-cyclodentrio, 30 mM sodium acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 55 (PC 55): 0.3 mg/ml nica- 60 rdipine hydrochloride, 0.75% sulfobutylether-6-cyclodestrin, 30 mM sodium acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 56 (PC 56): 0.3 mg/ml nicardipine hydrochloride, 0.5% sorbitol, 0.3% propylene 65 glycol, 50 mM acdium acetate, and 90 mM NaCl, wherein the pH of the composition is 5.2.

The excipient concentration in the control formulation (CF) is identical to the commercial product formulation (CFF), Cardene® I.V (ampul). However, the concentration of active ingredient in the commercial and control formulations is different. In the commercial product formulation (CPF), the concentration of micerdipine hydrochloride in the ampulis 2.5 mg/mL before dilution, and 0.1 mg/ml after dilution with appropriate IV fivids before administration. The control foramlation (CF), which is designed for premixed ready-to-use intravenous bags such that no further dilution with intravenous fluids is required, has a nicardipine hydrochloride concentration of 0.3 mg/mL. The purpose of the control formulation was to help assess the degradation propensity of the evaluated formulations. Comparable degradation profiles at 15 stressed conditions is indicative of comparable formulation stability.

Example 8

Vial Stubility Data with Sorbitol and Propylene Glycol Formulations

The stability in vials of pharmaceutical compositions of the rdipine hydrochloride, 0.75% sulfobutylether-\$-cyclo- 2s present invention comprising a co-solvent and a buffering agent were compared to the control formulation and the commercial product formulation. Stability was determined by comparing the drug concentration over time for the below compositions. Specifically, the below compositions were prepared according to the method in Example 7:

> 50 mM Na-acetate, pH 3.5. 4.1% sorbitol (PC 5), 50 mM Na-acetate, p.H 3.5, 1.9% propylene glycol (PC 6), 50 mM Na-acetate, pH 4.5, 4.1% sorbitol (PC 7). 50 mM Na-acetate, pH 4.5, 1.8% propylene glycol (PC 8), 50 mM Ns-acetate, pH 5.0, 3.7% sorbitol (PC 1),

> 50 mM Na-acotate, pH 5.0, 1.7% propylane glycol (PC 2), Control formulation: 0.3 mg/mL, 2.5 mM citrate, 5% sorbitol, pH 3.5 (CP), and

> Commercial product formulation: 2.5 mg/ml, 2.5 mM citrate, 5% sorbitol, pH 3.5 (CPF).

These stability studies were performed in 2 ml glass yials and at elevated temperature conditions, in this case 45° C. Formulation stability was monitored by measuring the drog concentration by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, 7 days and 21 days, except for the commercial product formulation, which measurements were taken at the start of the experiment and 46 days. These measurements were then converted into a percentage in order to show the percentage of drug remaining after a period of time.

5							
	PC#	Drug Cono. (µg/ml) t=0	% Drug Remaining	Drug Cens. (µg/ml) t = 7 skys	% Dang Remaining	Drug Cono. (ug/ml) t=21 days	% Drug Remaining
0	5	314	100	312	59	289	92
	6	302	100	305	101	282	93
	7	304	1.00	303	100	283	93
	8	304	100	304	100	282	93
	1	298	100	294	98	274	92
	2	290	100	302	104	264	91
5	CF	302	100	301	100	277	92

23

Ran

Davy Conc (µy/ml)

2-0

2553

PC#

CPF

100	2263	90	\$ PC#	(jg/m!) t=0	Deng Remaining	(µकृतिको) १ ~ 46 daya	Daig Remaini
% Drag mining	Drug Cons. (µg/ml) t = 46 days	Drug Remaining		Drug Conc.	56	Drug Cope.	%

The data show that the stability in vials, drug concentration over time, of the pharmaceutical compositions of the present invention that contain co-solvents are comparable to both the to control formulation (CF) and the current product formulation (CFF). In addition, the compositions had no additional degradation products relative to the control formulation (data not allows).

Example 9

Vial Stability Data with SBRBCD Formulations

The stability in vials of pharmaceutical compositions of the 20 present invention comprising a complexing agent and a buffering agent were compared to the control formulation and the commercial product formulation. Stability was determined by comparing the drug concentration over time for the below compositions. Specifically, the below compositions were prepared according to the method in Example 7:

50 mM Na-acetate, 8.5% SBU-beta cyclodextrin, pH 5.0 (PC 13),

50 mM Na-citrate, 8.5% SBE-beta cyclodextrin, pH 5.5 (PC 14),

50 mM Na-succinate, 8.5% SBE-beta cyclodextrin, pH 5.5 (PC 11),

50 mM Na-succinete, 8.5% SBE-beta cyclodextrin, pH 6.0 (PC 12),

Control formulation: 0.3 mg/mL, 2.5 mM citrate, 5% soc- 35 hitol, pH 3.5 (CF), and

Commercial product formulation: 2.5 mg/ml, 2.5 mM vitrate, 5% sorbitol, pH 3.5 (CPF).

These stability studies were performed in 2 ml gless vials and at vials and at elevated temperature conditions, in this 40 case 45° C. Formulation stability was monitored by measuring the drug concentration by RP-RPLC against a standard curve. The drug concentration measurements were taken at the tart of the experiment, 6 days, 13 days and 30 days, except for the commercial product formulation, which measurements were taken at the start of the experiment and 46 days. These measurements were then converted into a percentage in order to show a percentage of drug remaining after a period of time.

The data from these stability studies are shown in the 50 following Tables.

Ö	
	The data show that the stability in vials, drag concentration
	over time, of the pharmaceutical compositions of the present
	invention that contain SBEBCD are comparable to both the
5	control formulation (CF) and the commercial product formu-
	lation (CPF). In addition, the compositions had no additional
	degradation products relative to the control formulation (data
	not shown). It is also worth noting that the target concentra-
)	tion of 0,2-0,3 mg/mL could be readily attained in the pres-
	ence of sulfobrityether-6-cyclodextrin.

24

Example 10

Intravencus Bag Stability Data with Sorbitol and Propylene Glycol Formulations

The stability in intravenous bags of phermaceutical compositions of the present invention comprising a co-solvent and a buffering agent were compared to a control formulation. Stability was determined by comparing the drug concentration over time for the below compositions. Specifically, the below compositions were prepared according to the method in Example 7:

50 mM Na-acetate, pH 3.5, 4.1% sorbitol (PC 5),

50 mM Na-acetate, pH 3.5. 1.9% propylene glycol (PC 6), and

Control formulation: 0.3 mg/mL, 2.5 mM citrate, 5% sorbitol, pH 3.5 (CF).

These stability studies were performed in 50 ml intrave-15 note bags and at elevated temperature conditions, in this case 45° C. Formulation stability was monitored by measuring the drug concentration by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, 7 days and 21 days. These measurements were then converted into a percentage in order to show the percentage of drug remaining after a period of time.

PC#	[Drug] (pg/ml) t = 0	Marching Remaining	[Daug] (pg/ml) t=6d	% Drug Remaining	(Drug) (µg/ml) t = 13 d	% Drug Remaining	(148/ml) t = 30 d	% Drug Remaining
13	351	100	387	101	41.3	108	390	102
14	334	300	339	101	352	105	333	100
11	364	100	37 8	104	396	109	364	100
12	318	100	341	107	355	112	326	1,03
CF	339	100	352	104	363	107	338	100

The data from these stability studies are shown in the Table helow

PC#	Drug Conc. (µg/ml) t = 0	% Drug Remaining	Deig Conc. (pg/ml) t=7 days	% Drug Remaining	Deng Conc. (µg/ml) t=21 days	% Daug Remaining
5	314	100	317	101	319	102
6	302	100	311	103	297	98
CF	302	100	276	92	264	88

The data show that the stability in intravenous bags, drug concentration over time, of the pharmaceutical compositions of the present invention that contain co-solvents are comparable to the control formulation. In addition, the compositions had no additional degradation products relative to the control formulation (data not shown). Finally, drog adsorption on the bag surface was minimal at pH 3.5,

Example 11

Intravenous Bag Stability Data with HPCD Formulations

The stability of a pharmaceutical composition of the present invention comprising a complexing agent and a buffering agent was evaluated in both vials and intravenous bags. Stability was determined by comparing the drug concentration over time for the below composition. Specifically, the below composition was prepared according to the method in Example 7:

50 mM Na-acetate, pH 5.0, 22.5% HPCD (PC 15).

These stability studies were performed in 50 ml intrave- 35 Example 7: now beguend at elevated temperature conditions, in this case 45° C. The stability evaluations were done with a 10 mL fill volume in both the upright and inverted bag configurations. These evaluations were done relative to the same formulation in a 2 mL glass vial, as a control. Formulation stability was monitored by measuring the drug concentration by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, 1 day, 2 days, 6 days, 9 days and 16 days.

The data from these stability studies are shown in the Table 45 below.

upright configuration of the bag. The data also show that the recovery of drug product was poorer in the inverted bag configuration.

26

In order to determine why the composition was more stable in upright intravenous bags compared to inverted intravenous bags, additional experiments were conducted. The drop in drug concentration was not due to any new degradation product (data not shown). We believe that the drop in drug con-10 centration was due to drug adsorption on the bag surface. For many hydrophobic drugs, adsorption on PVC surfaces is a commonly reported concern. Therefore, it is likely that we observed significant adsorption in the inverted configuration because the drug is in contact with PVC surfaces. These results ruggest the use of non-PVC bags and/or the careful evaluation of the bag size (solution volume) as feasible options to minimize drug adsorption in order to achieve adequate drug product recovery.

Example 12

Intravenous Bag Stability Data with Sorbitol Fermulations

The stability of a pharmaceutical composition of the present invention comprising a cosolvent and a buffering gent was evaluated in both vials and intravenous bags. Stability was determined by comparing the drag concentration over time for the below composition. Specifically, the below composition was prepared according to the method in

50 mM Na-acetate, pH 5.0, 3.7% sorbitol (PC 1).

These stability studies were performed in 50 ml intravenous bags and at elevated temperature conditions, in this case 45° C. The stability evaluations were done with both 10 and 50 ml. fill volumes in both the upright and inverted bag configurations. These evaluations were done relative to the same formulation in a 2 mL glass vial, as a control. Formulation stability was monitored by measuring the drug concen-

	Daug Conc. (pg/ml) t=0	Daug Conc. (µg/ml) t = 1 day	Drug Conc. (µg/ml) t=2 days	Drug Cone. (µg/ml) t = 6 days	Drug Conc. (pg/ml) t=9 days	Drug Conc. (µg/m²) t = 16 days
Vid	271	271	263	260	269	274
Upright Bag	271	.256	244	264	270	301
Inverted Bag	271	233	203	175	172	150

time, of the pharmaceutical composition of the present invention that contains complexing agent is more promising in the

The data show that the stability, drug concentration over 15 tration by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, I day, 2 days, 5 days, 9 days and 16 days.

The data from these stability studies are shown in the below Inble.

the aqueous solution when stored in the container for at least three months at room temperature exhibiting (i) less than a

	Drug Conc. (pg/ml) t = 0	Drag Conc. (µg/ml) t=1 day	Drug Conc. (ug/ml) t=2 days	Drug Conc. (ug/ml) t = 6 days	Drug Conc. (µg/ml) t=9 days	Daug Cone. (ug/ml) 1 = 16 days
Vial	100	102	100	110	104	106
Upright Bag 10 ml	100	93	89	98	85	\$7
Upright Bag 50 ml	100	98	96	114	97	98
Invested Bag 10 ml	100	46	43	38	2 L	13
Inverted Pag 50 ml	100	E9	87	102	86	85

The data show that the stability, drug concentration over time, of the pharmaceutical composition of the present invention that contains condvent is more promising in the unright configuration of the bag. The data also show that the recovery 25 of drug product was poorer in the invested bag configuration.

In order to determine why the composition was more stable in upright intravenous bags compared to inverted intravenous bags, additional experiments were conducted. The drop in drug concentration was not due to any new degradation prod- 30 uct (data not shown). We believe that the drop in drug concentration was due to drug adsorption on the bag surface. For many hydrophobic drugs, adsorption on PVC surfaces is a commonly reported concern. Therefore, it is likely that we observed significant adsorption in the inverted configuration 35 because the drug is in contact with PVC surfaces. This belief is further supported by the fact that we observed poorer recovery of the drug in the 10 ml. fill configuration relative to the 50 mL fill configuration, although this poorer recovery may be partly due to the fact that the 10 mL fill configuration has a 40 higher surface area to volume ratio, which adversely impacts drug adsorption and recovery. In conclusion, these results suggest the use of non-PVC bags and/or the careful evaluation of the bag size (solution volume) as femilial options to minimize drug adsorption in order to achieve adequate drug 45 product recevery.

All publications, patents, patent applications and other documents cited in this application are hereby incorporated by reference in their entireties for all purposes to the same extent as if each individual publication, patent, patent appli- 50 cation or other document were individually indicated to be incorporated by reference for all purposes.

While various specific ambodiments have been illustrated and described, it will be appreciated that various changes can be made without departing from the spirit and scope of the 55 invention(s).

What is claimed is:

1. A method for treating acute elevations of blood pressure in a human subject in need thereof, said method comprising so mg/ml to about 4 mg/ml sorbitol. parenterally administering a pro-mixed aqueous solution comprising from about 0.1 to 0.4 mg/mL nicardipine or a pharmacentically acceptable salt thereof; a tonicity agent; and a buffer, wherein the aqueous solution requires no dilution before administration and has a pH from about 3.6 to 65 about 4.7, the equeous solution stored in a container such that the aqueous solution is in contact with non-polar polymera,

10% decrease in the concentration of nicardipine or pharmscentically acceptable salt thereof and (ii) a total impurity formation of less than about 3%.

- 2. A method for inducing hypotention in a human subject in need thereof, said method comprising parenterally administering a pre-mixed aqueous solution comprising from about 0.1 to 0.4 mg/mL nicardipine or a pharmaceutically acceptable salt thereof; a tonicity agent; and a buffer; wherein the aqueous solution requires no dilution before administration and has a pH from about 3.6 to about 4.7, the aqueous solution stored in a container such that the aqueous solution is in contact with non-polar polymers, the aqueous solution when stored in the container for at least three months at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine or pharmacentically acceptable salt thereof and (ii) a total impurity formation of less than
- 3. A method for treating acute elevations of blood pressure in a human subject in need thereof, said method comprising parenterally administering to a subject in need thereof, a pre-mixed aqueous solution with a pH from about 3.6 to about 4.7 comprising: from about 0.1 to 0.4 mg/mL nicentipine hydrochloride; a tonicity agent selected from (i) about 4.5% to about 5% descrose or (ii) about 0.8% to about 0.9% sodium chloride; and a buffer; the aqueous solution contained in a pharmaceutically acceptable container such that the aqueous solution is in contact with non-polar polymers, the aqueous solution when stored in the container for at least three months at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine or pharmaceutically acceptable salt thereof and a total impurity formation of less than about 3%.
- 4. The method of claim 3, further comprising at least one pH adjuster selected from the group consisting of hydrochloric acid, sodium hydroxide and a mixture thereof.
- 5. The method of claim 3, further comprising from about 1
- 6. The method of claim 3, wherein the non-polar polymers comprise copolyester, polyethylene or polyelefin.
- 7. The method of claim 3, wherein the pre-mixed aqueous actution comprises: from about 0.1 to about 0.2 mg/mL nicardipine hydrochloride; and a tonicity agent selected from (i) about 46 to about 50 mg/mL dextrose or (ii) about 8.3 to about 9 ma/mL sodium chloride.

29

8. A method for inducing hypotension in a human subject in need thereof said method comprising purenterally administering to a subject in need thereof, a pre-mixed aqueous solution with a pH from about 3.6 to about 4.7 comprising: from about 0.1 to 0.4 mg/mL nicardipine hydrochloride; a 5 touicity agent selected from (i) about 4.5% to about 5% dextrose or (ii) about 0.8% to about 0.9% sodium chloride; and a buffer; the aqueous solution contained in a pharmaceutically acceptable container such that the solution is in contact with non-polar polymers, the aqueous solution when stored in 10 the container for at least three months at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine or pharmaceutically acceptable sait thereof and (ii) a total impurity formation of less than about 3%.

9. The method of claim 8, further comprising at least one 15 pH adjuster selected from the group consisting of hydrochloric acid, sodium hydroxide and a mixture thereof.

10. The method of claim 8, further commising from about 1 mg/ml to about 4 mg/ml surbitol.

11. The method of claim 8, wherein the non-polar polymers 20 comprise copolyrates, polyethylene or polyoletin.

12. The method of claim 8, wherein the pre-mixed aqueous solution comprises; from about 0.1 to about 0.2 mg/mL nicardipine hydrochloride; and a tonicity agent selected from (i) about 46 to about 50 mg/mL destrose or (ii) about 8.3 to about 25 9 mg/mL sodium chloride.

13. The method of claim 1, wherein the wherein the nonpolar polymers comprise copolyceter, polychylese or polyolefin.

14. The method of claim 2, wherein the wherein the nonpolar polymers comprise copolyester, polyethylene or polyolefin

15. The method of claim 1, wherein the non-polar polymers comprise polyethylene.

16. The method of claim 2, wherein the non-polar polymers 35 comprise polyethylene.

 The method of claim 3, wherein the non-polar polymers comprise polyethylene.

 The method of claim 8, wherein the non-polar polymers comprise polyethylene. 19. The method of claim 1, wherein the aqueous solution when stored in the container for at least one year at room temperature exhibits (i) less than a 10% decrease in the concentration of nicardipine or pharmaceutically acceptable salt thereof and (ii) a total impurity formation of less than about

20. The method of claim 2, wherein the agreous solution when stored in the container for at least one year at room temperature exhibits (i) less than a 10% decrease in the concentration of micardipine or pharmaceutically acceptable solt thereof and (ii) a total impurity furnation of less than about 3%.

21. The method of claim 3, wherein the aqueous solution when stored in the container for at least one year at room temperature exhibits (i) less than a 10% decrease in the concentration of nicardipine or pharmaceutically acceptable saft thereof and (ii) a total impurity formation of less than about 3%.

22. The method of claim 8, wherein the squeous solution when stored in the container for at least one year at room temperature exhibits (i) less than a 10% decrease in the concentration of nicardipine or pharmaceutically acceptable salt thereof and (ii) a total impurity formation of less than about 3%.

The method of claim 1, further comprising from 0 mg/mL to about 4 mg/mL sorbitol.

24. The method of claim 2, further comprising from 0 mg/mL to about 4 mg/mL surbitol.

25. The method of claim 3, further comprising from 0 mg/mL to about 4 mg/mL sorbitol.

26. The method of claim 3, further comprising from 0 mg/mL to about 4 mg/mL sorbitol.

27. The method of claim 1, wherein the pre-mixed aqueous solution comprises from about 0.1 to about 0.2 mg/ml. nica-rdipine bydrochloride.

28. The method of claim 2, wherein the pre-mixed aqueous solution comprises from about 0.1 to about 0.2 mg/mL nicardipins hydrochloride.

.

EXHIBIT D



(12) United States Patent Duncan et al.

(10) Patent No.: (45) Date of Patent: US 7,659,290 B2 Feb. 9, 2010

(54) METHODS OF PREPARING PRE-MIXED. READY-TO-USE PHARMACEUTICAL COMPOSITIONS

(75) Inventors: Michelle Renee Duncan, Glenview, IL (US); Supriya Gupta, Supayvale, CA (US); David Hartley Hass, Fremoni, CA (US); Norma V. Stephens, Skokie, II. (US); Camellia Zamiri, Fremont, CA (US)

(73) Assignee: EKR Therapeutics, Inc., Bedminster, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: 12/407,551

(22) Filed: Mar. 19, 2009

(65)**Prior Publication Date** US 2009/0182017 A1 Jul. 16, 2009

Related U.S. Application Data

- (62) Division of application No. 11/788,076, filed on Apr. 18, 2007, now Pat. No. 7,612,102.
- (60) Provisional application No. 60/793,074, filed on Apr. 18, 2006.

(51) Int. Cl. A61K 31/44 (2006.01)

(52) U.S. Cl. 514/354; 424/400

(58) Field of Classification Search See application file for complete search history.

(56)References Cited

U.S. PATENT DOCUMENTS

3,985,758	A	10/1976	Municami
4,711,902	A	12/1987	Semo
4,880,823	A	11/1989	Ogawa et al 514/35
4,940,556	A	7/1990	MacFarlane
5,079,237	A	1/1992	Husu et al.
5,164,405	A	11/1992	McFarlage et al 514/33
5,198,226	A	3/1993	MacFarlans
RE34,518	E	5/1994	Ogawa
5,376,645	A	12/1994	Stella
5,519,012	A	5/1996	Fercej-Temeljotov
5,904,929	A	5/1999	Uekama
6,595,926	Bl	7/2003	Laragh
2007/0112041	A1	5/2007	Bhownick
2007/0244166	Àl	10/2007	Gupta
2007/0249689	ΑI	10/2007	Duncan

FOREIGN PATENT DOCUMENTS

EP	0149475	Bi	7/1985
EP	0162705	BI	11/1985
GB	2228412	A	B/1990

WO 01/07086 + 2/2001 WO

CITHER PUBLICATIONS

Kaise, Barb, et. al., Solutions to Health Care Waste: Life-Cycle Thinking and "green" purchasing, Environmental Health Perspec-

tives, vol. 109, No. 3, Mar. 2001, pp. 1-4.*
Pomponio, R. et. al., Photostability studies on alcandipinecyclodistrin complexes by capillary electrophoresia, Journal of Pharmaceutical and Biomedical Analysis 35 (2004)267-275.*

PDL Biopharma, Inc.; "Cardone IV (nicardipine hydrochloride)," Product Insert, Jan. 2006, USA.

Sweetana and Akers, "Solubility principles and practices for parenteral drug dosage form development," PDA J Pharmacoutical Science & Technology, 50(5):330-342 (1996).

Zhang et al., "The use of nicardipine for electroconvulsive therapy: a dose-ranging study," Anesth Analg, vol. 100:378-381 (Feb. 2005). Endoh et al., "Effects of nicardipine-, nitroglycerin-, and prostaglandin El-induced hypotension on human cerebrovascular carbon dioxide reactivity during proposol-fentanyl anesthesis," J Clin Anesth, vol. 11(7):545-549 (Nov. 1999).

Bernard et al., "Long-term hypotenzive technique with nicardipine and nitroprusticle during isoftware mesthesis for spinal surgery, Anesth Analy., vol. 75(2)179-185 (Aug. 1992).

Chen et al., "The comparative potentcy of intravenous nicardipine and verspermi on the cardiovascular response to trachesl intubation," Acts Amerikesiol Sin., vol. 34(4)197-202 (Dec. 1996). Song et al., "Optimal dose of nicardipine for maintenance of

hemodynamic stability after trached intubation and akin incision," Anesth Analg, vol. 85:1247-1251 (Dec. 1997).

Choung et al., 'Acute pharmacokinetic and homodynamic effects of intravenous bolus dosing of nicardipine," Am Heart J., vol. 119(2 Pt 2):438-442 (Feb. 1990).

Yalkowaky at al., "Fernantation-related problems associated with intravenous drug delivery," J Pharm Sciences, vol. 87(7):787-795 (Jul. 1998).

Maurin et al., "Solubilization of nicardipine hydrochloride via complexation and salt formation," J Phann Sciences, vol. 83(10):1418-1420 (Oct. 1994).

Yang et al., "Nicardipine versus nitroprosside infusion as antihypertensive therapy in hypertensive conergencies," J. Int Med Research, vol. 32(2):118-123 (Man.-Apr. 2004).

Atles et al., "The use of emple), alcardipine, or their combination to blust humodynamic changes after laryzgoscopy and tracheal intuba-tion," Anesth Analg, vol. 90:280-285 (Feb. 2000).

Aya et al., "Intravenous nicardiplas for severe hypertension in preeclampais—effects of an acute treatment on mother and foctor." Intensive Care Med., vol. 25(11):1277-1281 (Nov. 1999).

Choung et at, "Nicardipine intravenous bolus dosing for acutaly decreasing arterial blood pressure during general azesthesia for cardisc operations: pharmacokinetics, pharmacodynamics, and associ-ated effects on left ventricular function," Anesth Analg, vol. 89:1116-1123 (Nov. 1999).

Colson et al., "Haemodynamic heterogeneity and treatment with the calcium channel blocker nicardipine fluring phaeochromocytoma surgery," Act Anaesthexiol Scand., vol. 42(9):1114-1119 (Oct. 1998).

(Continued)

Primary Examiner-Robert A Wax Assistant Examiner-Lyndsey Beckhardt (74) Attorney, Agent, or Firm-Lowenstein Sandier PC

ABSTRACT

Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovescular conditions.

11 Claims, 5 Drawing Sheets

Page 2

OTHER PUBLICATIONS

Elatrous et al., "Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol," Intensive Care Med., vol. 28(9):1281-1286 (Jul. 26, 2002).

Fernandes et al., "Physiochemical characterization and in vitto dissolution behavior of nicardipine-cyclodestrins inclusion compounds," Eur. J. of Pharms. Sci. 15: pp. 79-88, 2002.

Flynn et al., "Intravenous nicardipine for treatment of severe hypertension in children," J Pediatr., vol. 139(1):38-43 (Jul. 2001).

Kwak et al., "Comparison of the effects of nicardipine and sodium nitroprunide for control of increased blood pressure after coronary artery bypass graft surgery," J Int Med Res, vol. 32:342-350 (Jul.-Aug. 2004).

Viscent et al., "Intravenous nicardipine in the treatment of postopessative atterial hypertension," J Cardiothorae Vasc Acesth, vol. 11(2):160-164 (Apr. 1997). Non Final Office Action for U.S. Appl. No. 11/737,067, dated Oct.

29, 2008.

* cited by examiner


U.S. Patent

Feb. 9, 2010


Sheet 1 of 5


US 7,659,290 B2


FIG. 1




U.S. Patent Feb. 9, 2010 Sheet 2 of 5 US 7,659,290 B2











U.S. Patent Feb. 9, 2010 Sheet 4 of 5 US 7,659,290 B2







U.S. Patent

Feb. 9, 2010

Sheet 5 of 5

US 7,659,290 B2





1

METHODS OF PREPARING PRE-MIXED, READY-TO-USE PHARMACEUTICAL COMPOSITIONS

1. CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 11/788,076, filed Apr. 18, 2007, and claims benefit under 35 U.S.C. §119(e) to U.S. Provisional application Ser. 10 No. 60/793,074, filed Apr. 18, 2006, the contents of both of which are incorporated herein by reference.

2. BACKGROUND

Nicardipine hydrochloride ((±)-2-(henzyl-methyl amino) ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3, 5-pyridinedicarboxylate mono hydrochloride) is a calcium ion influx inhibitor useful for the treatment of cardiovascular and cerebrovascular disorders (see, e.g., U.S. Pat. No. 3,985, 20 758). Nicardipine hydrochloride is currently sold in capsule form and in an injectable intravenous form. The capsple form is marketed as CARDENE® and is available as an immediate release oral capsule and as an extended release oral capsule. The injectable intravenous form of CARDENE® is marketed 25 in glass ampula suitable for intravenous administration following dilution in a compatible intravenous fluid, such as dextrose or sodium chloride (CARDENE® IV.). Each milliliter of a CARDENE & L.V. ampul contains 2.5 mg nicardipine hydrochloride in water, 48.0 mg sorbitol, buffered to pH 3.5 with 0.525 mg citric acid monohydrate and 0.09 mg sodium hydroxide. For infusion, each milliliter of the diluted formulation contains 0.1 mg of nicardipine hydrochloride, with a variable pH due to the diluent selected by the end user. U.S. Reissue Pat. No. RE. 34,618 (a reissue of U.S. Pat. No. 35 4,880,823) describes an injectable composition of nicardipine hydrochloride that is stored in a light resistant brown ampul. U.S. Pat. No. 5,164,405 describes a buffered pharmacentical composition containing nicardipine designed for parenteral administration, that is also stored in an ampul.

The requirement for diluting CARDENE® LV, before use is associated with a number of disadvantages. One disadvantage is that the diluted solution is only stable for 24 hours at room temperature. Another disadvantage is that the pH of the diluted formulation varies depending on the choice of diluent. 45 Since CARDENE® LV, can be used under emergency conditions to control blood pressure, dilution of the concentrated ampul formulation consumes valuable time that could be used to treat a patient. Other disadvantages associated with the dilution step include the potential for contamination, dosage cores, and safety hazards associated with the use of glass ampuls.

The pharmacentical compositions and methods described herein evercome these disadvantages. In particular, the ready-to-use, injectable formulations described herein are stable, 55 allow medical personal to use prepared containers containing an injectable formulation off the shelf without additional preparation, avoid potential contamination problems, and eliminate dosage errors.

3. SUMMARY

Described herein are ready-to-use, premixed pharmaceutical compositions of nicardipine or pharmaceutically acceptable salts thereof, which are suitable for continuous infravesous infusion. By providing ready-to-use, premixed pharmaceutical compositions with a buffered pH, these pharmaceutical compositions with a buffered pH.

maceutical compositions are stable at room temperature for at least one year. When stored at room temperature, the pharmaceutical compositions exhibit between 0% to about 15% loss of drug and between 0% to about 3% (w/w) total impurity formation over an eighteen to twenty four month period.

2

Additional benefits of the pre-mixed, ready-to-use, injectable pharmaceutical compositions include convenience and case of use as compared to an ampul formulation, improved safety for patients due to elimination of desage errors and solution contamination, reduction of medical waste, and ease of administration in emergency situations

The present disclosure relates to premixed pharmaceutical compositions comprising nicardipine or pharmaceutically acceptable salts thereof, one or more tunicity agents, and a buffer. In some embodiments, the compositions optionally comprise one or more cosolvents. Nicardipine hydrochloride can be present at concentrations between about 0.05 mg/ml to about 15 mg/ml. Typically, the concentration range for nicardipine hydrochloride is between about 0.1 mg/ml to about 0.2 mg/ml. Optionally, the pharmaceutical compositions can comprise acids and bases.

The pharmaceutical compositions described herein require no dilution prior to administration and typically have a pH within the range from about 3.6 to about 4.7. The compositions can be administered by parenteral routes, including, subcutaneous, intramuscular, intravental, or intra-arterial continuous infusion to a patient. The compositions are suitable for the short-term treatment of hypertension when oral therapy is not feasible or desirable.

Methods for making a premixed nicardipine hydrochloride formulation suitable for intravenous administration comprise the steps of providing an effective amount of nicardipine hydrochloride in a solution comprising one or more tonicity agents, a buffer, and optionally, one or more cosolvents. Sufficient water is added to make up the final volume. If required, the pH of the solution can be adjusted using a suitable pH adjuster. The compositions are dispensed in pharmaceutically acceptable containers for storage and direct administration to patients.

4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 provides a diagrammatic illustration of the effect of various diluents on the pH and stability of an ampul formulation post dilution over a twenty four hour period at room temperature.

FIGS. 2A and 2B provide a diagrammatic illustration of the effect of pH on drug loss (FIG. 2A) and total impurity formation (FIG. 2B) in a premixed non-sorbitol formulation comprising 0.1 mg/ml micardipine hydrochloride, 0.1 mM citric acid and 5% dextrose at 40° C.;

FIGS. 3A and 3B provide a diagrammatic illustration of the effect of pH on drug loss (PIG. 3A) and total impurity formation (PIG. 3B) in a premixed non-sorbital formulation comprising 0.1 mg/ml nicardipins hydrochloride, 0.1 mM citric acid and 0.9% saline at 40° C.;

FIGS. 4A and 4B provide a diagrammatic illustration of the effect of nicardipine concentration on impurity formation in non-sorbitol dextrose formulations comprising 0.1 mg/ml nicardipine hydrochloride, 0.1 mM citrate, 5% dextrose, or 0.2 mg/ml nicardipine hydrochloride, 0.2 mM citrate and 5% dextrose after six months at 40° C. (FIG. 4A); and, in non-sorbitol saline formulations comprising 0.1 mg/ml nicardipine hydrochloride, 0.1 mM citrate, 0.9% saline, or 0.2 mg/ml nicardipine hydrochloride, 0.2 mM citrate and 0.9% saline after 3 months at 40° C. (FIG. 4B); and

3

FIGS. 5A and 5B provide a diagrammatic illustration of the effect of incompatible (FIG. 5A) and compatible (FIG. 5B) plastic film composition on product stability at 40° C. in a premixed non-scrittol formulation comprising 0.2 mg/ml nicardipine HCL, 0.2 mM citric scid, 5% dextrose, at a pH of 5 4.0 to 4.2.

5. DETAILED DESCRIPTION

The premixed pharmaceutical compositions described herein comprise nicerdipine or a pharmaceutically acceptable salt thereof as the active ingredient, at least one tonicity agent and a buffer. As used herein, the term "pre-mixed" refers to a pharmaceutical composition that does not require reconstitution or dilution before administration to a patient. In contrast to ampul formulations comprising nicardipine hydrochloride that must be diluted prior to use in a diluent and container selected by hospital personnel, the premixed pharmaceutical compositions provided herein are stable at room temperature for 6 months or longer due to the inclusion of a buffer capable 20 of maintaining the pH within an optimal pH range, which is typically between 3.6 to about 4.7. In some embodiments, suitable pH adjusters and/or cosolvents are added to the pharmaceutical compositions.

5.2 Premixed Pharmaceutical Compositions

The production of stable, ready-to-use, premixed pharmaceutical compositions comprising nicardipine and/or its pharmaceutically acceptable salts as the active ingredient presents different development hurdles than does the development of the concentrated ampul product sold commercially as 30 CARDENEO LV. As shown in Fig. 1, the percent of nicardipine remaining in solution decreases as function of pH over a twenty-four hour period. The percent decrease in nicardipine varies with the diment and container chosen by the hospital staff.

As described in the Examples, pH (see, also, e.g., FIGS. 2A, 2B, 3A and 3B), the concentration of the active ingredient (see, also, e.g., FIGS. 4A and 4B), and the composition of the container material (see, also, e.g., FIGS, 5A and 5B) affect the stability of the active ingredient and the formation of impu- 40 rities. Thus, the development of a stable, ready-to-use premixed pharmaceutical composition requires simultaneous optimization of pH and nicardipine hydrochloride concentration, as well as selection of a pharmaceutically compatible container. The ready-to-use pharmaceutical compositions 45 described herein exhibit 0% to 15% drop in drug concentration and 0% to 3% formation of impurities when maintained at room temperature for 6 to at least 24 months. Typically, the pharmaceutical compositions are stable when maintained at room temperature for at least 6 months, at least 12 months, at 50 least 18 months, and at least 24 months. The compositions are also stable over extended periods of time when maintained at temperatures from about 2º to 8° C. The term "stable", as used herein, means remaining in a state or condition that is suitable for administration to a patient.

Compounds for use according to the compositions and methods described herein that can contain one or more asymmetric centers can occur as racemates, racemic mixtures, and as single enantiomers. Accordingly, the compositions and methods described herein are meant to comprehend all isomeric forms of such compounds.

The premixed pharmaceutical compositions described herein comprise nicardipine and/or its pharmaceutically acceptable salts. Nicardipine, its pharmaceutically acceptable salts, preparation, and use are known in the art (see, e.g., U.S. Pat. No. 3,985,758, incorporated herein by reference in its entirety). Examples of pharmaceutically acceptable salts

of nicardipine include hydrochlorides, sulfates, phosphates, acetates, fumarates, maleates and tartrates.

Typically, the premined pharmaceutical compositions comprise 0.05-15 mg/ml nicardipine or a pharmaceutically acceptable sait thereof. For example, suitable concentrations of nicardipine or a pharmaceutically acceptable sait thereof, include, but are not limited to: 0.05-0.1 mg/ml, 0.1-15 mg/ml, 0.1-10 mg/ml, 0.1-5 mg/ml, 0.1-3.0 mg/ml, 0.1-2.0 mg/ml, 0.1-1.0 mg/ml, 0.9 mg/ml, 0.8 mg/ml, 0.7 mg/ml, 0.6 mg/ml, 0.5 mg/ml, 0.4 mg/ml, 0.5 mg/ml, 0.4 mg/ml, 0.5 mg/ml, 0.4 mg/ml, 0.5 mg/ml, 0.4 mg/ml, 0.5 mg/ml, 0.8 mg/ml, 0.9 mg

In some embodiments, the premixed pharmaceutical compositions comprise nicardipine hydrochloride as the active ingredient at a concentration sufficient to permit intravenous administration at a concentration between 0.1 mg/ml to 0.2 mg/ml. In some embodiments, the concentration of nicardipine hydrochloride suitable for use in the compositions and methods described herein includes, but is not limited to, at least about 0.1 mg/ml. In other embodiments, the concentration of nicardipine hydrochloride suitable for use in the compositions and methods described herein includes, but is not limited to, at least about 0.2 mg/ml.

In some embodiments, the premixed formulation comprises, in addition to meardipine and/or its pharmaceutically acceptable salts, a buffer that has sufficient buffering capacity 25 to maintain the desired pH range throughout the shelf-life of the product. As shown in FIGS, 2A and 2B, pH is important for the long term stability of nicardipine in the premixed pharmaceutical compositions. Although the pH of the premixed phermacentical compositions can range from between about 3.0 to about 7.0, pharmaceutical compositions having a pH within the range of about 3.6 to about 4.7 exhibit a lower percentage of drug degradation and total impurities (See ITGS. 2A, 2B, 3A and 3B). Accordingly, suitable pH ranges for use in the premixed pharmaceutical compositions include, but are not limited to, pH range of at least about 3.0, at least about 3.1, at least about 3.2, at least about 3.3, at least about 3-4, at least about 3.5, at least about 3.6, at least about 3.7, at least about 3.8, at least about 3.9, at least about 4.0, at least about 4.1, at least about 4.2, at least about 4.3, at least about 4.4, at least about 4.5, at least about 4.6, at least about 4.7, at least about 4.8, at least about 4.9, at least about 5.0, at least about 5.2, at least about 5.5, at least about 6.0, at least about 6.5, at least about 7.0.

In some embodiments, the pH of the premixed pharmaceutical compositions is between about 3.0 to about 5.0. In other embodiments, the pH of the premixed pharmaceutical compositions is between about 3.6 to about 4.7. In other embodiments, the pH of the premixed pharmaceutical compositions is between about 4.0 to about 4.4. In yet other embodiments, the pH of the premixed pharmaceutical compositions is 4.2.

Buffers suitable for use in the pharmaceutical compositions described herein include, but are not limited to, phermaceutically acceptable salts and acids of acetate, glutamate, citrate, tartrate, benzoate, lactate, histidine or other amino 55 acide, gluconate, phosphate, malate, succinate, formate, propionate, and carbonate. "Pharmaceutically acceptable" is used herein in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Accordingly, the term "phannaceutically acceptable salt" references salt forms of the active compounds which are prepared with counter ions which are nontoxic under the conditions of use and are compatible with a stable formulation. The concentration of the buffer in the formulation can be expressed in mg/ml, g/L or as a molar concentration. In typical embodiments, from about 0.0001 mg/ml to about 100 mg/ml of a suitable buffer is present in the pharmaceutical compositions. Thus, the premixed pharma-

5

centical compositions can comprise from about 0.0001 to about 0.001 mg/ml of a suitable buffer, from about 0.001 to about 0.01 mg/ml of a suitable buffer, from about 0.01 to about 0.1 mg/ml of a suitable buffer, from about 0.1 to 1 mg/ml of a suitable buffer, from about 1 to about 5 mg/ml of 5 a suitable buffer, from about 5 to about 10 mg/ml of a suitable buffer, from about 10 to about 15 mg/ml of a suitable buffer, from about 20 mg/ml of a suitable buffer, from about 25 mg/ml of a suitable buffer, from about 25 mg/ml of a suitable buffer, from about 25 mg/ml of a suitable buffer, from about 50 mg/ml of a suitable buffer, from about 50 mg/ml of a suitable buffer, and from about 75 to about 10 mg/ml of a suitable buffer, sud from about 75 to about 100 mg/ml of a suitable buffer.

Alternatively, the buffer concentration can be expressed as molar concentrations. In typical embodiments, from about 0.1 to 100 mM of a suitable buffer is present in the pharma-15 cautical compositions. Thus, the premixed pharmaceutical compositions can comprise a suitable buffer having a concentration from about 0.1 to about 100 mM, from about 0.1 to about 0.5 mM, from about 0.5 to about 1.0 mM, from about 1.0 to about 5 mM, from about 5 to about 10 mM, from about 20 10 to about 15 mM, from about 15 to about 25 mM, from about 25 to about 10 mM, from about 50 to about 75 mM, and from about 75 to about 100 mM.

In some embodiments, the premixed pharmaceutical compositions further comprise a pH adjuster. Suitable pH adjust- 25 ers typically include at least an acid or a salt thereof, and/or a base or a salt thereof. Acids and bases can be added on an as needed basis in order to achieve a desired pH. For example, if the pH is greater than the desired pH, an acid can be used to lower the pH to the desired pH. Acids suitable for use in 30 premixed pharmaceutical compositions include, but are not limited to, hydrochloric acid, phosphoric acid, citric acid, ascorbic acid, acetic acid, atlphuric acid, carbonic acid and nitric acid. In some embodiments, hydrochloric acid is used to adjust the pH. By way of another example, if the pH is less 35 than the desired pH, a base can be used to adjust the pH to the desired pH. Buses suitable for use in premixed pharmaceutical compositions include, but are not limited to, sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, sodium citrate, sodium acetate, and magnesium 40 hydroxide. In some embodiments, sodium hydroxide is used to adjust the pH.

In some embodiments, the premixed pharmaceutical compositions further comprise one or more tonicity agents. Typically, tonicity agents are used to adjust the osmolality of the 4s premixed pharmaceutical compositions to bring it closer to the esmotic pressure of body fluids, such as blood or plasma. In some embodiments the tonicity of the premixed formulation can be modified by adjusting the concentration of buffer and/or other components present in the premixed formula-

Provided that the compositions are physiologically compatible, the compositions do not require any particular oamolality. Thus, the compositions can be hypotonic, isotonic or hypertonic. Typically the premixed pharmaceutical compositions have a tonicity between about 250 to about 350 mOsm/kg.

Suitable tonicity agents for use in the premixed pharmaceutical compositions include, but are not limited to, suhydrous or hydrous forms of sodium chloride, dextrose, sucrose, sylitol, fractose, glycorol, sorbitol, mannitol, potassium chloride, mannese, calcium chloride, magnesium chloride and other inorganic salts. The quantity of the tonicity agent in the formulation can be expressed in mg/ml or in g/L. In typical embodiments, the tunicity agent(s) is present from about 1 comg/ml to about 90 mg/ml. Thus, the premixed pharmaceutical compositions can comprise one or more tonicity agents at

about 1-5 mg/ml, at about 5-10 mg/ml, at about 10-15 mg/ml, at about 15-25 mg/ml, at about 25-50 mg/ml, at about 50-60 mg/ml, at about 60-70 mg/ml, at about 70-80 mg/ml, and at about 80 to 90 mg/ml, at well as combinations of the above ranges.

Alternatively, the tonicity agent concentration is measured in weight/volume percent. In typical embodiments, the tonicity agent(s) is present from about 0.1% to about 10%. For example, suitable tonicity agent concentrations include, but are not limited to, from about 0.1% to about 0.2%, from about 0.2% to about 0.3%, from about 0.3% to about 0.4%, from about 0.4% to about 0.5%, from about 0.6%, from about 0.6% to about 0.6% from about 0.6% to about 0.9% to about 0.9% to about 1%, from about 0.9% to about 1%, from about 1% to about 2%, from about 2% to about 3%, from about 3% to about 4%, from about 4% to about 5%, from about 5%, from about 4% to about 5%, from about 5% to about 5%, from about 6% to about 7%, from about 5% to about 5%, from about 6% to about 9%, and from about 9% to about 10%, as well as combinations of the above ranges.

In some embodiments, the tonicity agent is dextrose. Typically, the concentration of dextrose suitable for use in the premixed pharmaceutical compositions is between about 2.5% (w/v) to about 7.5%. By way of example, suitable dextrose concentrations include, but are not limited to, from about 2.5% to about 3%, from about 3.5% to about 3.5%, from about 3.5% to about 4% (which is equivalent to about 4.5% to about 5.5% from about 5.5% from about 5.5% to about 5.5%, from about 5.5% to about 5.5%, from about 6.5%, from about 6.5%, from about 6.5%, from about 6.5% to about 6.

In some embodiments, the tonicity agent is sodium chloride. Typically, the concentration of sodium chloride suitable for use in the premixed pharmaceutical compositions is between about 0.1% (w/v) to about 1.8%. By way of example, suitable sodium chloride concentrations include, but are not limited to, from about 0.1% to about 0.2%, from about 0.2% to about 0.3%, from about 0.3% to about 0.4%, from about 0.4% to about 0.5%, from about 0.5% to about 0.6%, from about 0.6% to about 0.7%, from about 0.7% to about 0.8% (which is equivalent to 5 mg/ml), from out 0.8% to about 0.9% (which is equivalent to 9 mg/ml), from about 0.9% to about 1.0%, from about 1.9% to about 1.2%, from about 1.4% to about 1.6%, and from about 1.4% to about 1.8%.

In some embodiments, the premixed pharmaceutical compositions comprise two, three, four, or more tunicity agents.
In these embodiments, the concentration of each tonicity
agent is typically less than the concentration that is used when
only a single agent is present in the premixed formulation. For
example, if the premixed formulation comprises sorbitol at
1.92 mg/ml, a suitable concentration of sodium chloride is 8.6
mg/ml. By way of another example, if the premixed formulation comprises 1.92 mg/ml sorbitol, a suitable concentration of dextrose is 48 mg/ml.

In some embodiments, the premixed pharmaceutical compositions further comprise one or more cosolvents. A "cosolvent" is a solvent which is added to the aqueous formulation in a weight amount which is less than that of water and assists in the solubilization of nicardipine and/or a pharmaceutically acceptable salt thereof, enhances stability of the premixed pharmaceutical compositions. Cosolvents suitable for use in the premixed pharmaceutical compositions include, but are

7

not limited to, glycols (e.g., polyethylene glycol, propylene glycol), ethanol, and polyhydric alcohols (e.g., sorbitol, mannitol, xylitol).

The quantity of the cosolvent used in the formulation can be expressed in mg/ml or in g/L. In typical embodiments, the cosolvent(s) is present from about 1 mg/ml to about 100 mg/ml. Thus, the premised pharmaceutical compositions can comprise one or more cosolvent(s) at about 1 to about 2 mg/ml, at about 2 to about 3 mg/ml, at about 3 to about 4 mg/ml, at about 4 to about 5 mg/ml, at about 5 to about 10 mg/ml, at about 10 to about 15 mg/ml, at about 15 to about 25 mg/ml, at about 25 to about 50 mg/ml, at about 50 to about 60 mg/ml, at about 60 to about 70 mg/ml, at about 70 to about 80 mg/ml, at about 80 to 90 mg/ml, and at about 90 to 100 mg/ml, as well as combination of the above ranges.

Alternatively, the ensolvent concentration is measured in weight/volume percent. In typical embodiments, the cosolvent(s) is present from about 0.1% to about 25%. For example, suitable cosolvent concentrations include, but are not limited to, at least about 0.1% to 0.3%, from about 0.3% at to about 0.5%, from about 0.5% to about 0.7%, from about 0.7% to about 0.9%, from about 0.9% to about 1%, from about 1% to about 3%, from about 3% to about 5% from about 5% to about 11%, from about 7% to about 19%, from about 11% to about 13% from about 11% to about 12%, from about 11% to about 13% from about 11% to about 15%, and from about 20% to about 25%, as well as combination of the above ranges.

In some embodiments, the premixed pharmaceutical compositions further comprise one or more cyclodextrins. Due to 30 their structure, cyclodextrins have the ability to form complexes, or inclusion complexes, with a variety of organic and inorganic molecules. Complexes of nicardipine with cyclodextrins have been described (see, e.g., U.S. Pat. No. 5,079, 237 which describes an inclusion complex of nicardipine or 35 its hydrochloride with siphs-cyclodextrin, beta-cyclodextrin or gamma-cyclodextrau; U.S. Pat. No. 5,519,012 which describes inclusion complexes of dihydropyridines, including nicardipine, with hydroxy-alkylated-β-cyclodextrins; and, U.S. Pat. No. 5,904,929 which describes numerous drugs 40 in a pharmaceutical composition with per-C2-18 acylated cyclodextrins). None of the above references discloses a dihydropyridine in combination with a cyclodextrin comprising a sulfate group. An example of a commercially available sulfated cyclodextrin is CAPTISOL®. CAPTISOL® is a polya- 45 nionic β-cyclodextrin derivative with a sodium sulfonate salt that is separated from the lipophilic cavity by a butyl ether spacer group, or sulfobutylether. Methods for making the sulfoalkyl ether cyclodextrin derivatives are well known in the art and are taught in U.S. Pat. No. 5,376,645. Methods for 50 forming complexes of the derivatives with a drug are also well known in the art as disclosed in U.S. Pat. No. 5,376,645.

The cyclodextrin concentration can be measured in weight/volume percent. In typical embodiments, cyclodextrin(s) is present from about 0.1% to about 25%. For example, suitable 35 cyclodextrin(s) concentrations include, but are not limited to, at least about 0.1% to 0.3%, from about 0.3% to about 0.5%, from about 0.5% to about 0.7%, from about 0.7% to about 0.9%, from about 1% to about 3%, from about 3% to about 5%, from about 5% to about 7%, so from about 7% to about 7%, from about 1% to about 11%, from about 11% to about 13% from about 12% to about 15%, from about 15% to about 15%, from about 20% to 20%

Examples of stable, premixed pharmaceutical compositions comprising the active ingredient, a tonicity agent, a buffer and optionally, a cosolvent are shown in Table 1. E TABLE 1

5	Active Ingredient	Tanicity Agent(s) (mg/ml)	Buffer (mg/ml)	Cosolvent (mg/ml)	рН
	nicardipine hydrochloride (0.1 mg/ml)	NaCi (6.6 mg/mi)	Citric soid, anhydrom (0.0192 mg/ml)	Sorbital (1.92 mg/ml)	3.6-4,7
10	nicardipine hydrochloride (0.1 mg/ml)	Destrose, hydrour (48 mg/ml)	Citric acid, anhydrous (0.0192 mg/ml)	Sorbitol (1.92 mg/ml)	3.6-4.7
	nicardipina hydrochlorido (0,1 ma/m1)	(a wakani) Kaci	Citric soid, anitydrosu (0.0192 mg/ml)	None	3.6-4.7
15	nicardipins hydrochlaride (0.1 mg/ml)	Dextrose, hydrots (50 mg/ml)	Citrie sold, anhydrous (0.0192 mg/ml)	None	3.6-4.7
	nicardipine hydrochloride (0.2 mg/ml)	NaCl (2 mg/ml)	Citric acid, embydrous (0.03 84 mg/m)	None	3,6-4.7
20	nicardiples hydrochloride (0.2 mg/ml)	Dexirone, hydroun (50 mg/ml)	Citric acid, anhydrous (0.0384 mg/ml)	None	3,6-4,7
	nicardipine kydrochloride (0.2 mp/ml)	NaCl (8.3 mg/m/)	Citrio soid, sabydrous (0.0384 mg/ml)	Sorbitol (3.84 mg/m))	3.6-4,7
5	nicardinine hydrochloride (0.2 mg/ml)	Dextraes, hydrour (46 mg/ml)	Citric sold, anhydrous (0.0384 mg/mi)	Sorbitol (3.84 mg/ml)	3.5-4.7
			-		

In some embodiments, the pharmaceutical compositions are any as described in U.S. Provisional Application Ser. No. 60/793,084, filed Apr. 18, 2006, which is incorporated herein by reference.

5.3 Methods

The order in which various components comprising the compositions is added to the buffered solution is not critical. provided that the resulting compositions are stable and are suitable for continuous intravenous infusion. Accordingly, the compositions described herein can be made by prepared in a number of different ways. For example, in some embodiments, the compositions can be prepared by adding buffer, a tonicity agent and/or a cosolvent to water, adding nicardipine to the buffered water solution; adding an pH adjuster to achieve the desired pH; and then adding sufficient water to make up the final volume. If necessary, the pH can be readjusted to achieve the desired pH range. By way of another example, the compositions can be prepared by adding buffer and nicardipine or a pharmaceutically acceptable salt thereof to water, adding a tonicity agent and/or cosolvent, adjusting the pH to achieve the desired pH range, and then adding sufficient water to make up the final volume. By way of another example, a cosolvent can be added prior to the addition of nicardipine or a pharmaceutically acceptable salt thereof, and a tonicity agent can be added after the addition of nicardipine or a pharmacentically acceptable salt thereof. By way of another example, a tonicity agent can be added prior to the addition of nicardipine or a pharmaceutically acceptable salt thereof, and a cosolvent can be added after the addition of nicardipine or a pharmacentically acceptable salt thereof. By way of another example, the compositions can be prepared by adding buffer, tonicity agent and/or cosolvent to water; adjusting the pH to a first pH range suitable for dissolving nicardipine (for example, less than pH 3.6); adding nicardipine or a pharmaceutically acceptable salt thereof; adjusting the pH to achieve the desired final pH range; and then adding sufficient water to make up the final volume.

In some embodiments, pharmaceutical compositions comprising nicardipine hydrochloride, dextrose, and citric buffer at pH 3.6-4.7 can be prepared by adding citric acid to water, 9

adding dectrose to the buffered water, adding nicardipine hydrochloride to the buffered water solution, adjusting the pH if necessary to the range 3.6-4.7, and adding sufficient water to make up the final volume. If necessary, the pH can be readjusted to between about 3.6 to about 4.7.

In some embodiments, pharmaceutical compositions comprising nicardipine hydrochloride, sodium chloride, and citrate buffer at pH 3.6 to about 4.7 can be prepared by adding citric acid to water, adding nicardipine to the buffered water solution, adding sodium chloride to the buffered water solution, adjusting the pH to between about 3.6 to about 4.7, and adding sufficient water to make up the final volume. If scribital is included in the formulation, sorbital is added at the same time as the citric acid.

In some embodiments, the pharmaceutical compositions 15 can be prepared by adding nicardipine or a pharmaceutically acceptable salt thereof to an acidic solution having a pH less than 5.0. For example, the acidic solution can be prepared by adding an acidic component of a buffer system. A buffer, one or more tonicity agents, and/or coolvents can be added to the acidic solution before or after dissolving the micardipine. Sufficient water is then added to make up the final volume. If necessary, the pH of the composition can be adjusted to between about 3.6 to about 4.7.

In some embodiments, the pharmscentical compositions 25 can be made by adding nicardipine or a pharmscentically acceptable salt thereof to a solution that has been heated to a temperature greater than 35° C.; adding buffer, one or more tonicity agents and/or cosolvents to the acidic solutions; and adding sufficient water to make up the final volume. If necessary, the pH of the composition can be adjusted to between about 3.6 to about 4.7.

The pharmaceutical compositions can be packaged for use in a variety of containers. The compositions are prefarably packaged in a pharmaceutically acceptable container, such as an intravenous bag or bottles. Due to the light sensitivity of nicardipine, packages can be used that reduce the amount of light which can reach the composition. For example, in some embodiments, the container may, optionally, further comprise a light barrier, such as an aluminum overpouch or a 40 carton.

In some embodiments, the premixed pharmaceutical compositions are dispensed in intravenous bags, such as pre-mix bags and admix bags. Intravenous bags are well known in the art and commercially available. Examples of intravenous 45 bags include, but are not limited to: GALAXY®, INTRA-VIA®, SOLOMIX®, STEDIM® 71, STEDIM® 100, VIAFLEX®, HXCEL®, VISIV®, VIAFLO™, ADDRASE®, ADD-VANTAGE®, DUPLEX™, FIRST CHOICE™, PROPYFLEX™ and BFS™.

In some embodiments, the components of the bag that come into contact with the pharmaceutical compositions should not contain polar polymers, such as polyvinyl chloride (PVC) and ethylens vinyl acetate (EVA). Examples of bags that do not contain polar polymers and thus, are suitable for 55 use in these embodiments, include, but are not limited to, GALAXY®, EXCEL®, VISIV®, and VIAFLOPS.

Procedures for filling pharmaceutical compositions in pharmaceutically acceptable containers, and their subsequent processing are known in the art. These procedures can be used so to produce sterile pharmaceutical drug products often required for health care. See, e.g., Center for Drug Evaluation and Research (CDRR) and Center for Veterinary Medicine (CVM), "Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications as for Human and Veterinary Drug Products", (November 1994). Examples of suitable procedures for producing sterile

pharmaceutical drug products include, but are not limited to, terminal moist heat sterilization, ethylene cotide, radiation (i.e., gamma and electron beam), and aseptic processing techniques. Any one of these sterilization procedures can be used to produce the sterile pharmaceutical compositions described

herein.

In some embodiments, starile pharmaceutical compositions can be prepared using aseptic processing techniques. Sterility is maintained by using sterile materials and a controlled working environment. All containers and apparatus are sterilized, preferably by heat sterilization, prior to filling. Then, the container is filled under susptic conditions, such as by passing the composition through a filter and filling the units. Therefore, the compositions can be sterile filled into a container to avoid the heat stress of terminal sterilization.

In some embodiments, the compositions are terminally sterilized using moist heat. Terminal sterilization can be used to destroy all viable microorganisms within the final, seeled container containing the pharmaceutical composition. An autoclave is typically used to accomplish terminal heat-sterilization of drug products in their final packaging. Typical autoclave cycles in the pharmaceutical industry to achieve terminal sterilization of the final product are 121° C, for at least 10 minutes.

The pharmaceutical compositions described herein can be used for prevention or treatment of acute elevations of blood pressure in a human patient in need thereof. In some embodiments, the patients being treated may be volume-restricted due to a co-existing medical condition and thus can benefit from the administration of higher concentration and lower fluid volume of nicerdipine. Examples of medical conditions in which it would be advantageous to administer low volume formulations include, renal failure, ascites, cerebral edema, congestive heart failure, liver failure, or a CNS injury. Dosages can be individualized depending upon the severity of hypertension and the response of the individual patient during dosing. Typically, the dosage is administered as a continuous infusion of a pre-mixed product. In some embodiments, the patient has an elevated blood pressure with a systolic equal to or greater than 150 mm Hg. In other embodiments, the subject has an elevated blood pressure with a diastolic value greater than or equal to 90 mm Hg.

In some embodiments, the pharmaceutical compositions can be used to prevent acute elevations of blood pressure associated with various medical procedures. Examples of medical procedures associated with acute elevations of blood pressure include, but are not limited to, electroconvulsive therapy (see, e.g., Avramov, et al., 1998, J. Chinical Anesthesia, 10:394-400), carotid endarterectomy (see, e.g., Donnan, et al., 2001, J. Clinical Anesthesia, 13:16-19, tracheal intubation (Song, et al., 2001, Anesth Analg., 85:1247-51) and akin incision (Song, et al., 2001, Anesth Analg., 85:1247-51).

In some embodiments, the pharmaceutical compositions can be used to treat acute alevations in blood pressure due to certain cardiovascular and cerebrovascular conditions. Inamples of cardiovascular conditions that are associated with acute elevations of blood pressure include, but are not limited to, essential hypertension, angina, acute ischemia, systemic arterial hypertension, congestive heart failure, coronary artery disease, myocardial inflarction, cardiac arrivthmias, cardiomyopathies and arterioaclerosis. Examples of cerebrovascular conditions are associated with acute elevations of blood pressure include, but are not limited to pulmonary hypertension, cerebral insufficiency and migraine headache.

In some embodiments, the pharmaceutical compositions can be used to treat other conditions that cause hypertension

11

including, but not limited to, renal disorders (e.g., renal parenchymal disorders or renal vascular disease), coarctation of the sorts, pheochromocytoma, hyperthyroidism, metabolic syndrome, solid organ transplant and drug-related hypertension.

In some embodiments, the pharmaceutical compositions can be used to induce hypotension during surgical procedures including, but not limited to cardiothoracic surgery, spinal surgeries and head and neck surgeries.

6. ALTERNATIVE ASPECTS

In an alternative aspect, the present invention relates to pre-mixed, ready-to-use, injectable pharmaceutical compositions comprising a cardiac medication or a pharmaceutically 15 acceptable salt thereof, and at least one of a co-solvent and a complexing agent, and a buffering agent. The composition may further comprise a tonicity agent. The compositions are preferably isotonic. The pH of the compositions is preferably between 3 and 7. The compositions are preferably packaged 20 in a pharmaceutically acceptable container, such as an intravenous bag, syringe or vial. Preferably, the compositions are used for the treatment of cardiovascular and cerebrovascular conditions. The present invention also relates to methods for preparing such compositions. In this other aspect, the term 25 'pre-mixed", as used herein, means a pharmacentical composition that is already mixed from the point of manufacture and does not require dilution or further processing before administration. The term "pre-mixed" may also mean a pharmaceutical composition wherein the liquid solution and the 30 active pharmaceutical ingredient are separated from the point of manufacture and in storage, such as when the solution is stored in an intravenous bag and the active pharmacoutical ingredient is lyophilized and stored in a vial that is connected to the bag, but not in fluid contact with the solution until just 35 before administration to a patient. Preferably, the pharmacoutical compositions are squeous solutions that are administered by injection. Alternatively, the pharmaceutical compositions may be lyophilized and then reconstituted in isotonic saline, for example, before intravenous administration.

In this alternative aspect, the pharmaceutical compositions of the present invention comprise a cardiac medication or a pharmaceutically acceptable salt thereof. Examples of classes of cardisc medications include beta-blockers, calcium channel antagonists, angiotensin converting enzyme inhibi- 41 tors, diurctics, vasodilators, nitrates, anti-platelet medications and anti-coagulants. Preferably, the cardiac medication is a calcium channel antagonist or a pharmaceutically acceptable salt thereof. More preferably, the cardisc medication is a dihydropyridine derivative or a pharmaceutically acceptable 50 salt thereof. Most preferably, the cardiac medication is nicardipine or a pharmaceutically acceptable salt thereof. Examples of pharmaceutically acceptable salts of nicardipine are hydrochlorides, sulfates, phosphates, acetates, fumarates, malcates and tartarates. The preferred pharmaceutically 55 acceptable salt of nicardipine is nicardipine hydrochloride. The pharmaceutical compositions may comprise 0.05-1.5 mg/ml of nicardipine or a pharmacentically acceptable salt thereof. Preferably, the pharmaceutical compositions comprise 0.15-0.35 mg/ml of nicardipine or a pharmaceutically acceptable salt thereof. More preferably, the compositions comprise 0.2-0.3 mg/ml of nicardipine or pharmaceutically acceptable salt thereof. Nicardipine and its pharmacentically acceptable salts, their preparation, and their use are known in the art. For example, they are disclosed in, among other 65 references, U.S. Pat. No. 3,985,758, which is incorporated herein by reference in its entirety.

12

In some embodiments, the pharmaceutical compositions comprise 0.1-15 mg/ml micardipins or a pharmaceutically socspitable salt thereof. For example, stituble concentrations of nicardipins or a pharmaceutically ecceptable salt thereof, include, but are not limited to: 0.1-15 mg/ml, 0.1-10 mg/ml, 0.1-5 mg/ml, 0.1-3.0 mg/ml, 0.1-2.0 mg/ml, 0.1-1.0 mg/ml, 0.9 mg/ml, 0.8 mg/ml, 0.7 mg/ml, 0.6 mg/ml, 0.5 mg/ml, 0.4 mg/ml, 0.3 mg/ml, 0.2 mg/ml or 0.1 mg/ml.

In this alternative aspect, the pharmaceutical compositions can be used to treat cardiac conditions. Preferably, the compositions can be used to treat conditions that are alleviated by the administration of calcium channel antagonists, such as cardiovascular and cerebrovascular conditions. Cardiovascular conditions that can be treated with the pharmaceutical compositions of the present invention include angina, is chemia, systemic arterial hypertension, congestive heart failure, coronary artery disease, myocardial infarction, cardiac anthythmias, cardiomyopathies and anteriosclerosis. Cerebrovascular conditions that can be treated with the pharmaceutical compositions of the present invention include pulmonary hypertension, cerebral insufficiency and migraine. Preferably, the compositions are used to treat hypertension.

In this alternative aspect, the pharmaceutical compositions of the present invention also comprise at least one of a conolvent and a complexing agent. Therefore, the compositions may comprise a cosolvent, a complexing agent, multiple cosolventa, multiple complexing agents, a cosolvent and a complexing agent, a cosolvent and multiple complexing agents, a complexing agent, a complexing agent, a complexing agent, a complexing agent and multiple cosolvents, or multiple cosolvents and multiple complexing agents.

In this alternative aspect, Nicardipine and its pharmaccutically acceptable salts are only slightly soluble in water. Cosolvents and complexing agents help solubilize nicardipine in the aqueous solution of the pharmaceutical composition. Cosolvents and complexing agents are especially beneficial when a high concentration of nicardipine is present, such as in the compositions of the present invention. An advantage of the compositions of the present invention is that they have a high concentration of nicardipine, which allows the composition to be administered using a lower volume of intravenous fluid. Such compositions can be a treatment option for a greater number of patients, especially volume restricted patients.

In this alternative aspect, patients and medical conditions that may benefit from a higher concentration and lower fluid volume of nicardipine include, but are not limited to, the following: acute congestive cardiac failure; pediatrics; hypertensive crises in alderly patients where fluid overload is a major concern; all acute stroke areas including AIS, ICH and SAH to control blood pressure; controlled hypotension during surgical procedures including cardiothoracic surgery (CABG, coarctation of the sorta, etc.), spinal surgeries, and head and neck surgeries; and neurosurgery for the control of breakthrough hypertension post carotid endarterectomy, tranmatic brain injury and potential treatment of hypertension and vasospasm.

In this alternative aspect, in addition to enhancing solubility, cosolvents and complexing agents enhance the stability of the pharmaceutical compositions. Furthermore, changes may be made to the concentration of cosolvents and complexing agents in the pharmaceutical compositions in urder to adjust the tonicity of the pharmaceutical compositions. Pharmaceutically acceptable consents are known in the art and are commercially available. Typical cosolvents include polyethylene glycol (PEG), propylene glycol (PG), ethanol and sorbitol. Preferably, the cosolvent concentration is 0.1-10% weight/volume percent, which will depend on the pH of the

13

composition. More preferably, the cosolvent concentration is 0.1-5%. Most preferably, the cosolvent concentration is 0.1-2%. Preferred cosolvents for the pharmaceutical compositions are propyleas glycol and sorbitol. Preferably, the concentration of propylene glycol is 0.1-2%. More preferably, the concentration of propylene glycol is 0.1-1%. Most preferably, the concentration of propylene glycol is 0.3%. A preferred concentration of sorbitol is 0.1-2%. An even more preferred concentration of sorbitol is 0.1-1%. A most preferred concentration of sorbitol is 0.5%.

In this alternative aspect, pharmaceutically acceptable complexing agents are known in the art and commercially available. Typical complexing agents include cycloderarins, such as natural cyclodextrins and chemically modified cyclodextrins. Preferably, the complexing agent is a beta cyclodex- 15 trin. Preferred complexing agents for the pharmaceutical compositions are 2-hydroxypropyl-β-cyclodextrin (2HP-BCD) and sulfobutylether-β-cyclodextrin (SBEBCD). Preferably, the complexing agent concentration is 0.1-25% weight/volume percent. More preferably, the complexing 20 agent concentration is 0.1-10%. Most preferably, the complexing agent concentration is 0.1-5%. Preferably, the concentration of ZHPBCD is 15-25%. More preferably, the concentration of 2HPBCD is 20-25%. The preferred concentration of SBEBCD is 0.1-10%. An even more pre- 25 ferred concentration of SBEBCD is 0.1-5%. The most preferred concentration of SBEBCD is 0.75 to 1%

In addition, the pharmaceutical compositions in this alternative aspect can comprise a buffering agent. However, the compositions may comprise multiple buffering agents. The pharmaceutical compositions of the present invention are preferably close to physiological pH in order to minimize the incidence of phlebitis upon administration. However, the pH of the pharmaceutical composition also affects the solubility and stability of nicardipine in the composition. Generally, as the pH of the pharmaceutical composition increases, it is difficult to solubility of nicardipine decreases. As a result, it is difficult to solubility nicardipine close to physiological pH. In addition, the composition should have sufficient buffering capacity such that the solution does not precipitate upon dilution with blood when administered.

In this alternative aspect, typical buffering agents include acctate, glutamate, citrate, tartrate, benzoste, lactate, histidine or other amino acids, gluconate, phosphate and succinate. The preferred buffering agents are acetate and succinate. A preferred buffering agent concentration is 1-100 mM. A more preferred buffering agent concentration is 1-50 mM. An more preferred buffering agent concentration is 25-35 mM.

In this alternative aspect, preferably, the pharmaceutical compositions of the present invention are isotonic, i.e., in the range of 270-328 mOsm/kg. However, the compositions may have a tonicity in the range of 250-350 mOsm/kg. Therefore, the compositions may be either slightly hypotonic, 250-269 mOsm/kg, or slightly hypertonic, 329-350 mOsm/kg. Preferably, the tonicity of the pharmaceutical compositions is rendered isotonic by adjusting the concentration of any one or more of cosolvent, complexing agent and buffering agent in the solution.

In this afternative aspect, the pharmaceutical compositions of the present invention may further comprise a tonicity agent. However, the compositions may further comprise multiple tonicity agents. Tonicity agents are well known in the art and commercially available. Typical tonicity agents include 65 acdium chloride and dextrose. The preferred tonicity agent is sodium chloride. A preferred tonicity agent concentration is

1-200 mM. A more preferred tonicity agent concentration is 75-125 mM. An even more preferred tonicity agent concentration is 90-110 mM.

The pharmaceutical compositions of the present invention are preferably packaged in pharmaceutically acceptable containers in this alternative aspect. Pharmaceutically acceptable containers include intravenous bags, bottles, vials, and syringes. Preferred containers include intravenous bags and syringes, which are preferably polymer-based, and vials and 10 intravecous bottles, which are preferably made of glass. It is also preferred that the components of the comminer that come into contact with the pharmaceutical composition do not contain polyvinylchloride (PVC). The most preferred container is an intravenous bag that does not have any PVC containing components in contact with the pharmscentical composition. It is also desirable to protect the pharmaceutical compositions from light. Therefore, the container may, optionally, further comprise a light barrier. A preferred light barrier is an aluminum overpouch.

This alternative aspect also provides methods as described above for preparing the pharmaceutical compositions which are sterile.

7. EXAMPLES

Examples 1 through 6 are intended to be illustrative and not limiting as to the general disclosure. Examples 7 through 12 disclose specific embodiments of the pharmaceutical compositions that are principally illustrative of the alternative aspects described herein.

Examples 1 Through 6

Example 1

Effect of Various Diluents on Stability of Concentrated CARDENEELV.

Stability results for the concentrated ampul product diluted to 0.1 mg/ml with various commonly used intravenous infusion fluids in an IV bag are shown in FIG. 1. pH after mixing was measured and is reported on the X-axis. Product stability was measured by monitoring the % drug remaining after duration of 24 hours by RP-HPLC and is shown on the Y-axis.

As shown in FIG. 1, the instability of nicardipine hydrochloride is related to the initial pH of the infusion fluid and to the final pH of the solution after mixing. The magnitude of drug loss post dilution increases as the final pH of the solution after mixing increases, for example, a very pronounced drug loss is obtained when the pH is above 4.5. Based on these findings, the product insert for the marketed ampul product requires product dilution be carried out using specific infusion fluids. Furthermore, the diluted product must be used within 24 hours.

Example 2

Effect of pH on Stability

Stability results for a 0.1 mg/ml. nicardipine HCl, 0.1 mM citric acid, and 5% dextrose formulation dispensed in a GAL-AXY® bag are shown in FIGS. 2A and 2B. Stability results for a 0.1 mg/ml. meardipine HCl, 0.1 mM citric acid, 0.9% saline formulation dispensed in a GALAXY® bag are shown in FIGS. 3A and 3B. Stability assessments are done by measuring the % drug remaining and the total impurity formation as a function of time using RP-HPLC.

15

Stability testing was done at an accelerated temperature of 40° C. Based on published literature, activation energies for drug decompositions usually fall in the range of 12 to 24 Kcal/mol, with typical value of 19-20 Kcal/mol. Under these conditions (assumption Ea=19.4 Kcal/mol) 15 weeks storage at 40° C. corresponds to a product with approximately 18 months expiration at 25° C. (see, e.g., Connors, K. A., et al., Chemical Stability of Pharmaceuticals, A Handbook for Pharmacists, John Wiley & Sons, 2d ed. 1986).

As shown in FIGS. 2A and 3A, loss in product potency (drop in % drug remaining) due to degradation and adsorption on to the bag surface increased as the formulation pH was increased. For example, after 6 months storage at 40° C. for the dextrose formulations, a clear trend indicating increased drug loss for formulations at pH 4.4 and 4.7 can be observed. 15 At pH 3.3, the drop in % drug remaining is attributed to an increase in total impurities (FIGS. 2B and 3B), rather than drug loss due to adsorption. In addition to the observed drug loss, the formation of nicardipine-related impurities (FIGS. 2B and 3B) was also found to be strongly pH dependent. In this case, however, the reverse trend was observed; as the pH was decreased, the total impurities increased.

The results from this study indicate that the formulation pH has a significant effect on stability of a ready-to-use diluted product. The findings of this study indicate that the optimal 25 formulation pH range is between about 3.6 to about 4.7. However, depending on the degree of acceptable drug degradation and/or total impurity formation, other pH ranges can be chosen.

Example 3

Effect of Nicardipine Concentration on Impurity Formation

The effect of nicardipine concentration on impurity formation in ready to use premixed compositions comprising 0.1 mg/mL and 0.2 mg/ml non-sorbitol formulations with dextrose over 6 months at 40° C. is shown in FIG. 4A. The effect of nicardipine concentration on impurity formation in ready to use premixed compositions comprising 0.1 mg/ml and 0.2 mg/mL non-sorbitol formulations with saline over 3 months at 40° C. is shown in FIG. 4B. The formulations are dispensed in GALAXY® hags. Stability assessments are done as described in Example 2.

As shown in FIGS. 4A and 4B, in addition to pH, product concentration is another factor that impacts product stability, in particular the formation of nicardipine-related impurities. The concentration dependence observed with respect to total impurity formation is minimized as the formulation pH is 50 increased. For example, in FIGS. 4A and B, the effect of concentration is significant at pH 3.3 and is minimized as the pH approaches 4.7.

These results indicate that impurity formation is greater for the 0.1 mg/ml formulations as compared to the 0.2 mg/ml 55 formulations for both the dextrose and saline formulations. Simultaneous optimization of the drug concentration along with the viable formulation pH range is important in the development of ready-to-use premixed drug formulations.

Example 4

Stability Comparison of Sorbitol and Non-Sorbitol Formulations

A stability comparison of sorbitol and non-sorbitol formulations was conducted under accelerated conditions (4 weeks

16

at 40° C.) using a 0.1 mg/mL nicardipine HCl, 1.92 mg/mL sorbitol, 48 mg/mL dextrose, 0.0192 mg/mL citric acid, pH 4.2 and a 0.1 mg/mL nicardipine HCl, 50 mg/mL dextrose, 0.0192 mg/mL citric acid, pH 4.0. Both formulations were dispensed in GALAXY® bags. Stability assessments were done by measuring the % drug remaining and total impurity formation as a function of time using RP-HPLC. The results are shown in Tables 2 and 3.

TABLE 2

Devinose Formulation without Sorbitol						
Time	% Drug Remaining	14 Total Impurities				
0	100,0 98.1	0.08 8.17				

TABLE 3

De	days Kamulatina with	Sorbital_
Time	% Drug Remaining	% Total Impurities
0 4	100.0 96.4	NMT ¹ 0.05 0.13

INMT refers to no more than.

As shown in Tables 2 and 3, minimal differences between the two formulations were observed in the measured parameters. Based on these results, as well as the results shown in Examples 1 and 2, the presence or absence of sorbitol is not predicted to alter the impact of formulation pH and drag concentration on the stability of the premixed pharmaceutical compositions comprising nicardipine HCl and dextrose or sodium chloride.

Example 5

The Effect of Plastic Film Composition on Stability

The effect of plastic film composition on the stability of ready to use premixed compositions comprising 0.2 mg/mL nicardipine HCl, 0.2 mM citrate, 5% dextrose, pH 4.0-4.2 for "incompatible" bags and "compatible" bags is shown in FIGS. 5A and 5B respectively. "Incompatible" bags contain polar polymers, such as polyvinyl chloride (PVC) and ethylene vinyl acetate (EVA), "Compatible" bags do not contain polar polymers.

Stability evaluations were done for the 0.2 mg/mL nonsorbitol dextrose formulation in various commercially available IV infusion bag systems. EXCRL®, VIAFLEX®, VIAFLO™, INTRAVIA®, and VISIV® bags were rinsed in
water and covered with aluminum feil over pouches. The
bags were filled with the above formulation and antoclaved at
105° C for 21 minutes. STEDIM®71 and GALAXY® bags
were asseptically filled with the above formulation. Stability
assessments were done by measuring the % drug remaining
and total impurity formation (data not shown) as a function of
time using RP-HPIC for samples incubated for up to 24
weeks at 40° C. The % drug remaining was calculated relative
to the concentration measured post-mixing in tank.

As shown in FIG. SA, various commercially available IV bags were not compatible with nicardipine HCl. Significant loss in product potency was observed upon storage primarily due to product adsorption in bags that contained the polymer

45

17

PVC (e.g., VIAFLEX® and INTRAVIA®). Nicardipine was also incompatible with bags containing the polymer ethylene-vinyl acetate (EVA) in the contact layer (e.g., STHDIM®71). PVC and EVA are examples are of polar plastic materials that are incompatible with nicardipine HCl. Because nicardipine 5 HCl is a weak base with a pKa of ~7.2, it is increasingly hydrophobic as the formulation pH increases, and therefore, compatibility with polymeric contact surfaces is dependent on surface charge-related properties.

As shown in FIG. 5B, minimal drop in product potency was 10 observed with commercial bags comprising copolyester (e.g., EXCEL®), polyethylene (e.g., GALAXY®), and polyelefin blends (e.g., VISIV® and VIAFLO™).

Example 6

Effect of CAPTISOL® on Product Stability

The effect of CAPTISOL® on the stability of ready to use premixed compositions comprising 0.3 mg/ml Nicardipine, 20 30 mM NaAcetate, 1.8% Captisol, 112 mM NaCl, pH 4.5 or 0.3 mg/ml Nicardipine, 30 mM NaAcetate, 1.8% Captisol, 3.7% Dextrose, pH 4.5 dispensed in 100 ml GALAXY® bags was monitored for 12 weeks at 5, 25 and 40° C. in (see, e.g., Table 4). Because the drug was stable at 5° C., the data is not 25 shown. In addition, the formulations were monitored at 45° C. in 2 mL glass vials (see, e.g., Table 5). All formulations were filled aseptically into the vials and bags by filtering the solution through a 0.22 µm filter.

TARLE 4

			TABLE 4			
	% D	nie Romainine s	t 25° C. and 40°	C.Ingalax	@ Bar	
		% Date remai	ning at 25° C.	% Drug remai	ning at 40° C.	٠,
	ime	NaCl Formulation	Denizoso Formulation	NaC3 Formulation	Dentrose Formulation	•
	0	100,00	100.00	100,00	100.00	
	1	96.57	99.86	97,15	98.86	
	2	98.09	100.80	97.07	100.40	
	4	99,45	104.01	98.46	102.56	4
1	2	97.23	8E.101	95.36	99.00	

TABLE 5

		*61
Destrose Formulation	NaCl Formulation	Time (weeks)
100.00	100.00	0
105.78	107,69	2
105.22	105.18	4
102.80	102.22	14
	Destrose Fermulation 100.00 105.78 105.22	Formulation Destrow Fermulation 100.00 100.00 107.69 105.78 105.18 105.22

Pharmaceutical compositions comprising CAPITSOL® exhibited minimal drug loss and impurity formation (data not shown) as a function of time and temperature. Based on the accelerated stability data at 40° and 45° C., formulations comprising CAPTISOL®, dextrose or NACI should be stable so at room temperature for at least 12 months.

Examples 7 Through 12

Examples 7-12 illustrate experiments performed using 65 specific embodiments. The experiments in Examples 7-12 were performed at 45° C. in order to simulate stressed con-

ditions that cause sufficient product degradation in a relatively short period of time. Stability comparisons were done against the control formulation (CF) and/or the commercial product formulation (CFF) in order to assess relative differ-

ences in their degradation profiles. The CPF is a marketed drug product and, therefore, degradation behavior of the molecule is well understood as a function of temperature and time. Stability data are available for the marketed product up to 36 months at room temperature, 22-27° C., and 40° C.

The rationale used in this preliminary screening evaluation is that if the degradation kinetics of the evaluated formulation prototypes were comparable to the CPF at stressed temperatures, drug product stability would likely be comparable or better at room temperature. The current prototype formulation is stable for at least 18 months at 25° C., and therefore it is projected that the evaluated formulation prototypes can have comparable or better stability.

Example 7

Formulation Preparation and Analysis

Appropriate buffers, such as acetate or succinate, containing the desired cosolvents, such as sorbitol or propylene givcol, and/or complexing agents, such as SBEBCD or 2HPSCD, were prepared. Appropriate tonicity agents, such as sodium chloride, were prepared and added to some of the pharmaceutical compositions. Based upon the final formulation volume and the target drug concentration, usually 0.2-0.3 30 mg/ml., nicardipine was weighed into an appropriate glass container and prepared buffer was added to dissolve the drug, Tonicity agent, if any, was then added. The solution was then sonicated for up to 45 minutes to facilitate drug dissolution. Following drug dissolution, the solution was littered through 35 a 0.45 µm syringe filter (Acrodisc LC 13 mm Syringe filter, PVDF Membrane from Life Sciences, PN 4452T). When filtering, the first few drops were discarded and the remaining solution was collected into another glass container. The prepared formulations were subsequently dispensed into either vials or intravenous bags.

The following isotonic pharmaceutical compositions were made according to the above protocol:

Pharmaceutical Composition I (PC1): 0.2-0.3 mg/ml nicantiping hydrochloride, 3.7% sorbitol, and 50 mM Naacetate, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 2 (PC 2): 0.2-0.3 mg/ml nicardipine hydrochloride, 1.7% propylene glycol, and 50 mM Na-acetate, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 3 (PC3): 0.2-0.3 mg/ml nicardipine hydrochloride, 2.8% sorbitol, and 50 mM Nasuccinate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 4 (PC 4): 0.2-0.3 mg/ml nicardipine hydrochloride, 1.1% propylene glycol, and 50 mM Na-succinate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 5 (PC 5): 0.2-0.3 mg/ml nicardipine hydrochloride, 4.1% sorbitol, and 50 mM Nascatate, wherein the pH of the composition is 3.5.

Pharmaceutical Composition 6 (PC 6): 0.2-0.3 mg/ml nicardipine hydrochloride, 1.9% propylene glycol, and 50 mM Na-acetate, wherein the pH of the composition is 3.5.

Pharmaceutical Composition 7 (PC 7): 0.2-0.3 mg/ml nicardipine hydrochlorids, 4.1% sorbitol, and 50 mM Naacetate, wherein the pH of the composition is 4.5.

- Pharmaceutical Composition 8 (PC 8): 0.2-0.3 mg/ml nicardipine hydrochloride, 1.8% propylene glycol, and 50 mM Na-acetate, wherein the pH of the composition is 4.5.
- Pharmaceutical Composition 9 (PC 9): 0.2-0.3 mg/ml nicardipine hydrochleride, 6.5% sulfobutylether-β-cyclodextrin, and 50 mM Na-succinate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 10 (PC 10); 0.2-0.3 mg/ml nicerdipine hydrochloride, 6.5% sulfobutylether-β-cy- 10 clodestrin, and 50 mM Na-succinate, wherein the pH of the composition is 6.0.
- Pharmaceutical Composition 11 (PC 11): 0.2-0.3 mg/ml nicardipms hydrochloride, 8.5% sulfobutylether-β-cyclodextrin, and 50 mM Na-succinate, wherein the pH of ¹⁵ the composition is 5.5.
- Pharmaceutical Composition 12 (PC 12): 0.2-0.3 mg/ml nicardipine hydrochloride, 8.5% sulfobutylether-β-cyclodextrin, and 50 mM Na-succinate, wherein the pH of the composition is 6.0.
- Pharmaceutical Composition 13 (PC 13): 0.2-0.3 mg/ml nicardipine hydrochloride, 8.5% sulfobutylether-β-cyclodestrin, and 50 mM Na-acetate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 14 (PC 14): 0.2-0.3 mg/ml ²⁵ nicardipine hydrochloride, 8.5% sulfobutylether-β-cyclodextrin, and 50 mM Na-citrate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 15 (PC 15): 0.2-0.3 mg/ml nicardipine hydrochloride, 22.5% 2-hydroxypropyl-β-cyclodextrin, and 50 mM Ns-acetate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 16 (PC 16): 0.2-0.3 mg/ml nicardipine hydrochloride, 22.5% 2-hydroxypropyl-β-cyclodextrin, and 50 mM Na-succinate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 17 (PC 17): 0.2-0.3 mg/ml nicardipine hydrochloride, 17.5% 2-hydroxypropyl-β-cyclodextrin, and 50 mM Na-acetate, wherein the pH of the composition is 5.0.
- Phannaceutical Composition 18 (PC 18): 0.2-0.3 mg/ml nicardipine hydrochloride, 17.5% 2-hydroxypropyl-βcyclodextrin, and 50 mM Na-succinate, wherein the pH of the composition is 5.5.
- Commercial Product (Ampul) Formulation (CPF): 2.5 mg/ml nicardipine hydrochloride, 2.5 mM citrate, and 5% sorbitol, wherein the pH of the composition is 3.5.
- Control Formulation (CF): 0.3 mg/ml nicerdipine hydrochloride, 2.5 mM citrate, and 5% sorbitol, wherein the pH of the composition is 3.5.
- Pharmaceutical Composition 19 (PC 19): 0.3 mg/ml nicardipine hydrochloride, 50 mM sodium sectate, 50 mM sodium citrate, and 50 mM disodium seccinate, wherein the pH of the composition is 3.5.
- Pharmaceutical Composition 20 (PC 20): 0.3 mg/ml nicardipine hydrochlorids, 50 mM sodium acetate, 50 mM sodium citrate, and 50 mM disodium succinate, wherein the pH of the composition is 4.5.
- Pharmaceutical Composition 21 (PC 21): 0.3 mg/ml nicardipine hydrochloride, 50 mM sodium acetate, 50 mM sodium citrate, and 50 mM disodium succinate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 22 (PC 22): 0.3 mg/ml nicardipine hydrochloride, 50 mM sodium scetate, 50 mM 63 sodium citrate, and 25 mM disodium succinate, wherein the pH of the composition is 5.5.

Pharmaceutical Composition 23 (PC 23): 0.3 mg/ml nicardipine hydrochloride, 4.1% sorbitol, and 50 mlM sodium acetate, wherein the pH of the composition is

20

- Pharmaceutical Composition 24 (PC 24): 0.3 mg/ml nicardipine hydrochloride, 4.1% sorbitol, and 50 mlM sodium acetate, wherein the pH of the composition is 4.5
- Pharmaceutical Composition 25 (PC 25): 0,3 mg/ml nicantipine hydrochloride, 3.7% surbital, and 50 mM sodium scetate, wherein the pH of the composition is 5.0
- Pharmaceutical Composition 26 (PC 26): 0.3 mg/ml nicardipine hydrochloride, 2.8% sorbitol, and 50 mM sodium sectate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 27 (PC 27): 0.3 mg/ml nicardipins hydrochloride, 1.9% propylene glycol, and 50 mM sodium acetate, wherein the pH of the composition is 3.5.
- Pharmaceutical Composition 28 (PC 28): 0.3 mg/ml nicardipine hydrochloride, 1.8% propylene glycol, and 50 mM sodium acetate, wherein the pH of the composition is 4.5.
- Pharmaceutical Composition 29 (PC 29): 0.3 mg/ml nicardipine hydrochloride, 1.7% propylene glycol, and 50 mM sodium acetate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 30 (PC 30): 0.3 mg/ml nicardipine hydrochloride, 1.1% propylene glycol, and 50 mM sodium succinate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 31 (PC 31): 0.3 mg/ml nicardipine hydrochloride, 6.5% sulfobutylether-β-cyclodextrin, and 50 mM sodium succinate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 32 (PC 32): 0.3 mg/ml nitardipine hydrochleride, 6.5% sulfolutylether-fi-cyclodectrin, and 50 mM sodium succinate, wherein the pH of the composition is 6.0.
- Pharmaceutical Composition 33 (PC 33): 0.3 mg/ml nicardipine hydrochloride, 22.5% 2-hydroxypropyl-β-cyclodextrin, and 50 mM sodium acetate, wherein the pH of the composition is 5.0.
- Pharmacentical Composition 34 (PC 34): 0.3 mg/ml nicardipine hydrochloride, 17% 2-hydroxypropyl-β-cyclodextrin, and 50 mM disodium succinate, wherein the pH of the composition is 5.5.
- Pharmaceutical Composition 35 (PC 35): 0.3 mg/ml nicardipine hydrochloride, 0.3% propylene glycol, 0.5% sorbitol, 30 mM sodium acetate, and 90 mM NaCl, wherein the pH of the composition is 5.2.
- Pharmaceutical Composition 36 (PC 36): 0.3 mg/ml nicardipine hydrochloride, 0.3% propylene glycol, 2.0% sorbitol, 30 mM sodium scetste, 45 mM NsCl, wherein the pH of the composition is 5.2.
- Pharmaceutical Composition 37 (PC 37): 1.5 mg/ml nicardinine hydrochloride, 9% sulfobutylether-β-cyclodextrin, and 30 mM sodium acetate, wherein the pH of the composition is 4.5.
- Pharmaceutical Composition 38 (PC 38): 1.5 mg/ml nicardipine hydrochloride, 9% sulfobutylether-β-cyclodestrin, and 30 mM sodium acetate, wherein the pH of the composition is 5.0.
- Pharmaceutical Composition 39 (PC 39): 0.3 mg/ml nicardipine hydrochloride, and 30 mM sodium acetate, wherein the pH of the composition is 3.5.

21

Pharmaceutical Composition 40 (PC 49): 0.3 mg/mi nicardipins hydrochloride, and 30 mM sodium acetate, wherein the pH of the composition is 4.0.

Pharmaceutical Composition 41 (PC 41): 0.3 mg/ml nleardipine hydrochloride, and 30 mM sodium acetate, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 42 (PC 42): 0.3 mg/ml nicardipine hydrochloride, 1.8% sulfobutylether-β-cyclodextrin, 30 mM sodium acetate, and 110 mM NaCl, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 43 (PC 43): 0.3 mg/ml nicardipine hydrochloride, 1.8% sulfobutylether-fi-cyclodextrin, 0.3% propylene glycol, 30 mM sodium acetate, and

85 mM NaCl, wherein the pH of the composition is 5.0. Pharmaceutical Composition 44 (PC 44): 0.3 mg/ml nica-ndipine hydrochloride, 1.8% sulfobutylether-β-cyclodeutrin, 30 mM sodium acetate, and 110 mM NsCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 45 (PC 45): 0.3 mg/ml nicardipine hydrochloride, 1.8% sulfobutylether-β-cyclodextrin, 30 mM sodium acetate, and 200 mM dextrose, wherein the pH of the composition is 4.5.

Pharmaccatical Composition 46 (PC 46): 0.3 mg/ml nicardipine hydrochloride, 0.75% sulfobutylether-β-cyclodextrin, 30 mM sodium acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 47 (PC 47): 0.3 mg/ml nicardipine hydrochloride, 1.0% sulfobutylether-β-cyclodextrin, 30 mM sodium acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 48 (PC 48): 0.3 mg/ml nicardipine hydrochloride, 3.4% sorbitol, and 50 mM sodium succinate, wherein the pH of the composition is 5.6.

Phannaceutical Composition 49 (PC 49): 0.3 mg/ml nicardipine hydrochloride, 1.3% propylene glycol, and 50 mM sodium acetate, wherein the pH of the composition is 5.6.

Pharmaceutical Composition 50 (PC 50): 0.3 mg/ml nica-40 rdipine hydrochloride, 1.8% sulfobutylether-β-cyclo-dextrin, 30 mM sodium acetate, and 110 mM NaCl, wherein the pH of the composition is 5.0.

Pharmaceutical Composition 51 (PC 51): 0.3 mg/ml nicardinine hydrochloride, 0.75% sulfobusylether-β-cyclodextrin, 30 mM sodium acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 52 (PC 52): 0.3 mg/ml nicardipine hydrochloride, 1.0% sulfobutylether-β-cyclodextrin, 30 mM sodium acetate, and 125 mM NaCl, 50 wherein the pH of the composition is 4.5.

Pharmaceutical Composition 53 (PC 53): 0.3 mg/ml picardipins hydrochloride, 0.5% sorbitol, 0.3% propylene glycol, 30 mM sodium acetate, and 90 mM NsCl, wherein the pH of the composition is 5.2.

Pharmaceutical Composition 54 (PC 54): 0.3 mg/ml nicanlipine hydrochlorids, 1.0% sulfobutylether-β-cyclodeutein, 30 mM sodium acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 55 (PC 55): 0.3 mg/ml nicasolipine hydrochloride, 0.75% sulfobutylether-β-cyclodextrin, 30 mM section acetate, and 125 mM NaCl, wherein the pH of the composition is 4.5.

Pharmaceutical Composition 56 (PC 56): 0.3 mg/ml nicandipine hydrochleride, 0.5% sorbitol, 0.3% propylene 65 glycol, 50 mM sodium acetste, and 90 mM NaCl, wherein the pH of the composition is 5.2. 22

The excipient concentration in the control formulation (CF) is identical to the commercial product formulation (CPF), Cardene® I.V (ampul). However, the concentration of active ingredient in the commercial and control formulations is different. In the commercial product formulation (CPF), the concentration of nicerdipine hydrochloride in the amoul is 2.5 mg/mL before dilution, and 0.1 mg/ml after dilution with appropriate IV fluids before administration. The control formulation (CF), which is designed for premixed ready-to-use 10 intravenous bags such that no further dilution with intravenous fluids is required, has a nicardipine hydrochloride concentration of 0.3 mg/mL. The purpose of the control formulation was to help assess the degradation propensity of the evaluated formulations. Comparable degradation profiles at stressed conditions is indicative of comparable formulation stability.

Example 8

Vial Stability Data with Sorbital and Propylene Glycol Formulations

The stability in vials of pharmaceutical compositions of the present invention comprising a co-solvent and a buffering agent were compared to the control formulation and the commercial product formulation. Stability was determined by comparing the drug concentration over time for the below compositions. Specifically, the below compositions were prepared according to the method in Example 7:

50 mM Ns-acetate, pH 3.5. 4.1% sorbital (PC 5), 50 mM Ns-acetate, pH 3.5. 1.9% propylene glycol (PC 6), 50 mM Ns-acetate, pH 4.5, 4.1% sorbital (PC 7), 50 mM Ns-acetate, pH 4.5, 4.1% sorbital (PC 7),

50 mM Na-acetate, pH 4.5, 1.8% propylene giycol (PC 8), 50 mM Na-acetate, pH 5.0, 3.7% aurhitol (PC 1), 50 mM Na-acetate, pH 5.0, 1.7% aurhitol (PC 1),

50 mM Na-acetate, pH 5.0, 1.7% propylene glycol (PC 2), Control formulation: 0.3 mg/mL, 2.5 mM citrate, 5% scrbital, pH 3.5 (CF), and

Commercial product formulation: 2.5 mg/ml, 2.5 mM citrate, 5% sorbitol, pH 3.5 (CPF).

These stability studies were performed in 2 ml glass visits and at elevated temperature conditions, in this case 45° C. Rommlation stability was monitored by measuring the drug concentration by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, 7 days and 21 days, except for the commercial product formulation, which measurements were taken at the start of the experiment and 46 days. These measurements were then converted into a percentage in order to show the percentage of drug remaining after a period of time.

5	PC #	Drug Conc. (µg/ml) 1 = 0	% Drug Remaining	Drug Conc. (µg/ml) t ~ 7 days	% Drug Remaining	Drug Conc. (µg/ml) 1 = 21 days	% Drug Remaining
, .	5	314	100	312	99	289	52
	6	302	100	305	101	282	93
	7	304	100	303	100	283	93
	E	304	1.00	304	100	282	93
	1	291	100	294	98	274	52
	2	290	100	302	104	264	91
,	CF	302	100	301	100	111	92

23

PC#	Drug Cone, (pg/ml) t=0	% Drug Remaining	Drug Cone. (hg/ml) t = 46 days	% Drug Remaining	9
CPF	2553	100	2265	89	

The data show that the stability in vials, drug concentration over time, of the pharmaceutical compositions of the present 10 invention that contain co-solvents are comparable to both the control formulation (CF) and the current product formulation (CFF). In addition, the compositions had no additional degradation products relative to the control formulation (data not shown).

Example 9

Vial Stability Data with SBEBCD Formulations

The stability in vials of pharmaceutical compositions of the present invention comprising a complexing agent and a buffering agent were compared to the control formulation and the commercial product formulation. Stability was determined by comparing the drug concentration over time for the below 25 compositions. Specifically, the below compositions were prepared according to the method in Example 7:

50 mM Na-acetate, 8.5% SBE-beta cyclodextrin, pH 5.0

50 mM Na-citrate, 8.5% SBE-beta cyclodextrin, pH 5.5 30 (PC 14),

50 mM Na-succinate, 8.5% SBE-beta cyclodextrin, pH 5.5 (PC 11),

50 mMNs-succinate, 8.5% SBE-bets cyclodextrin, pH 6.0

Control formulation: 0.3 mg/mL, 2.5 mM citrate, 5% sorbitol, pH 3.5 (CF), and

Commercial product formulation: 2.5 mg/ml, 2.5 mM citrate, 5% sorbitol, pH 3.5 (CPF).

These stability studies were performed in 2 ml glass vials and at vials and at elevated temperature conditions, in this case 45° C. Formulation stability was monitored by measuring the drug concentration by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, 6 days, 13 days and 30 days, except for the commercial product formulation, which measurements were taken at the start of the experiment and 46 days. These measurements were then converted into a percentage in order to show a percentage of drug remaining after a period of time.

The data from these stability studies are shown in the following Tables.

R	}C#	Drug Conc. (pg/ml) t=0	% Drug Remaining	Drug Conc. (pg/ml) t = 46 days	% Drug Remaining
	CPF	2553	100	2265	89

24

The data show that the stability in vials, drug concentration over time, of the pharmscentical compositions of the present invention that contain SBEBCD are comparable to both the control formulation (CF) and the commercial product formulation (CFF). In addition, the compositions had no additional degradation products relative to the control formulation (data not shown). It is also worth noting that the target concentration of 0.2-0.3 mg/mL could be readily attained in the presence of sulfobutylether-β-cyclodextrin.

Example 10

Intravenous Bag Stability Data with Sorbitol and Propylene Glycol Formulations

The stability in intravenous bags of pharmaceutical compositions of the present invention comprising a co-solvent and a buffering agent were compared to a control formulation. Stability was determined by comparing the drug concentration over time for the below compositions. Specifically, the below compositions were prepared according to the method in Example 7:

50 mM Na-acetate, pH 3.5. 4.1% sorbitol (PC 5),

50 mM Na-acetate, pH 3.5. 1.9% propylene glycol (PC 6), and

Control formulation: 0.3 mg/mL, 2.5 mM citrate, 5% sorbitol, pH 3.5 (CF).

These stability studies were performed in 50 ml intravenous bags and at elevated temperature conditions, in this case 45° C. Formulation stability was monitured by measuring the drug concentration by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, 7 days and 21 days. These measurements were then converted into a percentage in order to show the percentage of drug remaining after a period of time.

The data from these stability studies are shown in the Table below.

PC W	[Drug] (µg/ml) t=0	% Drug Romaining	[Drug] (µg/ml) t=6 d	% Drug Remaining	[Drug] (µg/ml) t = 13 d	% Daug Remaining	[Drug] (µg/ml) t = 30 d	% Drug Remaining
13	381	100	387	101	413	108	390	102
14	334	100	339	101	352	105	333	100
11	364	100	378	104	396	109	364	100
12	316	300	341	107	355	112	325	103
CF	339	001	352	104	363	107	338	100

Dang

(pg/ml)

t=7

daya

317

311

奖

Drug

Remaining

101

103

92

Conc

16

Drug

100

100

100

Drug

Coins.

(Ler/mi)

302

307

б

CF

88

Drug

Come

(hB/prr)

t=21

days

319

264

The data show that the stability in intravenous bags, drug concentration over time, of the pharmaceutical compositions of the present invention that contain co-solvents are comparable to the control formulation. In addition, the compositions had no additional degradation products relative to the control formulation (data not shown). Finally, drug adsorption on the bag surface was minimal at pH 3.5.

Example 11

lutravenous Bag Stability Data with HPCD Formulations

The stability of a pharmaceutical composition of the present invention comprising a complexing agent and a buffering agent was evaluated in both vials and intravenous bags. Stability was determined by comparing the drug concentration over time for the balow composition. Specifically, the below composition was prepared according to the method in Example 7:

50 mM Na-acctate, pH 5.0, 22.5% HPCD (PC 15).

These stability studies were performed in 50 ml intravenous bags and at elevated temperature conditions, in this case 45° C. The stability evaluations were done with a 10 mL fill volume in both the noright and inverted beg configurations. These evaluations were done relative to the same formulation in a 2 mL glass vial, as a control. Formulation stability was monitored by measuring the drug concentration by RP-HPLC 40 against a standard curve. The drug concentration measurements were taken at the start of the experiment, 1 day, 2 days, 6 days, 9 days and 16 days.

The data from these stability studies are shown in the Table helms

	Drug Cone. (ug/ml) t=0	Drug Conc. (µg/ml) 1=1 dsy	Drug Conc. (pg/ml) t = 2 days	Drug Conc. (µg/ml) t=6 days	Drug Conc. (jug/ml) t=9 days	Drug Conc. (µg/ml) t = 16 days
Vial	271	271	263	260	269	274
Upright Bag	271	256	244	264	270	301
Inverted Bag	271	233	203	175	172	150

The data show that the stability, drug concentration over time, of the pharmaceutical composition of the present inven- 60 tion that contains complexing agent is more promising in the upright configuration of the bag. The data also show that the recovery of drug product was poorer in the inverted bag configuration.

In order to determine why the composition was more stable 63 in upright intravenous bags compared to inverted intravenous bags, additional experiments were conducted. The drop in

drug concentration was not due to any new degradation prodtext (data not shown). We believe that the drop in drug concontration was due to drug adsorption on the bag surface. For many hydrophobic drugs, adsorption on PVC surfaces is a commonly reported concern. Therefore, it is likely that we observed significant adsorption in the inverted configuration because the drug is in contact with PVC surfaces. These results suggest the use of non-PVC bags and/or the careful evaluation of the bag size (solution volume) as feasible 10 options to minimize drug adsorption in order to achieve adequate drug product recovery.

Example 12

Intravenous Bag Stability Data with Sorbitol **Pormulations**

The stability of a pharmaceutical composition of the present invention comprising a cosolvent and a buffering agent was evaluated in both vials and intravenous bags. Stability was determined by comparing the drug concentration over time for the below composition. Specifically, the below composition was prepared according to the method in Example 7:

50 mM Na-acetate, pH 5.0, 3.7% sorbital (PC 1).

These stability studies were performed in 50 ml intravenous bags and at elevated temperature conditions, in this case 45° C. The stability evaluations were done with both 10 and 50 mL fill volumes in both the upright and inverted bag configurations. These evaluations were done relative to the same formulation in a 2 mL glass vial, as a control. Formulation stability was monitored by measuring the drug concentretion by RP-HPLC against a standard curve. The drug concentration measurements were taken at the start of the experiment, 1 day, 2 days, 5 days, 9 days and 16 days.

The data from these stability studies are shown in the below

40	-						
45		Darg Conc. (pg/ml) t = 0	Drug Conc. (ng/ml) t-1 day	Drug Cons (µg/ml) t=2 days	Drug Conc. (µg/ml) t=6 days	Drug Conc. (pg/ml) t=9 days	Drug Conc. (µg/ml) t = 16 days
	Vial	100	102	100	110	104	106
	Opright Beg 10 ml	100	93	20	98	85	87
	Upright Hag 50 ml	100	98	96	11,4	97	98
	Inverted Bag 10 mJ	100	45	43	38	21	13
55	Invested Hag 50 ml	100	89	87	102	86	85

The data show that the stability, drug concentration over time, of the pharmaceutical composition of the present invention that contains cosolvent is more promising in the upright configuration of the bag. The data also show that the recovery of drug product was poorer in the inverted bag configuration.

In order to determine why the composition was more stable in upright intravenous bags compared to inverted intravenous bags, additional experiments were conducted. The drop in drug concentration was not due to any new degradation product (data not shown). We believe that the drop in drug con-

27

centration was due to drug adsorption on the bag surface. For many hydrophobic drugs, adsorption on PVC surfaces is a commonly reported concern. Therefore, it is likely that we observed significant adsorption in the inverted configuration because the drug is in contact with PVC surfaces. This belief is further supported by the fact that we observed poorer recovery of the drug in the 10 mL fill configuration relative to the 50 mL fill configuration, although this poorer recovery may be partly due to the fact that the 10 mL fill configuration has a higher surface area to volume ratio, which adversely impacts a higher surface area to volume ratio, which adversely impacts suggest the use of non-PVC bags and/or the careful evaluation of the bag size (solution volume) as feasible options to minimize drug adsorption in order to achieve adequate drug product recovery.

All publications, patents, patent applications and other documents cited in this application are hereby incorporated by reference in their entireties for all purposes to the same extent as if each individual publication, patent, patent application or other document were individually indicated to be 20 incorporated by reference for all purposes.

While various specific embodiments have been illustrated and described, it will be appreciated that various changes can be made without departing from the spirit and scope of the invention(s).

What is claimed is:

- A method for making a pharmacentical composition for intravenous administration comprising;
 - providing a solution comprising a tonicity agent, a buffer, and at least one active ingredient selected from the group consisting of nicardipine and/or pharmaceutically acceptable salts thereof;
- adjusting the pH of the composition as necessary to achieve a pH within the range of from about 3.6 to 4.7:
- further diluting the composition to a final active ingredient 35 concentration from about 0.1 to 0.4 mg/mL; and
- filling pharmaceutically acceptable containers with the pre-mixed composition;
- the aqueous solution when stored in the container for at least one year at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine hydrochloride and (ii) a total impurity formation of less than about 3%.
- The method according to claim 1, in which the tonicity agent is selected from the group consisting of dextrose and sodium chloride.
- 3. The method according to claim 1, further comprising adding at least one cosolvent to the buffered solution.
- The method according to claim 3, in which the cosolvent is sorbitol.

5. The method according to claim 2, wherein providing the solution comprises the steps of providing an initial solution comprising water and at least one buffer at a pH leas than about 5.0, and thereafter adding at least one active ingredient to the initial solution.

28

6. The method according to claim 5, wherein the initial solution has a pH less than about 3.6.

7. A method for making a pharmaceutical composition for intravenous administration comprising: packaging in a pharmaceutically acceptable container a pre-mixed aqueous solution with a pH from about 3.6 to about 4.7 comprising:

from about 0.1 to 0.4 mg/mL nicardipine hydrochloride; a tonicity agent selected from (i) about 4.5% to about 5% dextrose or (ii) about 0.8% to about 0.9% sodium chloride; and

from about 0.01 to about 0.1 mg/mL citric acid;

such that the aqueous solution contained in the pharmaceutically acceptable container does not come into contact with polar polymers;

the aqueous solution when stored in the container for at least one year at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine hydrochloride and (ii) a total impurity formation of less than about 3%.

The method of claim 7, further comprising at least one pH adjuster selected from the group consisting of hydrochloric acid, sodium hydroxide and a mixture thereof.

 The method of claim 7, further comprising from about 1 mg/ml to about 4 mg/ml perbitol

10. The method of claim 7, wherein the container comprises copolyester, polyethylene or polyolefin.

11. A method for making a pharmaceutical composition for intravenous administration comprising: packaging in a pharmaceutically acceptable container a pre-mixed aqueous solution with a pH from about 3.6 to about 4.7 comprising:

from about 0.1 to about 0.2 mg/mL nicardipine hydrochloride;

a tonicity agent selected from (i) about 46 to about 50 mg/mL dextrose or (ii) about 8.3 to about 9 mg/mL sodium chloride; and

from about 0.0192 to about 0.0384 mg/mL citric acid; such that the aqueous solution contained in the pharmaceutically acceptable container does not come into contact with polar polymers;

the aqueous solution when stored in the container for at least one year at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine hydrochloride and (ii) a total impurity formation of less than about 3%.

.